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Abstract: 
 
E-cadherin is a cell adhesion protein required for epithelial tissue integrity. In many cancer 
cells mis-regulation of E-cadherin adhesions causes increased progression and invasion of 
cancer. Alteration in E-cadherin dynamics could therefore serve as an early molecular 
biomarker of metastasis. In this project, I used E-cadherin FRAP to asses real time dynamics 
of cadherin junctions in a pancreatic cancer mice model of in a variety of micro-
environments. My data showed that p53 mutation drives metastasis through mobilizing E-
cadherin in junctions. Also, I used FRAP as a pharmaco-dynamic marker to assess the effect 
of an anti-invasive drug (dasatinib) in pancreatic tumours in vivo. Moreover, my E-cadherin 
FRAP data along with cross-linking experiments and disruption of E-cadherin interactions 
by mutation provided a comprehensive framework for understanding E-cadherin dynamics at 
cell-cell. Here, I have identified four distinct populations of E-cadherin within regions of 
cell-cell contact and characterized the interactions governing their mobility using FRAP. 
These pancreatic cancer cells had the immobile fraction (Fi) of E-cadherin-GFP comprised 
adhesive and non-adhesive populations. The remaining mobile fraction (Fm) also comprised 
of non-adhesive and adhesive populations, one population moves at the rate of pure 
diffusion, and therefore represents free E-cadherin monomers. The other population moves 
more slowly, and represents E-cadherin monomers turning over within immobile complexes. 
Inclusion of E-cadherin into either adhesive population requires cis-, trans-, and actin 
interactions. The signaling pathways in cells dramatically affect the fractions of these 
cadherin components. I showed that understanding the dynamics of these four populations of 
E-cadherins could be used to design or interpretation of future pharmacological and genetic 
experiments to probe the function of E-cadherin in development, disease progression, and 
response to therapy. 
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1.1. Understanding cancer cell metastasis. 
 
1.1.1. Cancer  
 
Each year 10.9 million people are diagnosed with cancer globally and 7.5 million die 
from it (Jemal 2011). Therefore, Cancer is a key global health and economic issue. 
Cancer is an extremely complex disease. Each organ can have diverse tumour types 
which originated from different cell types. Moreover, each tumour includes various 
cell clones, where each clone evolves by different set of random mutations in their 
genome (Nowell 1976).  
It has been observed pathologically in several cancer types, that invasive cancer cells 
evolve from normal cells in multiple steps of premalignant lesions. Each step reflects 
different genetic mutations (Thiery 2002, Foulds 1954). These genetic alterations 
vary from single point mutations to large chromosomal deletions which affects many 
genes. Therefore, there is cascade of random genetic alteration which transforms 
normal calls to cancer cells. Genomic instability in cancer cells generates genetic 
diversity that leads to acquisition of biological capabilities during cancer 
progression. These “hallmarks of cancer” include sustaining proliferative signalling, 
evading growth suppression, resisting cell death, enabling replicative immortality, 
inducing angiogenesis, reprogramming of energy metabolism, escaping immune 
system inhibition and activating invasion and metastasis (Hanahan 2011). Also, it’s 
not only the cancer cells that acquire physiological changes, but also other cell types 
in a tumour site create a specific “tumour microenvironment” which exceedingly 
affects progression of cancer (Figure 1.1) (Hanahan 2011). In early steps of tumour 
formation, hypoxia occurs which favours the selection of cells with up-regulated 
glycolysis and resistance to acidosis in tumours. This adaptation in cells reduces 
their sensitivity to extracellular acidosis and resistance to acid-mediated apoptosis 
through mutations in p53 or other pro-apoptotic pathways. This resistance to 
apoptosis and cell cycle checkpoints and defective DNA repair mechanisms 
dramatically increase genomic instability in hypoxic cells. This genetic instability 
accelerates the genetic alterations which will give the cancer cell a new growth 
advantage, and leads to transformation of normal cells to cancer (Gillies 2007).  
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Figure 1. 1. Genomic instability in cancer cells let them evolve different biological capabilities. 
(adapted from Hanahan 2011) 
 
1.1.2. A hallmark of epithelial cancer is loss of cell polarity. 
 
The majority of human cancers are carcinomas derived from epithelial tissues. 
Carcinomas represent about 85% of cancers (Jemal 2011). Based on histological 
features of the tumour, carcinoma can be divided in to several subtypes. More 
common types are Squamous cell carcinoma (flat, surface covering cells called 
squamous cells) and Adenocarcinoma (of glandular cells). 
Epithelial tissues cover the external and internal surfaces of the body and have many 
characteristic functions or structures. In all epithelial tissues retaining the integrity of 
the architecture is essential for proper function. Commonly, epithelial cells are 
polarized and their plasma membrane is divided into apical and baso-lateral 
domains. The apical-basal polarisation is crucial for maintaining cell-cell adhesion, 
communication, transport and permeability through epithelial layer (Dow 2007).  
Loss of epithelial characteristics of tissue and the appearance of more mesenchymal-
like cells is one of the important hallmarks of evolving invasive tumours. Studies in 
Drosophila melanogaster have shown there are several tumour-suppressor genes 
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involved in establishing and maintaining a correct apical-basal polarity, suggesting 
that a link exists between disruption of epithelial polarity and the control of cell 
proliferation (Wodartz 2007, Bilder 2000, Humbert 2003). 
The tumour suppressive function of polarity complexes has been extensively studied 
in Drosophila.  Many studies showed that proteins that maintain polarity in human 
epithelia are also cellular targets of human oncogenes, and several tumour 
suppressors have been shown to regulate polarity pathways. However, there are not 
strong evidences that loss of polarity is directly causing tumorigenesis (Royer 2011). 
In epithelial cells apical-basal polarity proteins hinder progression of cancer through 
two mechanisms. First is control of asymmetric cell division, which affects 
regulation of stem cell numbers and the differentiation of daughter cells. Therefore, 
disruption of asymmetric cell division of epithelial stem cells disrupts cells 
differentiation. Consequently, disrupting the asymmetric cell division could promote 
formation of tumours (Royer 2011). 
Moreover, baso-lateral polarity in epithelial cells also regulates formation of AJC 
(Apical Junctional Complex). Adherens and tight junctions form AJC adhesion 
complexes which hinder invasion and metastasis in epithelial cells. In several human 
cancers, components of Adherens and tight junctions are mutated. Loss of E-
cadherin, which is a key component of adherens junctions, in later stages of 
tumourigenesis is one of the essential steps of epithelial mesenchymal transition 
(EMT). This transition strongly enhances cancer metastasis.  
 
1.1.3. Pancreatic cancer 
 
Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor prognosis. It has 
one of the highest fatality rates of all cancers. While it forms only 2.5% of 
occurrence of cancer, pancreatic cancer is responsible for 6% of cancer related death 
(Anderson 2006). 80% of patients die in the first year after the time of diagnosis of 
tumour because the disease is already advanced and the tumours are metastatic and 
surgically unresectable (Jemal 2011). Because of this high failure rate for therapies it 
is very important to have a better understanding of this cancer, to develop more 
effective strategies and discover better targets for new drugs. One approach is to 
study mouse models of PDAC. In this section, first the genetic alterations in 
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pancreatic cancer are described; then the mouse model of pancreatic cancer which is 
used in this study is introduced. 
 
1.1.3.1. Genetic background 
 
PDAC occurs from pre-invasive lesions called pancreatic intraepithelial neoplasms 
(PanINs). PanINs are microscopic papillary or flat, noninvasive epithelial lesions that 
are usually in the smaller (<5 mm) pancreatic ducts. The progression of cancer from 
low-grade PanIN, then to high-grade, and to invasive carcinoma is associated with 
the accumulation of mutations in several oncogene and tumor suppressor genes.  
 
Figure 1.2. PDAC develops from PanINs. From left to right, progression of ductal adenocarcinoma 
from normal epithelium to low-grade PanIns, to high-grade PanIN, to invasive carcinoma. 
Accumulation of several genetic mutations drives the progression of the disease. In early stage 
mutation in the oncogene KRAS is happens in 90% of PanIns. In later stages the most important 
mutations happens in the tumor suppressors CDKN2, TP53, SMAD4/DPC4 and BRCA2. (adapted 
from Bardeesy 2002 and Hezel 2006)  
 
Activating point mutations in the KRAS oncogene are the most important genetic 
alteration in pancreatic cancers. In 90% of pancreatic tumours KRAS is mutated. 
This mutation happens early and plays an important role for formation of human 
PanINs (Almoguera 1998). Inactivation of cell cycle inhibitor p16 (CDKN2/INK4A 
locus) happens in similar frequencies and leads to progression of early PanIns to high 
grade PanIns. Moreover, TP53 tumor suppressor is mutated in 50-75% of pancreatic 
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cancers (Scarpa 1993). Most of these mutations are mis-sense mutations which often 
result in accumulation of mutant p53 protein. Around 80% 0f genetic alterations in 
TP53 in cancer are mis-sence mutations not deletion. This suggests the gain-of-
function or dominant-negative properties of the mutant p53 are more important than 
loss of its expression in cancer progression. Mutated p53 could provide tumor cell 
growth advantages. Commonly mutant p53 have a dominant–negative effect to 
disrupt wild-type p53 function mostly by forming mixed tetramers that are unable to 
bind to DNA. Moreover, many mutant p53 isoforms could bind and inactivate the 
p53-related tumour suppressor proteins p63 and p73 (Weisz 2007). 
In addition, in 55% of pancreatic tumors SMAD4 is mutated. BRCA2 mutations are 
also reported in 10% of sporadic pancreatic cancers and around 19% of familial cases 
(Hruban 2000). 
Despite of all advances in understanding the genetic alteration in progression of 
pancreatic cancer, there has been no significant improvement in the survival rate of 
clinical treatments. Therefore, it is important to investigate the molecular 
mechanisms of PDAC progression to find new targets for therapy. 
 
1.1.3.2. P53 is a tumour suppressor protein. 
 
P53 is a member of the p53-family of transcription factors. It is a well known tumour 
suppressor protein and has a vital role in DNA repair and induction of apoptosis and 
senescence in damaged cells. P53 is activated by cellular stresses like DNA damage 
or over activated oncogenes and then p53 activates its transcription targets that can 
mediate a various responses, as an example cell cycle arrest, DNA repair, anti-
angiogenic effects, senescence and apoptosis. Therefore, p53 prevents the 
accumulation of malignant cells.  
Mostly tumour cells escape the control of p53 by either disruption upstream and 
downstream of p53, or by mutating p53 itself. Loss of p53 inhibits senescence and 
apoptosis in tumor cells; moreover it disrupts cell-cycle checkpoints. These cells 
continue to divide regardless of their DNA damage and it results in accumulation of 
additional mutations in their DNA. 
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1.1.3.2.1. Mutant p53 drives invasion in many cancer models.  
 
In vivo studies in mouse cancer models showed that expression of mutant p53 is not 
similar to p53 loss, and that mutant p53 can acquire new functions to drive cell 
migration, invasion, and metastasis. However, p53 null mouse tumors do not 
metastasize frequently (Muller 2011, Attardi 1999). Commonly Tp53 mutations are 
mis-sense mutations in exons 4–9, which encode the DNA binding domain of the 
protein. 30 % of these mutations are in six residues: R175, G245, R248, R249, R273, 
and R282. Genetically engineered mouse with expression of R175H or R273H 
mutant p53 have increased occurrence of highly metastatic tumours (Lang 2004, 
Olive 2004).  
These mutant proteins are found at high concentrations in tumor cells relative to WT 
p53 (Yu 2012) and are not able to bind to DNA and their function as tumour 
suppressor is disrupted. However, these mutations give mutant p53 a gain of 
function property to drive invasion in tumour cells (Muller 2011). These mutations 
disrupt DNA binding function therefore this gain of function in promoting metastasis 
is due to non-transcriptional functions of p53. It is possible that mutant p53 exert 
their effects by modifying the function of other proteins, including the p53 family 
members p63 and p73 (Muller 2011). Mutant p53 drives cell invasion by inhibiting 
p63 function. One suggested mechanism is that that oncogenic RAS and TGF-β 
cooperate with mutant p53 to form a mutant p53/p63 complex that serves to inhibit 
the function of p63 and targets two metastasis suppressors: Sharp-1 and cyclin G2 
(Adorno 2009) 
 
1.1.3.2. Mouse PDAC model  
 
Here I used a mouse model of Pancreatic ductal adenocarcinoma, in which activation 
of oncogene KRAS by G12D mutation initiates the formation of PanINs similar to 
the three stages found in human pancreatic cancer. Occasionally, mice with PanINs 
spontaneously developed locally invasive adenocarcinoma (Morton 2010). However, 
KRASG12D mutation is only an initiating step in PDAC and p53 mutation is also 
needed for formation of the malignant tumours. Therefore, to develop a pancreatic 
mouse model endogenous expression of KRASG12D and p53R172H were targeted to the 
mouse pancreas by expression of cre recombinase under control of the Pdx1 
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pancreatic progenitor cell gene promoter. This results in the formation of pre-
invasive PanIN neoplasms that later developed into invasive and metastatic 
pancreatic tumours. In this model tumours appear in mice after around 10 weeks 
(Hingorani 2005).  
In addition, mice with KRAS mutation and a loss of P53 (instead of mutant p53) 
developed PanINs and tumours later. However, these tumours were not invasive. In 
this model, mice with KRASG12D and p53R172H genetic background develop 
metastatic pancreatic cancer; in contrast, mice that have a KRASG12D and Trp53 null 
allele, despite similar kinetics of primary tumor formation, rarely develop metastasis. 
In other words, activation of KRAS and loss of p53 function is sufficient for 
development of tumours. However, these tumours are not invasive. Only tumours 
with expression of mutant p53 developed metastasis. 
The p53 gain of function mutant accumulates in PDAC cells and promotes 
metastasis. Two PDAC cell lines were derived from these primary pancreatic 
tumours of KPC mouse model. PDAC cell with loss of p53 expression (here called 
PDACfl) are not invasive in an in vitro invasion assay. On the other hand, PDAC 
cells from tumours with p53R172H mutation (here called PDACR172H) are more 
progressive and highly invasive than PDACfl cells (Morton 2010). Moreover, 
expression of human mutant p53 protein (p53R175H) in PDACfl cells is sufficient to 
activate cell invasion in PDACfl cells. PDACfl and PDACR172H are cell lines derived 
from mice tumours, consequently these cells could have gained random mutations in 
their genome during progression of tumours. However, PDACfl cells transfected with 
p53R175H mutant (here called PDACflR175H) are genetically similar to PDACfl cell 
line and the only difference is mutant p53 mutation.  
Therefore, in this model one genetic alteration (loss of p53 in contrast to mutation) 
determines either the tumors are metastatic or not. This gives us a very good tool to 
study metastasis; as this model recapitulates the human disease in many features, it 
provides an excellent system to study the disease progression and metastasis in vitro 
and in vivo.  
 
1.1.4. Metastasis 
 
Tumours can be classified depending on the degree of aggressiveness. Those which 
grow at the site of origin without invading the surrounding tissue are classed as 
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benign tumours, whereas tumours which have infiltrated the nearby tissue or spread 
to distant organs are classified as malignant. (Weinberg 2007). 
Metastasis is the process by which cancer cells leave the primary tumour and spread 
to distant sites where they proliferate and form secondary tumour mass. These 
secondary tumours are the most usual cause of death in cancer. Because of this 
significance in clinical outcome of cancer treatment, it is important to have a 
complete understanding of the mechanisms of metastasis. 
 
1.1.4.1. Metastasis is a complex process. 
 
Metastasis is a complex and multi-step process, comprising many steps such as 
alterations in cell adhesion, acquisition of invasive abilities, entry into the circulation 
and transfer to distant tissues, followed by exit into new sites and ultimately 
colonisation of secondary tumour (figure 1.3). 
Metastasis can happen in many different forms, but commonly there are several 
critical steps in metastasis from primary tumour to formation of secondary mass 
(reviewed in Brooks 2010). Initially, before metastasis starts new bloods vessels 
should develop at the primary tumour (angiogenesis). Next step is dissociation of 
tumour cells from the primary tumour mass. Down-regulation of cell-cell adhesion in 
tumour cells through Epithelial-to-mesenchymal transition (EMT) is a key process in 
this step. However, sometimes collective migration enables cancer cells to migrate in 
a group, without going through EMT transition and loosing cell-cell adhesions.  
Then the detached mesenchymal cells invade and migrate through the basement 
membrane and extracellular matrix (ECM) surrounding the tumour epithelium, and 
subsequently invade through the basement membrane of the endothelium of local 
blood vessels. Basement membrane is a dense meshwork of glycoproteins and 
proteoglycans (such as type IV collagen and laminins). For penetrating through this 
structure matrix-degrading proteases such as matrix metallo-proteinases (MMPs) are 
needed. Normal epithelial cells have very low activity of these proteases. However, 
during the progression of cancer, malignant cells down-regulate matrix protease 
inhibitors. At the same time cells upgrade integrin expression to mediate adhesion to 
the ECM. The process of penetration of tumour cells into tumour-associated 
vasculature is referred to as intravasation. Following intravasation, tumour cells 
travel to secondary sites through the circulatory system (Brooks 2010). 
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Figure 1.3. There are several critical steps in metastasis from primary tumour to formation of 
secondary mass. 1. Tumour angiogenesis, 2. EMT and dissociation of tumour cells from the primary 
tumour mass, 3. Invasion through the BM and ECM surrounding the tumour epithelium and 
subsequent invasion through the BM of the endothelium, 4. Intravasation of the tumour cells prior to 
hematogeneous dissemination, 5. Adhesion of the circulating tumour cells to the endothelial cell 
lining at the capillary bed of the target organ site, 6. Extravasation (invasion of the tumour cells 
through the endothelium, surrounding BM and target organ tissue), 7. Colonization (the development 
of secondary tumour foci at the target organ site.) (adapted from Alexander 2011) 
 
After arriving at a secondary site, tumour cells form cell-cell adhesion to endothelial 
cells through selectins, integrins and members of the immunoglobulin superfamily. 
Then tumour cells invade through the endothelial cell layer (extravasation) (Brooks 
2010). 
Vascular endothelial growth factor (VEGF) released by metastatic cells is thought to 
increase vascular permeability by activating Src family kinases in the endothelial 
cells and thus disturbing endothelial cell- cell junctions. This in turn can facilitate 
extravasation of circulating tumour cells and metastatic spread (Criscuoli 2005). 
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In the final stage of metastasis, cancer cells colonize as a secondary tumour at the 
target organ tissue. 
 
1.1.5. Dissociation of cell-cell adhesions is necessary for tumour cells metastasis 
 
As explained above, loss of cell-cell adhesion in primary tumour cells is critical for 
their dissociation and permits their initial dissemination. As the cancer progress, 
epithelial cells lose their cell-cell adhesion and polarity and undergo a developmental 
switch to highly invasive cells having a fibroblastoid or mesenchymal phenotype. 
This process is called epithelial-mesenchymal transition (EMT). 
 
1.1.5.1. EMT (Epithelial-to-mesenchymal transition) 
 
Strong cell-cell adhesion is necessary for maintaining epithelial structure. This 
includes tight junctions, cadherin based adherens junctions, gap junctions and 
desmosomes. Epithelial cells also have cell-ECM (extracellular matrix) adhesions 
mediated by integrins. During EMT cell-cell and cell-ECM adhesions are disrupted 
to release the epithelial cells from the surrounding tissue. These cells loose their 
polarity. Then by reorganization of the actin cytoskeleton these cells gain the ability 
to migrate. Moreover, expression of matrix degrading metallo-proteinases (MMPs) 
allows the cells to invade through a three-dimensional ECM.  
Several oncogenic signalling pathways induce the process of EMT such as TGF-β, 
Receptor Tyrosine Kinases (RTK)/Ras signalling, integrin, Wnt/ β-catenin, Notch, 
Hedgehog and NF-kB-dependent pathways (Polyak 2009). 
However, ‘EMT’ includes a broad range of changes in epithelial plasticity. In each 
cellular model, activation of different pathways, or their combinations, can induce or 
repress the progression of the epithelial cell’s gene expression program towards a 
mesenchymal phenotype to a varying extent, which creates some subtypes of EMT.  
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Figure 1.4. The epithelial-mesenchymal transition (EMT).  The epithelial-mesenchymal transition 
is associated with disruption of cell-cell adhesions adhesion, down-regulation of E-cadherin 
expression and increased cell mobility. (Radisky 2005) 
 
1.1.5.2. De-regulation of E-cadherin mediated cell-cell adhesion is a key step 
during the EMT process: 
 
Inhibition of E-cadherin function is a critical step driving EMT (Yap 1998-2, 
Birchmeier 1994). During tumor progression, E-cadherin expression can be down-
regulated or it can be functionally inactivated by different mechanisms. These 
mechanisms include post-translational control, somatic mutations, and down-
regulation of gene expression through promoter hypermethylation, histone 
deacetylation and transcriptional repression (Huber 2005). Several EMT-inducing 
developmental regulators, for example snail and slug, repress E-cadherin 
transcription. Up-regulation of Snail correlates with metastasis and poor prognosis, 
whereas silencing of Snail can reduce tumour growth and invasiveness. Slug has also 
been shown to induce EMT and metastasis through the repression of E-cadherin 
(Huber 2005).   
However, it is not always necessary for epithelial cells to undergo EMT and loose E-
cadherin expression to migrate. Cells which have retained their epithelial phenotype, 
keep their adhesions while they migrate as a group. This is called collective 
migration. One of examples of collective migration happens during wound healing. 
As the barrier function of the epithelial sheet is very essential, cells migrate while 
Chapter 1: Introduction                                                                                                              28 
cell-cell adhesions are kept. Signalling pathways (particularly the pathways which 
play a role in EMT) and interactions with ECM have been shown to effect either the 
cell migrate collectively or individually (Rorth 2009). It has been shown that 
cadherin adhesions play a role in collective migration probably through coordinating 
traction forces (Li 2012). Moreover, catenins which associate with cadherins for 
formation of adhesions are important for regulation of actin reorganization (Hidalgo 
2010, Rorth 2009). 
In summary, the ability of tumour cells to invade and metastasize requires 
modulation of cell-cell adhesions. Disruption of cell-cell adhesion occurs not just 
through down-regulation of E-cadherin levels, but also through mis-regulation of its 
dynamics and interaction with other proteins (Gumbiner 2000). Moreover, EMT is 
not an all or nothing process and in different cells represents various level of 
mesenchymal phenotype. Therefore although loss of E-cadherin is on of key mark of 
EMT process, not all the cells undergoing EMT completely lose E-cadherin 
expression (Hollestelle 2013). Many forms of metastatic cancers retain E-cadherin 
expression (Gaida 2012). This suggests that, alteration in E-cadherin dynamics can 
be used as a marker for metastasis. In the next section, the basis of cadherin mediated 
cell-cell adhesion in epithelial cells is introduced.  
 
1. 2. Cadherin mediated cell-cell adhesions 
 
1.2.1. Adherens junction structure 
 
The ability of cells to stick to one another is a crucial property in the evolution of 
multi-cellular organisms. Classical cadherins are a family of trans-membrane 
proteins that mediate cell-cell adhesion at adherens junctions. In epithelial cells, 
intercellular adhesion is primarily mediated by E-cadherin, one of members of this 
family; other members of this family include N-, P, and R-cadherin (Takeichi 1990). 
Cadherin adhesions play a critical function for cell recognition and cell sorting 
during development and morphogenesis (Takeichi 1995). Retaining of adherent 
junctions is crucial for maintaining tissue homeostasis, resistance to mechanical force 
and sheer stress. Moreover, cell-cell adhesions are important for regulation of 
permeability and barrier function of epithelia (Niessen 2007). 
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Cadherin molecules cluster by homophilic interaction of their extracellular domains 
with molecules from neighbouring cells (trans) and on the same cell (cis). In 
addition, the intracellular domain of cadherins interacts with two catenin proteins, 
p120 and β-catenin. Interaction of β-catenin with α-catenin and other actin binding 
protein mediate anchoring cadherin complexes to actin cytoskeleton (Aberle1994). 
Moreover, formation of acto-myosin and contractile ring stabilizes cadherin 
adhesions at mature cell-cell junctions (Vasioukhin 2000). 
Adherens junctions show huge variation in their morphology and protein 
composition. As an example cadherin forms two different adherens junctions in 
epithelial cells: apical adherens junctions (zonulae adhaerentes) and spot-like 
adherens junctions (puncta adhaerentia) present on the lateral cell surfaces. The 
apical adherens junctions typically associate with a group of cytosolic actin-binding 
proteins such as vinculin, VASP, and EPLIN. Also, another trans-membrane 
adhesion receptor, nectin, interacts with cadherins (Meng 2009). In contrast, spot-
like lateral junctions do not exhibit association with these proteins. These lateral 
junctions still interact with actin and this interaction results in their basal to apical 
flow in many cells (Kametani 2007). 
Although homophilic interaction of cadherin and their anchoring to actin is the basis 
of formation of adherens junctions the details of these structures are not completely 
understood. Moreover, adherens junctions are very dynamic structures which 
continuously loose and gain cadherin. The assembly and disassembly are regulated 
by diverse intracellular signalling pathways which affect endocytosis, recycling and 
degradation of cadherins.  
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Figure 1.5. Adherens junction structure: A) Cell-cell adhesion in epithelial cells is a crucial and 
tightly controlled process. The integrity of cell-cell contacts is essential for the regulation of 
paracellular permeability.  B) In polarized epithelial cells Adherens Junctions, Tight Junctions and 
desmosomes are responsible for the establishment of contacts between neighbouring cells. The 
Adherens Junctions consist of Cadherin and Nectin cell adhesion molecules. C) E-Cadherin is a Ca2+ 
dependent cell adhesion molecule at Adherens Junctions. The intracellular domain of cadherin is 
anchored to the Actin cytoskeleton through interaction with α-catenin and β-catenin (Gooding 2004).  
 
1.2.2. Cadherin-catenin complex is the main component of adherens junctions 
 
1.2.2.1. E-cadherin molecular structure 
 
After protein translation, a 130 amino acid prodomain is cleaved from the E-cadherin 
protein precursor. The mature 728 residue mature protein includes an extracellular 
domain, a short trans-membrane domain and a 150 amino acid cytoplasmic domain 
(figure 1.6) (Nagafuchi 1987). E-cadherin structure is highly conserved during 
evolution. The 550 residue extracellular domain has 5 repeated domains (EC1-EC5). 
These EC repeats are present in all cadherin superfamily proteins. Binding of Ca2+ 
to each EC domain is required for the correct conformational organization of the 
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cadherin extracellular domain (Pokutta 1994). The cytoplasmic domain of E-
cadherin is divided into two domains, the juxtamembrane domain (JMD) that binds 
p120-catenin (Yap 1998-1), and the β-catenin binding domain (CBD) (Aberle 1994). 
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Figure1.6. E-cadherin molecular structure and domains map. 
 
1.2.3. Extracellular domain of cadherin forms several homo-dimer interactions 
 
In this section the structure of extracellular domain of E-cadherin is described. The 
E-cadherin forms three interactions through extra-cellular domain: strand-swapping, 
X-dimerization and cis interaction. 
 
1.2.3.1. Strand swapping 
 
The basis of cadherin adhesions is the homophilic interactions of extracellular 
domain of E-cadherin molecules. Nose et al, showed that expression of a chimera 
consisting of P-cadherin with EC1 domain of E-cadherin, results in aggregation of 
the cells with E-cadherin expressing cells (Nose 1990). The interaction of EC1 
domains was confirmed by more advanced technique as electron microscopy 
(Tomschy 1996, Zhang 2009, Kim 2011). Point mutations provided more 
information about the adhesive site of cadherins (Kitagawa 2000; Laur 2002).  
Moreover, cross-linking experiments confirmed that exchange of N-terminal β 
strands of the EC1 domains (A*) between two cadherin molecules is the basis of 
strand-swap cadherin dimerization. The amino-terminal amino group stabilizes 
strand swapping by the salt bridge with Glu89 so proteolytic removal of the 
prodomain is essential for strand swapping as (Troyanovsky 2003, Troyanovsky 
2005, Zhang 2009, Kim 2011). The A*-A strand contacts the B and G strands of the 
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seven β strands that form the core of the EC1 domain. The N-terminal segment of the 
A*-A strand (A*), which include 1 to 3 residue (including Trp2) forms hydrogen 
bonds with the B strand. Trp2 is inserted in the core of the EC1 domain where it 
forms several hydrophobic bonds. In monomeric cadherin all of these contacts are 
intra-molecular. To form strand swap dimers, the A* strand is swapped to another 
molecule EC1 domain and forms exactly the same contacts (Fig. 1.4) Although 
strand swap dimerization is the stronger than other cadherin–cadherin interactions, it 
is still a weak interaction, and corresponds to a KD of 100mM in solution (9–11kT) 
(Vendome 2011). However, force measurements using atomic force microscopy 
showed that single cadherins adhere strongly, indicating that cadherin trans dimers 
are stabilized in the presence of a pulling force (Rakshit 2012). 
Cross-linking experiments on E-cadherins in cell culture showed that strand 
swapping can form both lateral (cis) and adhesive (trans) dimers on the cell surface 
(Chitaev 1998, Harrison 2005). Although, there is no evidence that these strand-
swapped cis dimers are necessary for adhesion.  
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Figure.1.7. Cadherin molecules cluster through strand swap (trans) and cis interactions. a) The 
strand swap dimerization forms by insertion of the Trp2 residue (dark blue rectangle) from A* strand 
(dark blue line) in to a pocket in the core of EC1 domain which can be intra- or inter-molecular. The 
intra molecule interaction (or closed form) need to be opened in order that the free A* strand form a 
strand swap interaction with another molecule. b) The topology diagram of the seven β strands in EC1 
domain of E-cadherin. The first strand is divided into two strands A* and A. in strand swapping A* 
forms a contact with strand B. c) Schematic representation of cis interaction between two cadherin 
molecules in same membrane. Only EC1 and EC2 domains are shown. d) Formation of cis and trans 
dimers clusters cadherin molecules. Cadherin molecules shown with blue colour formed a linear array 
by cis interactions (periodicity 72 Å). Each molecule in this array forms a strand swap trans 
interaction with a cadherin molecule on opposite cell membrane (shown in magenta), which belong to 
the cell. Each of the magneta molecules is part of its own cis array of cadherin molecules which are 
placed in a 90˚ angle compared to neighbouring membrane cis arrays.  (Harris 2012) 
 
1.2.3.2. X dimerization 
 
Nagar et al showed that two-domain (EC1-EC2) E-cadherin fragments can form 
dimers through another interaction other than strand-swapping (Nagar 1996). The 
dimerized molecules contact each other via calcium binding interfaces which forms 
an X shaped structure of two molecules. Initially, the X dimerization was considered 
as a crystal-packing artefact (Häussinger 2004). However, recently more data 
revealed that this dimerization happens in cells and it probably plays a role in 
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formation of cadherin clusters (Hong 2011). X dimers are very unstable (KD~ 900 
μM) and are transient intermediate to formation of strand-swap dimers. Disruption of 
X dimer formation by point mutations leaded to a very slow kinetics of strand-swap 
formation. Moreover, dissociation of strand swapped dimers is extremely slow in this 
mutant (Harrison 2010; Vunnam 2001). However, expression of the X dimer mutant 
in A431 cells showed that although adhesions formed in these cells have slower 
association/dissociation rates, they still form functional junctions (Hong 2011).  
 
1.2.3.3. Cis dimerization clusters cadherin molecule. 
 
In order to form clusters from individual strand swapped trans dimers probably some 
form of cis interactions is necessary. Computational analyses also suggested that 
cadherin clusters are formed by formation of cis interactions between linear arrays of 
trans dimers (Wu 2011). Cis interactions are too weak to be detected in solution, and 
not able to produce clusters in the absence of trans interactions. Therefore, 
biochemical approaches including cross-linking or co-immunoprecipitation assays 
are not able to show formation of such cis interactions (Harrison 2011, Shapiro 1995, 
Troyanovsky 2007, reviewed in De Beco 2012).  However, Structural analysis in the 
E-, N-, and C-cadherin crystals showed formation of cis interaction was (Harrison 
2011). These cis dimers are formed by a nonsymmetrical interaction between the 
concave face of the EC1 domain of one molecule and the convex face of the EC2 
domain of the other cadherin. The EC1 cis binding surface is oriented 90˚ compared 
to the trans dimer interface. Each cadherin molecule can form two cis interaction in 
its concave EC1 and convex EC2 surfaces simultaneously. This could arrange the cis 
dimerized molecules into a linear array.  
Each cadherin molecule in the linear array of cis interacting molecules could also 
form a trans strand swapped dimer with a cadherin located at the opposing plasma 
membrane. Moreover, since trans dimerized cadherin molecules are in a 90˚ angle to 
each other, the cis dimerized linear arrays of cadherin molecules on the opposing 
surfaces crisscross at right angles (Figure. 1.7). 
Disruption of cis interaction by (V81D/L175D) mutations, which destroy the 
hydrophobic core of the cis interface, inhibits cadherin junction assembly. These 
cadherin mutants can form trans interactions, and they are localize into cell–cell 
contacts. However, the junctions formed by the cis mutant cadherin adhesions are 
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transient and unstable (Harrison 2011). Although the cis interactions are too weak to 
be detected in solution, in cooperation with trans interactions, they produce stable 
and ordered adhesive clusters of E-cadherins (Harrison 2011).  
 
1.2.4. E-cadherin Cytoplasmic interactions 
 
E-cadherin molecule has a 150 residue cytoplasmic domain which interacts with 
actin through catenins and several other cytoplasmic proteins. The cytoplasmic 
domain is divided into the juxtamembrane domain (JMD) that binds p120-catenin 
and the β-catenin binding domain (CBD). 
 
1.2.4.1. β-Catenin 
 
β-catenin protein sequence include 13 repeats of the 42 amino acids armadillo 
domain that form a triple α-helix structure (Huber 1997) (Fig 1.8.). The armadillo 
domains in β-catenin interact with the CBD domain of cadherin. Association of β-
catenin to E-cadherin is necessary for transportation of the E-cadherins from the 
endoplasmic reticulum to cell membrane and E-cadherin is normally found to be 
linked to β-catenin in plasma membranes (Chen 1999). 
The N-terminal domain of β-catenin interacts with α-catenin and this interaction 
anchors cadherin to the actin cytoskeleton. How this interaction with β- and α-
catenin clusters the cadherins and stabilize the junctions will be explained in next 
section. In addition, β-catenin plays an important role in cell signalling pathways. 
Free β-catenin moves from the cytoplasm to nucleus and where it binds to the 
TCF/LEF transcription factor to activate the expression of numerous genes involved 
in proliferation and development (Klaus 2008). 
 
1.2.4.2. Interaction of E-cadherin to actin cytoskeleton through β-catenin and α-
catenin 
 
The cytoplasmic domain of E-cadherin binds to the central armadillo domain of β-
catenin (Aberle 1994) and β-catenin binds to α-catenin by interaction of their N-
terminal domains (Rimm 1995) (figure 1.8). Figure 1.5.C shows the commonly 
accepted model for cadherin-catenin-actin interaction based on these data. E-
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cadherin binds to β-catenin.  β-catenin attaches to α-catenin. α–catenin 
simultaneously interacts with β-catenin and actin. Also vinculin homology domain 3 
(VH3) of α-catenin binds to vinculin which is an actin binding protein. These 
interactions anchor the E-cadherin clusters to actin cytoskeleton (Rimm 1995).  
 
 
Fig. 1.8. Catenin molecules structures and interactions. (A) p120-catenin, (B) β-catenin, and (C) α-
catenin. All three proteins interact with additional proteins which regulate actin cytoskeleton. 
(Hartsock 2008) 
 
Recently the Nelson group proposed a different model: α-catenin does not bind to 
actin and β-catenin simultaneously (Yamada 2005). α-catenin exists in either a 
monomeric or homo-dimeric state. The β-catenin binding domain and the α-catenin 
homodimerization domains overlap within amino acids 57–143 on α-catenin (Pokutta 
2000), consequently, only monomeric α-catenin binds β-catenin. On the other hand, 
homo-dimeric α-catenin binds actin filaments but not β-catenin (Yamada 2005). 
Although experimental data showed there is a direct physical link between E-
cadherin\β-catenin complex and actin, this may happen through interaction of other 
actin binding proteins with α-catenin (Desai 2013). Based on these data a new model 
proposed that α-catenin shifts between inactive homodimer formats bound to actin 
and active monomeric form which binds to β-catenin-E-cadherin complex (Yamada 
2005). 
In vitro studies showed that dimerization of α-catenin occurs at a 10-fold higher 
concentration than that of the monomeric pool of α-catenin in the cytoplasm of 
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epithelial cells, which suggests that α-catenin must be locally concentrated prior to 
dimerization probably through binding to the cadherin–catenin complex during cell–
cell adhesion. In other words, binding to the cadherin–catenin complexes at cell-cell 
junctions increases the local concentration of α-catenin. This local increase in α-
catenin concentration drives α-catenin dimerization. α-catenin dimers would locally 
inhibit Arp2/3 and thereby the formation of branching networks of actin filaments 
characteristic of lamellipodia of migrating cells. At the same time, α-catenin dimers 
bind to and bundle existing actin filaments, resulting in actin reorganization from 
branched to bundled arrays (Drees 2005). 
 
Figure 1.9. Regulation of actin organization by α-catenin.  Clustering of cadherins at the growing 
newly formed contacts leads to accumulation of cadherin-catenin complexes. This leads to a high 
local concentration of α-catenin as it dissociates from these complexes. α-catenin is present both in 
monomer or homodimer forms. The α-catenin dimers compete with Arp2/3 complex for binding to 
actin filaments. This interaction disrupts Arp2/3-mediated actin assembly that drives lamellipodia 
formation (the monomeric form are less potent to interact with actin than dimers). α-catenin also 
bundles actin filaments, which may contribute to the reorganization of actin in the mature contact. 
 (Drees 2005). 
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1.2.4.2.1. Phosphorylation of β-catenin regulates its function 
 
The interaction of E-cadherin with β-catenin is regulated by phosphorylation 
(Daugherty 2007). CKII and GSK-3β kinases phosphorylate E-cadherin at three 
serine residues in the cytoplasmic domain (S684, S686, S692). This phosphorylation 
enables formation of additional interactions which leads to increase in affinity of E-
cadherin and β-catenin interaction. Expression of E-cadherin molecules with 
mutations in putative CKII sites reduced cell-cell adhesion (Lickert 2000).  
In the other hand, phosphorylation of β-catenin at Y489 by Abl kinase and at Y654 
by Src or EGF receptor weakens interaction with cadherin (Lilien 2002, Rhee 2002, 
Roura 1999, Hoschuetzky 1994). The structural basis for these effects is due to β-
catenin Y654 forming a hydrogen bond with E-cadherin Asp 665, which stabilizes 
the interaction of the cadherin region 2 helix with the last two armadillo repeats of β-
catenin (Huber 2001); phosphorylation of Y654 would prevent this interaction 
thereby eliminating binding of this region of cadherin and sharply reducing the 
cadherin/β-catenin affinity. Moreover, Tyrosine phosphorylation of β-catenin at 
Y142 by Fer kinase weakens its binding to α-catenin (Piedra 2003). Phosphorylation 
at this site increases β-catenin cytoplasmic level and its interaction with BCL9-2, a 
transcription factor involved in inducing EMT (Brembeck 2004). 
 
1.2.4.3. P120 catenin 
 
P120 was originally discovered as a Src substrate and later classified as a cadherin 
binding catenin through its sequence homology to the armadillo domain of β-catenin 
(Reynolds 1992). P120 has a short C-ter and N-ter domain and in the middle there is 
an ARM domain which consists of 10 arm repeats. These Arm repeats interact with 
cadherin juxtamembrane domain (Anastasiadis 2000). The juxtamembrane domain is 
a 22 AA domain proximal to membrane with a conserved sequence motif, 
YDEEGGGEED. Mutation in this motif results in unbinding of p120 catenin from 
the E-cadherin complex (Yap 1998-1). Expressing this mutant in E-cadherin null 
cells is not adequate to restore cell-cell adhesion in contrast to wild type E-cadheirn 
(Thoreson 2000, Yap 1998-1). P120 binding inhibits endocytosis and subsequent 
degradation of E-cadherin molecules. Therefore, loss of this interaction destabilizes 
cadherin localization to the membrane and inhibits its accumulation at cell borders 
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(Yap 1998-2). This indicates that, interaction of cadherin with P120 is essential for 
maintaining cadherin adhesion. 
In the E-cadherin sequence there is an YYY sequence adjacent to the p120 binding 
motif which can be phosphorylated by kinases such as Src. Phosphorylation of this 
site disrupts p120 and E-cadherin interaction which leads to interaction of E-cadherin 
with Hakai, a c-Cbl-like E3 ubiquitin-ligase. Ubiquitination of E-cadherin results in 
endocytosis and degradation of E-cadherin molecules (Fujita 2002). Although 
interaction with p120 enhanced cell-cell adhesion, it is not necessary for localization 
of E-cadherin to cell-cell junctions. However, disruption of this interaction increases 
the turnover of E-cadherins on cell-cell junctions (Davis 2003).  P120 binding to E-
cadherin stabilizes E-cadherins junctions. It has been shown that loss of p120 
function disrupts cell-cell adhesions and increases tumor progression and invasion  in 
cancer (Conacci-Sorrell 2002). 
 
1.2.4.4. Additional proteins in adherens junctions regulate the dynamics of 
cadherin-catenin-actin interactions. 
 
While the basic structure of cadherin junctions are cadherin-catenin complexes, 
many other proteins are reported to be present at adherens junction. For example 
formin, an actin nucleator binds α-catenin (Kobielak 2004) and cortactin, an actin 
assembly regulator, binds p120-catenin (Boguslavsky 2007). Both formin and 
cortactin are necessary for the formation of linear actin bundles in mature cell–cell 
contacts (Kobielak 2004, Helwani 2004). 
In addition, Ankrin-G binds to the juxtamembrane domain of E-cadherin and recruits 
beta-2 spectrin to E-cadherin/β-catenin complexes providing another potential link to 
the actin cytoskeleton (Kizhatil 2007).  
Moreover, the interaction of other transmembrane receptors has been shown to affect 
cadherin junctions. The interaction of cadherin with γ-secretase, a large 
transmembrane proteolytic enzyme, excludes cadherin molecules from junction 
assembly. A complex consisting of E-cadherin and γ-secretase is mostly present 
within the extrajunctional lateral surface of epithelial cells (Kiss 2008). Another 
transmembrane protein which has been studied extensively is nectin. Nectin is a cell-
cell adhesion molecule which can form adhesion clusters in the absence of cadherins. 
When cadherin is present, nectin colocalizes with cadherin molecules. Although this 
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interaction is not necessary for formation of individual junctions, several studies 
showed disruption of this interaction can affect cadherin junction organization 
(Takahashi 1999, Takai 2008). 
 
1.2.5. Cadherin clusters to mature junctions. 
 
Linear arrays of Cis and trans interacting E-cadherin molecules are the basis of 
clustering of E-cadherin molecules at cell-cell junctions. Tailless mutant cadherin 
molecules are still able to form these clusters (Troyanovsky 2006, Hong 2010). Upon 
formation of cell-cell contacts, cadherin molecules cluster at contact sites and the 
newly formed puncta junctions spread laterally to form mature linear junctions 
(Adams 1998, Vaezi 2002). In cell culture, the initial junction contact is established 
by lamellipodia of two adjacent cells (in MDCK cells McNeill 1993, Adams 1998-2) 
or the initial contact is made by crosssing filopodia that form transient point contacts, 
which then zipper into a continuous mature junction (in mouse keratinocytes, 
Vasioukhin 2001).  Also, catenin interactions are required for formation of mature 
junctions (Yap 1998-1). The catenin bindings are also responsible for regulation of 
actin cytoskeleton. When junctions start to expand laterally from initial contact point 
of two lamellipodia, the branched organization of actin cytoskeleton in the 
lamellipodia reorganizes to bundles of actin fibers in mature junctions. Formation of 
acto-myosin contractility is necessary for organization of actin cytoskeleton and 
maturation of junctions (Cavey 2008, Vasioukhin 2000). 
 
1.2.6. Adherens junctions continuously exchange cadherins.  
 
Cadherin-mediated adherens junctions are not static structures. During development 
or wound healing cells require to dissociate from each other, to migrate or to form 
new junctions and dynamic structure of the junctions enables the cell to remodel 
adhesions in respond cell signalling. They are constantly remodelled to be able to 
respond to developmental growth, cell renewal, cell migration and wound healing.  
FRAP (fluorescence recovery after photobleaching) analysis of dynamics of 
fluorescent tagged cadherin molecules showed that junctions continuously exchange 
cadherins (E-cadherins FRAP experiment are explained in detail in section 1.4). It is 
commonly assumed the recovery of bleached molecules is duo to association and 
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dissociation of extrajunctional cadherin molecules from junctional complexes 
(Kusumi 1999, Serrels 2009). Some experiments show that dissociation of cadherins 
from junctions is an active process and ATP depletion decreases mobile cadherins at 
junctions (Troyanovsky 2006, Hong 2010). However, it is not clear that what the 
active mechanisms that remove cadherins from membranes are. One possible 
mechanism is that catenin interactions induce conformational changes needed for 
dissociation of cadherins. Also, endocytosis plays a role in physically removing 
cadherin from the membrane.   
 
1.2.6.1. Endocytosis 
 
Endocytosis is one of the mechanisms that direct remodelling of adherens junctions. 
It has been shown that regulation of E-cadherins endocytosis by signalling pathways 
during development, wound healing or cancer metastasis controls assembly, 
disassembly and stabilization of adherens junctions. (Gumbiner, 2000). Inhibition of 
clathrin mediated endocytosis (by 0.4 M sucrose in A431 cells (Troyanovsky et al. 
2006; Hong et al. 2010) or by dynasore or MiTMAB, in MDCK cells (de Beco 
2009)) is shown to stabilise cadherin at junctions  
However, the process that unlocks cadherin and removes it from the junctions is 
more complex. For example, point mutations of cadherin endocytic motifs to inhibit 
endocytosis do not stop the release of cadherin from junctions in A431 cells (Hong 
2010). Or the same inhibitors, dynasore and MiTMAB that blocked cadherin 
junctional turnover in MDCK cells produce little effect in MCF7 cells (de Beco 
2009). 
 
1.3. E-cadherin dynamics as marker for metastasis 
 
1.3.1. E-cadherin dynamics are related to cell migration. 
 
As mentioned before, de-regulation of E-cadherin junctions is a critical step during 
metastasis. Disruption of cell-cell adhesions happens not just through down-
regulation of E-cadherin levels, but also through mis-regulation of its dynamics and 
interaction with other proteins (Gumbiner 2000). Many forms of metastatic cancer 
retain E-cadherin expression (Gaida 2012), and recent evidence supports the 
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hypothesis that mis-regulation of E-cadherin dynamics can also drive metastasis 
(Serrels 2009). 
Consequently, alteration in E-cadherin dynamics could serve as an early molecular 
biomarker of metastasis. Serrels et al used photo-bleaching and photo-activation to 
quantify GFP-E-cadherin dynamics in vitro and in vivo. They showed that E-
cadherin is mobilized in cell-cell junctions between migrating cells. Their in vitro 
experiments showed that E-cadherin mobility in cell-cell junctions is related to cell 
migration. Moreover, they measured E-cadherin dynamics in vivo in xenograft 
tumours and their data showed E-cadherin has significantly different dynamics in 
cells in the tumour 3D environment compared to cells in cell culture (Serrels 2009). 
 
1.3.2. In vivo imaging is critical for investigating metastasis. 
 
Metastasis is greatly affected by the cancer cell local micro-environment (niche) and 
its interaction with the extracellular matrix (ECM). Cancer de-regulates biochemical 
and biomechanical properties of the tumour ECM. For example, the tumour ECM 
changes stiffness which affects the interaction of cells with ECM and affect cell 
invasion (Pathak 2013). Moreover, the tumour micro-environment and interaction of 
tumour associated macrophages (TAMs) affects cell invasion. Therefore, cell 
migration and invasion show different patterns in vivo compared to in vitro 
situations. For example, cancer cells move more quickly in vivo than in vitro, by 
tracking along ECM fibres, and this could affect to predicting metastatic properties 
of cells (Condeelis 2003). In vivo studies are therefore required to completely 
understand the metastatic process.  
The use of new in vivo imaging techniques has greatly enhanced our understanding 
of how this process occurs (reviewed in Nobis 2013). Initial in vivo imaging studies 
used cytoplasmic fluorescent proteins (for example GFP) to label whole cell and then 
the migration of these labelled cells was observed in vivo (Naumov 1999, Ito 2001). 
Tracking of fluorescent labelled cell migration in tissues revealed several aspects of 
cancer cell metastasis such as “cell morphology changes, track cell movement and 
velocity, or gauge vector-based persistence over time or interactions with ECM” 
(Nobis 2013). These fluorescently-labelled cells were also used to study circulating 
tumour cells to analyse later stages of metastasis in colonization, extravasation or 
tumour dormancy. (Condeelis 2003) 
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Although it is important to understand cellular dynamics, we also want to understand 
protein dynamics within cells. One approach which has been widely used in the 
study of cell adhesion is a family of techniques known as FRAP including 
fluorescent recovery after photo-bleaching (FRAP) (this methods is explained in 
section 1.4.1), photo-activation or photo-switching.  
Moreover, these techniques can be applied to study real-time disease in an in vivo 
setting (Timpson 2011, Lippincott-Schwartz 2003). The functional and physiological 
properties of surrounding tissue micro-environment significantly affect protein 
kinetics. Consequently, imaging disease processes in an in vivo setting is therefore 
critical to accurately understand disease aetiology and develop effective treatment 
strategies. 
 
1.4. Studying dynamics of E-cadherin mediated cell-cell adhesion by 
FRAP 
 
Here, I first introduce the FRAP technique and basis of data analysis, then explain in 
more detail FRAP of GFP-E-cadherin. 
 
1.4.1. Fluorescence Recovery After Photobleaching: FRAP 
 
Fluorescence Recovery After Photobleaching (FRAP) is commonly employed to 
study protein mobility in live cells. Initially this technique was used to measure the 
diffusion rate of lipophilic or hydrophilic fluorophores, like fluorescein, coupled to 
proteins and lipids especially in cellular membranes (for example Axelrod 1976). 
With the development of fluorescent protein technology and advanced confocal 
microscopy, FRAP has become widely used to study protein mobility in living cells. 
Green fluorescent protein (GFP) can be attached to virtually any protein of interest. 
GFP protein chimaeras provided excellent tools to understand the dynamics of many 
cellular proteins. FRAP can be used to quantify the mobility of proteins in the 
cytoplasm, nucleus, organelle lumens and membranes of living cells.  In addition to 
the study of mobility and diffusion rates, FRAP has also been extensively utilized to 
address protein interactions (Reits 2001, Carrero 2003, Kimura 2004).  
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1.4.2. How FRAP is performed? 
 
FRAP involves irreversibly bleaching fluorophores in a small region of a cell, then 
monitoring the recovery of fluorescence molecules into the bleached region as 
surrounding non-bleached molecules diffuse into bleached region over time while 
bleached molecules move out of region (Figure 1.10). FRAP analysis can be used to 
estimate kinetic parameters of a protein, including diffusion rate, mobile fraction, or 
binding/ dissociation rate from other proteins (Reits 2001, Sprague 2005).  
Developing the FRAP technique on the laser-scanning confocal microscope has 
made this technique widely available. Confocal microscope obtain the image by 
scanning a focused laser beam across the specimen, then the emitted fluorescence is 
collected through a pinhole in front of light detector. The same laser beam in higher 
power can be utilized to irreversibly bleach the fluorescent molecules in the region of 
interest (ROI) (Lippincott 2003). Accurate analysis of FRAP data requires that the 
bleach event is much shorter than the recovery time, preferably as short as possible. 
In analysis of FRAP data the duration of the bleach time is assumed to be zero. 
However, in practice, it is satisfactory that bleach time is much smaller than the 
recovery time. 
Moreover, the accurate quantification of the immobile fraction requires that the 
recovery must be monitored until a recovery plateau is achieved. 
 
 
1.4.3. Analysis of FRAP data: Quantifying recovery curve by T1/2 and Fi 
 
FRAP recovery curves can provide information about the mobility of a fluorescent 
protein in living cells. Two values are derived from a FRAP recovery curve: half time 
of recovery (T1/2) and immobile fraction (Fi%) (Figure 1.10. B).   
(1) The “half time of recovery” (T1/2) is the time it takes for fluorescence intensity 
to return to half of its recovered value. The rate of fluorescence recovery provides a 
measure of how quickly fluorescent molecules move in and out of the bleached 
region. If motion is not due to active transport or directional flow, then this 
‘mobility’ is determined, in part, by the rates of diffusion and transport for the 
fluorescent molecule through the cell membrane. Mobility can also be influenced by 
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binding interactions, which detain molecules that would otherwise diffuse freely 
(Reits 2001).  
(2) The immobile fraction (Fi%) refers to the unrecovered fraction of fluorescence 
intensity in a FRAP recovery curve. The immobile fraction can be determined by 
comparing the fluorescence in the bleached region after full recovery (F∞) with the 
fluorescence before bleaching (Ft0) and just after bleaching (FB). The mobile fraction 
Fi is defined as:   Fi% = (F∞-FB)/(Fi-Ft0)×100 
The rate of mobility of molecules could be affected by rate of association and 
dissociation of transient binding of fluorescently labelled proteins with other 
molecules or membranes. Membrane barriers and micro domains in the membrane 
can also affect the mobile fraction. These discontinuities can prevent, or temporarily 
restrict, the free diffusion of membrane molecules. 
 
A) 
 
 
B) 
 
Figure 1.10. Schematic diagram of FRAP curve. (A) FRAP involves bleaching a small region of a 
cell with high laser power, then monitoring recovery of fluorescence molecules over time. (B) Two 
values are derived from a FRAP recovery curve. The “half time of recovery” (T1/2) is the time it 
takes for half of the affected molecules to recover. The immobile fraction (Fi%) refers to the 
unrecovered fraction of fluorescence intensity in a FRAP recovery curve . 
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1.4.4. Analysing FRAP recovery of free molecules without binding 
 
Recovery which occurs in the absence of binding/dissociation, active transport or 
unidirectional flow, is due to Brownian motion. In this case, the mobility can be 
expressed as the diffusion coefficient D, which is related to the half time of recovery 
T1/2. Generally the two-dimensional diffusion equation described by Axelrod et al 
(Axelrod 1976) is used to calculate D: 
 
T1/2=β2/4D 
 
Where  is defined as the radius of the focused circular laser beam and β is a 
function of the degree of bleaching. This equation assumes unrestricted two-
dimensional diffusion in a circular bleached area, with no recovery from above and 
below the focal plane. This is the case expected in the plasma membrane. 
However, diffusion can be hindered by cellular structures, such as cytoskeleton 
networks, that trap the random movements of a freely diffusing molecule. These 
‘molecular sieving’ effects, which depend on the molecular size, are more significant 
in cell membrane compared to cell cytoplasm (Edidin 1994, Saxton 1999).  
 
1.4.4.1. Transmembrane proteins do not diffuse freely in the plasma membrane. 
 
Diffusion coefficients measured for transmembrane proteins in the plasma membrane 
are generally much smaller than D (diffusion coefficient) calculated for 
transmembrane proteins in an artificial lipid bilayer. Several different factors affect 
the free diffusion of trasmembrane proteins. One is the presence of membrane 
microdomains with high viscosity such as lipid rafts. Big protein complexes also 
hinder free diffusion.  Moreover, the cytoskeleton network underneath the plasma 
membrane acts as a fence which obstructs the lateral movement of molecules 
(Kusumi, 1996). 
This process strongly affects the free diffusion of trans-membrane proteins. To 
understand the effect of molecular sieving on diffusion, more complicated models 
are required. More importantly, in the presence of hindered diffusion it is important 
to distinguish between the contribution of obstructed diffusion and the contribution 
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of protein binding to a FRAP recovery. To understand if a fluorescent molecule has 
interactions with other molecules or not (which will respectively retard its recovery),  
FRAP should be measured on an inert molecule of the same size as the GFP-fusion 
molecule. This will set the base line for free diffusion. When binding interactions are 
present, they retard FRAP recovery in relation to what would be observed for free 
diffusion of an inert molecule. 
Analyzing FRAP recovery curves is more complicated when a molecule undergoes 
binding and dissociation from intracellular structures, or exists as a monomer and 
multimeric forms. In addition, the molecule movement might not be just diffusing 
but be affected by movement driven by molecular motors or membrane tension flow 
and endocytosis. 
 
1.4.5. Analysing FRAP recovery in the presence of binding interactions 
 
If the fluorescent molecules associate\dissociate from stationary complexes during 
FRAP, the interpretation of data is more complicated. In this case the recovery curve 
is slower, recovers partially (an immobile fraction presents) or may have several 
components with different slopes (as different association\dissociation reactions have 
different rates) (Sprague 2004, Sprague 2005) 
To analyse these complicated FRAP recovery curves Kinetic modelling methods and 
computer simulations can be used. Initially biophysical parameters of the reaction 
like association\dissociation rates and diffusion constants are used to define a kinetic 
model. Then the model is simulated with a computer program to calculate different 
values to find the parameters that best fit the experimental data. Then the model can 
be tested against experimental data (Phair 2001). 
However, to analyse a FRAP recovery curve in the presence of binding, the first step 
is to determine the relevant role of diffusion and binding to the recovery curve. 
FRAP recovery is either ‘diffusion-uncoupled’ or ‘diffusion-coupled’ depending on 
whether the diffusion time can be ignored relative to association rate or not (Figure 
1.11) (reviewed in Sprague 2005).  The time required for a freely diffusing molecule 
to move across the bleached region, is diffusion time. The association rate is the rate 
of binding multiplied by the concentration of available binding sites at equilibrium. 
The next section will describe how the relative magnitude of these two parameters 
creates two distinctive FRAP recovery regimes.  
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*** *
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* 
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*
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A) Diffusion Uncoupled Recovery 
 
B) Diffusion Coupled Recovery 
 
  
Figure 1.11. Diffusion coupled and diffusion uncoupled recovery. A) Diffusion-uncoupled FRAP. 
Initially free bleached proteins rapidly diffuse out of ROI. The bound bleached proteins which were 
bound to stationary complexes remain in the ROI. The dissociation\association of molecules from 
binding sites gradually releases the bleached molecules and they rapidly leave the ROI and 
Fluorescent molecules replace them in clusters. The diffusion-uncoupled FRAP recovery curve 
consists of two separable fragments: in the first part (in red) the recovery is fast and it is due to 
diffusion and in the second part (in blue) recovery is slower and it is because of binding\unbinding of 
fluorescent proteins from binding sites. B) Diffusion-coupled FRAP. The association of free 
molecules to binding sites is faster than the time for diffusion of free bleached molecules out of ROI. 
so the bleached molecules associate with another cluster  before diffusing out of ROI. In a diffusion-
coupled FRAP curve (purple) diffusion and dissociation happens at same time, so it cannot be 
separated into distinct segments (Sprague 2005). 
*
1 
 
1.4.5.1. Diffusion-uncoupled FRAP recoveries 
 
If diffusion of fluorescent molecules in the ROI is much faster than association with 
binding sites, the recovery is diffusion uncoupled (Figure 1.11). This means that the 
recovery due to diffusion happens first, and is followed by dissociation of bleached 
molecules and binding of unbleached molecules. Consequently, the recovery curve 
can be separated in two phases. The first part is due to diffusion of free unbleached 
 
*** *
*** 
* 
  * * * *2 
*** * * 
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molecules into the ROI and happens over timescale of few seconds. However, 
exchange at stationary binding sites is much slower. Therefore most of recovery 
curve reflects dissociation/binding rates rather than diffusion rates. So, longer 
recovery rate indicate that binding interactions are stronger, and in this case the 
recovery rate can be used to determine binding strength. Moreover, if the recovery 
curve can be separated into components with different slopes, it indicates that the 
fluorescent molecules engage in different binding reactions. The location of each 
shoulder in curve gives an estimate of fraction of molecules in each binding reaction 
(Phair 2004). 
In many studies, particularly in the case of a single binding reaction, the FRAP 
recovery curve has been used to calculate kon and koff of binding reactions.  The 
recovery is modelled by a single component exponential curve (Sprague 2004) 
F (t)= 1-Ceq exp(-koff t) 
Once this equation has been fit to a FRAP recovery curve Koff can be calculated. In 
this equation Ceq is the equilibrium concentration of the bound state. In the case that 
concentration of binding sites can be assumed constant, Ceq can be used to calculate 
kon of the binding reaction (Sprague 2004).  
 
1.4.5.2. Diffusion-coupled FRAP recoveries 
 
If the diffusion time for fluorescent molecules across the ROI is longer than the time 
needed to form new binding, the FRAP recovery is said to be diffusion coupled. In 
this case, the fluorescent molecules may bind and unbind several times as they move 
across the bleached region. Since diffusion and binding are mixed through recovery, 
the FRAP curve cannot be separated into a diffusive phase and a binding phase.   
As a result, to be able to calculate binding parameters from FRAP recovery, it is 
important to study diffusion baseline by looking at an inert free diffusing molecule of 
the same size. Because this baseline diffusive behaviour must be included, the 
equations describing diffusion-coupled FRAP are, in most cases, more complex than 
those used to describe diffusion-uncoupled FRAP. 
In addition, as diffusion is not separated from binding and continues during recovery, 
it affects recovery more significantly. So, analysis of binding reactions in diffusion-
coupled FRAP recoveries is more complicated and requires a number of assumptions 
to ensure proper analysing of diffusion, which are not significant in diffusion 
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uncoupled recoveries. For example, the bleach time should be very fast in relation to 
the diffusion rate, or the binding site should have a homogeneous distribution that is 
assumed to be immobile during the fluorescence recovery (Sprague 2005). 
 
1.4.5.3. Distinguishing diffusion-coupled from diffusion uncoupled FRAP 
 
In order to be able to estimate the biophysical characteristic of binding reactions of 
fluorescent molecules from FRAP recovery curves, it is necessary to distinguish 
between diffusion coupled and uncoupled recovery first. One approach is to measure 
fluorescent intensities in different sub-regions of bleached ROI. In diffusion 
uncoupled recovery, the diffusion of free molecules in the ROI is much faster than 
dissociation\association from binding sites.  Therefore, if the recovery is diffusion 
uncoupled different regions of the bleached ROI will have similar fluorescent 
intensity (Phair 2004). Another approach is to perform FRAP using different sizes of 
bleached region. In the diffusion-uncoupled mode, there is almost no change in the 
recovery rate with bleach spot size because diffusion happens approximately 
instantly and there would be a negligible difference by changing bleach size. 
However, in the diffusion-coupled mode, diffusion and binding/dissociation happen 
simultaneously during measured recovery phase, and there will be a detectable 
change in recovery time (Sprague 2004, reviewed in Sprague 2005).  
 
1.5. FRAP on GFP-E-cadherin molecules reveals the factors which 
influence E-cadherin mobility. 
 
Cadherin-mediated cell-cell adhesions are very dynamic structures which allow rapid 
modification of junctions in response to signalling during processes such as 
morphogenesis or wound healing. FRAP has been used to study the dynamics of 
cadherins in cell-cell adhesion.  It is generally believed that there are two populations 
of E-cadherin molecules on the membrane: the free defusing monomers and the 
molecules clustered together in junctions. And the recovery of photo-bleached 
fluorescent molecules probably indicates the exchange of cadherin molecules 
between these two populations (Kusumi 1999, Adams 1998). Previous FRAP 
experiments on VE-cadherin junctions showed that different ROI sizes recovered at 
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similar rates, suggesting that recovery is diffusion uncoupled (Nanes 2012); In other 
words, the VE-cadherin recovery rate is not limited by diffusion rate of monomers 
but instead by dissociation\association of monomers from clusters. 
It is not clear which E-cadherin interactions drive diffusible molecules into clusters. 
Photo-switching experiments on a tailless E-cadherin mutant showed that formation 
of cis and trans dimmers is enough for formation of clusters (Klingelhöfer 2002, 
Hong 2010). Disruption of either cis (by V81D/V175D mutation (Harrison 2011)) or 
trans (by W2A mutations (Klingelhöfer 2002)) dimer formation inhibits formation of 
E-cadherins clusters. In these studies a slower ( or no difference in ) recovery rate is 
reported for the tailless mutant compared to intact molecules, however, they just 
measured the initial recovery rate of fluorescent intensity in the junctions and their 
recovery curve does not measure if there is any difference in immobile fraction or 
not (Hong 2010). 
On the other hand, other photo-bleaching experiments reported that interaction with 
actin stabilizes cadherin clusters (Cavey 2008, Hong 2013). Disruption of α-catenin 
interaction with cadherin also inhibits assembly and maintenance of adherens 
junctions (Vasioukhin 2000, Pappas 2006, Kwiatkowski 2010). 
Moreover it has been reported that interaction of E-cadherin molecules with actin 
cytoskeleton cooperates with formation of cis interactions and enhances cluster 
formation (Hong 2013) 
Interaction with actin not only stabilizes spot like E-cadherin clusters on cell-cell 
junctions, it is also responsible for movement of these clusters toward apical surface 
in A431 cells (Kametani 2007, Hong 2010). 
The recovery of E-cadherin-GFP FRAP is an active process and ATP depletion 
decreases mobile cadherins at junctions (Troyanovsky 2006, Hong 2010). However, 
it is not clear what are the active mechanisms that remove cadherins from membrane. 
One of possible mechanisms is that interactions with catenins or modification of 
catenin interaction with phosphorylation of E-cadherin or catenins induce 
conformational changes needed for dissociation of cadheins. Also, there is evidence 
to suggest that endocytosis has an important role to physically remove cadherin from 
membrane. It has been shown that inhibition of clathrin mediated endocytosis 
stabilizes cadherin at junctions (Troyanovsky 2006; Hong 2010, de Beco 2009).  
Moreover, p120 regulates endocytosis of cadherins. Disruption of interaction of VE-
cadherin with p120 (by mutation in p120 binding domains) stabilizes VE-cadherin 
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junctions and inhibits induction of cell migration by vascular endothelial growth 
factor (Nanes 2012).  
Finally, E-cadherin FRAP recovery is also affected by non-specific trapping in 
membrane (Kusumi 2005). Single particle tracking (SPT) and optical tweezers (OT) 
studies on both wild-type and tailless mutant E-cadherin on dorsal surface of cells 
also showed that movement of a population of E-cadherin molecules is hindered by 
trapping in membrane corrals by the cortical actin cytoskeleton (Sako 1998). 
 
1.6. Aims: 
 
The first aim of this thesis is to understand E-cadherin cell-cell adhesion dynamics 
using the FRAP technique. I want to understand how E-cadherin interactions and 
organization of cadherin molecules in junctions affects FRAP parameter Fi% and 
T1/2. Although FRAP has been used extensively for investigating E-cadherin 
dynamics, it’s not clear how interpretation of FRAP results can informs us about 
molecular interactions of cadherin molecule. So, I want to use this data to have a 
better understanding of organization of cadherin molecules in adherent junctions. 
In second part of this thesis, I will use the information from first section to 
understand how FRAP on GFP-E-cadherin molecules can be used as a method to 
evaluate the metastatic capability of tumour cells in vivo in a mouse pancreatic 
cancer model. 
Then I will use FRAP to assess how mutant p53 affects E-cadherin dynamics, in 
order to understand how mutant 53 drives metastasis in this model.  
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2.           Materials and Methods 
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2.1. Materials 
 
2.1.1 General reagents 
 
The sources of all chemicals, reagents and enzymes mentioned in this work are 
listed. 
 
Table 2.1. Chemicals and reagents. 
Material: Source: 
35 mm glass-bottomed dishes MatTek 
6×DNA loading dye Fermentas 
10X T4 DNA Ligase Buffer Invitrogen 
12 well transwell supports costar 
Agar Beatson Central Services 
Agarose Sigma-Aldrich 
Ampicillin Sigma-Aldrich 
Antibody (horse anti-mouse IgG) HRP-linked NEB (Cell Signaling) 
Anti-E-cadherin antibody BD Transduction Laboratories 
ATP (adenosine-5’-triphosphate) Roche 
BglII Invitrogen 
Bromophenol blue Sigma-Aldrich 
BSA (bovine serum albumin) Sigma-Aldrich 
BS3 Thermo Scientific 
Cell Line Nucleofactor® Kit V                          Amaxa 
CDM glass bottom dish Beatson Molecular Services 
cOmplete Protease inhibitor cocktail Roche 
DAPI (4’,6-diamidino-2-phenylindole) Sigma-Aldrich 
Dispase II Sigma 
DMEM (Dulbecco's modified Eagle medium) Life Technologies 
DMSO (dimethyl sulfoxide) Sigma-Aldrich 
DNase Roche 
dNTPs  Invitrogen 
DMEM Gibco 
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EDTA Sigma-Aldrich 
Ethanol Thermo Fisher Scientific 
Ethidiumbromide solution Sigma 
Fetal Bovine Serum Healthcare 
G148 Sigma 
Glutamine Life technologies 
Glycerol Sigma-Aldrich 
HBS buffer Biacore 
HindIII enzyme Invitrogen 
Kanamycin Sigma-Aldrich 
L-Glutamine Gibco 
Neomycin Sigma 
Nitrocellulose membranes Perkin Elmer 
Not I enzyme NEB 
NuPage Tris-acetate gradient gels Life Technologies 
NuPAGE Tris acetate running buffer (20x) Life Technologies 
O’GeneRuler 1kb  Fermentas 
Paraformaldehyde 16% Solution Electron microscopy sciences 
Pen-Strep Gibco 
PonceauS Sigma-Aldrich 
Protease inhibitor cocktail Roche 
Puromycin Sigma-Aldrich 
QIAquick®Gel Extraction Kit Qiagen 
QIAprep® Spin Miniprep Kit Qiagen 
QIAquick® PCR Purification Kit                       Qiagen 
Quick Change® Site-Directed Mutagenesis 
Kit   
Stratagene 
Spectra multicolor high range protein ladder Thermo Fisher Scientific 
T4 DNA Ligase Invitrogen 
Tris-HCL Sigma-Aldrich 
TritonX-100 Sigma-Aldrich 
Trypsin 2.5% Life technologies 
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Tween-20 Sigma-Aldrich 
β-Mercaptoethanol Sigma-Aldrich 
Xho enzyme Roche 
Xba enzyme Roche 
 
 
2.1.2 Solutions and buffers 
 
The buffers and solutions used in this study are listed with the composition of 
buffers. 
 
Table 2.2. Buffers composition. 
Buffer Composition 
Culture medium: 
 
450ml DMEM (Gibco) 
50ml Foetal Bovine Serum (PAA laboratories) 
5ml of 200mM L-Glutamine solution 
(Invitogen) 
5ml of PenStrep (10000U/ml) (Gibco) 
Tris-Buffered Saline (TBS) 
 
25mM Tris-HCl pH 7.4 
137mM NaCl 
5mM KCL 
Phosphate Buffered Saline (PBS) 
 
170mM NaCl 
3.3mM KCl 
1.8mM Na2HPO4 
10.6mM KH2PO4 
pH 7.4 
Lysogeny broth (LB) 
 
1% Bacto-tryptone 
86mM NaCl 
0.5% yeast extract 
1.5% agar 
Tris-EDTA (TE) 
 
10mM Tris-HCl pH 8 
1mM EDTA 
SDS-PAGE (polyacrylamide gel 125mM Tris pH 6.8 
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electrophoresis) sample buffer 4% SDS 
10% β-mercaptoethanol 
15% glycerol 
0.01% bromophenol blue 
SDS-PAGE running buffer 0.1% SDS 
192mM glycine 
25mM Tris-HCl pH 8.3 
Electroblotting buffer 
 
192mM glycine 
25mM Tris 
20% methanol 
Laemmli sample buffer 62.5 mM Tris-HCl pH6.8,  
10% Glycerol, 2% SDS,  
5% Mercaptoethanol,  
0.0025% Bromphenol Blue 
Blocking solution (Western 
blotting)  
5% milk powder in TBS-T 
 
Blocking solution 
(immunostaining) 
1% BSA in PBS 
 
Fixing solution (cells or tissue) 4% PFA in PBS 
Cross-linking buffer 
(HEPES/PBS) 
 
20 mM HEPES, pH7.6, 
1 mM CaCl2,  
150 mM NaCl 
Quenching buffer (cross-linking) 20 mM Tris-HCl, pH7.5 
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2.2 Methods 
 
2.2.1. Plasmids 
 
The pAcGFP1-F plasmid (referred here as the GFP-f plasmid) was obtained from 
Clontech. This plasmid encodes a fusion protein consisting of a 20-amino-acid 
farnesylation signal from c-HRas fused to the C-terminus of AcGFP1. Post-
translation of this farnesylation signal targets AcGFP1-F to the inner leaflet of the 
plasma membrane. pAcGFP1-F is designed for use as a plasma membrane marker, as 
well as a cotransfection marker, because it remains attached to the plasma membrane 
and it can be detected by fluorescence microscopy. Here, GFP-f FRAP recovery time 
is used for analysis of diffusion rate in plasma membrane. 
 
 
Figure 2.1. GFP-F (pAcGFP1-F) plasmid map. 
 
The GFP-E-cadherin plasmid was a gift from Jennifer Stow (Serrels 2009). As this 
plasmid map showed in figure 2.1, the EGFP sequence is fused to C-terminal of E-
cadherin. So, the GFP protein is fused to the cytoplasmic domain of E-cadherin. 
Moreover, the neomycin resistance gene allows stably transfected eukaryotic cells to 
be selected using G418. 
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pcDNA3-Ecad-GFP seq
8846 bp
E-cadherin
Ecad-GFP
SV40 enhancer
EGFP
NeomycinR
AmpicillinR CMV promoter
SV40 promoter
T7 promoter
f1 ori
SV40 ori
BamHI (1746)
HindIII (890)
Asp718I (2394)
BglII (13)
EagI (5586)
EcoRV (898)
KpnI (2398)
NdeI (485)
SpeI (250)
XbaI (4384)
ApaLI (7345)
ApaLI (8591)
SmaI (3262)
SmaI (5493)
XmaI (3260)
XmaI (5491)
SnaBI (591)
SnaBI (2036)
AvaI (2648)
AvaI (3260)
AvaI (5491)
EcoRI (902)
EcoRI (1798)
EcoRI (3164)
EheI (986)
EheI (1147)
EheI (5681)
KasI (984)
KasI (1145)
KasI (5679)
Nco I (611)
Nco I (1016)
Nco I (5377)
Nco I (6112)
PstI (3335)
PstI (3811)
PstI (3872)
PstI (4196)
SacI (819)
SacI (1949)
SacI (3556)
SacI (4426)
SalI (33)SalI (8845)
SalI (1202)
SalI (6657)
Pvu II (1502)
Pvu II (2098)
Pvu II (3330)
Pvu II (4689)
Pvu II (5786)
Pvu II (6855)
AflI (2016)
AflI (2930)
AflI (3306)
AflI (4320)
AflI (6196)
AflI (8284)
AflI (8062)
 
Figure 2.2. GFP-E-cadherin plasmid map. 
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2.2.2. Mutant GFP-E-cadheirn plasmids 
 
All mutant E-cadherin-GFP plasmid used in this study are cloned from the wild type 
GFP-E-cadherin plasmid described above. Site directed mutagenesis was used for 
cloning each mutants.  
For disrupting the trans interaction the W2 residue (Laur 2002) was mutated by 
Quick Change Lightning site directed mutagenesis kit (Agilent technologies) 
according to manufacturer’s protocol.  
Primers for W2A mutation: 
Sense primer: 5'-CAG AAG ACA GAA GAG AGA CGC GGT TAT TCC TCC 
CAT CAG C-3' 
Antisense primer: 5'-GCT GAT GGG AGG AAT AAC CGC GTC TCT CTT CTG 
TCT TCT G-3' 
For disrupting the cis interaction V81D, V175D mutations were used as previously 
reported in Harrison et al. (Harrison 2011).  
Primers for human sequence mutation:V81D,V175D mutation: 
T402A antisense primer: 5'-CCA GCC CAG TGG TGT CCA CAC TGA TGA CT-3' 
T120A G121C antisense primer: 5'-GCA TTC CCG TTG GAT GAG TCA GCG 
TGA GAG AAG AGA-3' 
T402A sense primer:  5'-AGT CAT CAG TGT GGA CAC CAC TGG GCT GG-3' 
T120A G121C sense primer : 5'-TCT CTT CTC TCA CGC TGA CTC ATC CAA 
CGG GAA TGC-3' 
For deletion of the cytoplasmic domain (∆cyt mutant) the Quick Change Lightning 
site directed mutagenesis kit was used to introduce two new NotI restriction sites on 
each side of cytoplasmic domain. Then NotI restriction enzyme (NEB) was used to 
cut out the residues 580 to 726.  
For Deletion of the EC1 domain, two XhoI (Roche) sites were introduced in the same 
way to excise the region encoding residues 2 to 109.  
In the following section the cloning method used for making these mutants is 
explained in more detail. 
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2.2.2.1. Mutagenesis PCR reaction with quick change lightning kit 
        
Total reaction volume 50μl 
DNA Template (0.1μg/μl) 1 μl 
10x Buffer 5 μl 
dNTP mix 1 μl 
Quick solution 1.5μl 
Primer Sense (0.1μg/μl) 5 μl  
Primer Antisense (0.1μg/μl) 5 μl  
Polymerase 1 μl  
H2O  ad 50 μl 
 
PCR program: 
1x  95°C 2 min 
18x 95°C 20 sec   
            60°C 10 sec 
            68°C 30 sec per kb plasmid DNA 
1x  68°C 5 min 
 
The PCR mix was then treated with DpnI restriction enzyme to remove the template 
DNA. 
 
2.2.2.2. Restriction digest reaction 
 
Treatment 150 
minutes at 37°C 
50μl 
(Total volume) 
DNA /PCR Prod. 5 μl (~1μg) 
10 x RE-Buffer 5 μl (~1μg) 
R-Enzyme 1 1 μl (10-20U) 
R-Enzyme 2 1 μl  (10-20U) 
H2O bid. (sterile) ad 50 μl 
 
2.2.2.3. Agarose gel electrophoresis 
 
Agarose gel electrophoresis was used for the analysis of DNA from PCR and also for 
separation of band after restriction digests. 1% agarose gels in 1×TAE buffer was 
boiled in the microwave, allowed to cool and poured into the casting tray. The DNA 
was mixed with 6×DNA loading dye (Fermentas) and loaded into the gel. 
O’GeneRuler 1kb (Fermentas) was used as size marker. The gel was run for 30 min 
at 100V and after the electrophoresis the gel was incubated in EtBr bath for 15 Min. 
the stained bands were visualized by the Syngene Genius Bio imaging system. 
 
 
Chapter 2: Materials and Methods                                                                                              62 
2.2.2.4. Gel extraction  
 
After cutting the band from the gel, QIAquick gel extraction kit (Qiagen) was used to 
extract each plasmid segment from the gel.  
 
2.2.2.5. Ligation reaction 
 
Treatment 150 min at Room Temp. 10μl 
(Total volume) 
10x Ligase buffer 1 μl 
vector DNA 1 μl 
insert DNA 7 μl 
ATP (25mM) 0.4 μl 
Ligase enzyme 0.6 μl 
 
 
2.2.2.6. Transformation of E.coli and DNA preparation 
 
For DNA preparation of mutant plasmid DNA E. Coli DH5α competent cells were 
thawed on ice. Then 0.5 μg of DNA plasmid (or 5 μl of ligation reaction) was added 
to 50 μl of bacteria and incubated on ice for 20 min. For heat shocking the bacteria 
were heated at 42°C for 45 seconds then immediately cooled on ice. Then the 
bacteria were incubated in 0.5 ml LB for 1 hour at 37°C with shaking at 450rpm. 
Cells were spread on agar plates with ampicillin or kanamycin and grown upside 
down at 37°C overnight. The next day the colonies were inoculated in 3 ml LB with 
appropriate antibiotic and grown overnight at 37°C whilst shaking. Then QIAprep 
spin kit (Qiagen) was used to extract DNA from culture according to manufacturer’s 
protocol. 
 
2.2.2.7. DNA sequencing 
 
DNA sequencing was carried out by the Molecular Technology Service at the 
Beatson Institute using the BigDye® Terminator v3.1 Cycle Sequencing Kit 
(Applied Biosystems). 
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2.2.3. Cell culture methods 
 
2.2.3.1. L cells 
 
L cells (ATCC® CRL-2648) are mouse fibroblast cells which do not express E-
cadherin molecule endogenously. The cells were maintained in DMEM 
supplemented with 10 % FCS/2 mM L-glutamine / 1% penicillin/streptomycin 
solution (Gibco).  
 
2.2.3.2. PDAC cells 
 
PDACR172H cells are primary mouse cells with KRAS mutation and p53R172H 
mutation. These cells are derived from pancreatic tumors harvested from Pdx1-Cre, 
LSL-KRASG12D/+, LSL-Trp53R172H/+ mice (Morton 2010).  I have also used PDACfl 
cells, mouse tumour cells isolated from Pdx1-Cre, LSL-KRASG12D/+, Trp53LoxP/+ 
mice (Morton 2010).   
PDACflR175H and PDACflvector cells are PDACfl cells which were transfected 
stably with p53R175H or empty vector respectively. In FRAP experiments reported in 
this thesis all this cell lines are stably transfected with GFP-E-cadherin plasmid. 
PDAC cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) 
supplemented with 10% FBS, 2 mM L-glutamine (Invitrogen) and 1 % 
penicillin/streptomycin solution. 
 
2.2.3.3. Passaging cells 
 
After the cells had got to confluency an aliquot of the cells was passaged to a new 
flask to continue cells growth. For passaging the cells in T75 flasks (both PDAC and 
L cells), the media was first aspirated from the cells and they were washed with 10 
ml of 37°C PBS. Then 1 ml of 1% trypsin in PBS was added to the flask. The flask 
was kept at the 37°C incubator until the cells had detached form the plate. Once 
detached, 10 ml of fresh pre-warmed cell culture media was added to the cells to 
inactivate the trypsin. An aliquot of this cell suspension was then added to a new 
flask containing fresh media. Then the cells were kept in incubator and allowed to 
adhere again and start to grow.  
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2.2.3.4. Counting the cells  
 
Cells were counted using the automated Casy® Cell Counter and Analyser System 
(Innovatis). The appropriate dilution of cells following trypsinisation was 
automatically counted by the machine set to exclude debris from the calculation.  
 
2.2.3.5. Cryogenetic preservation of cell lines 
 
For long term storage of cells, cell culture flasks which were not yet reach to 70% 
confluency and they were still in the log phase of growth, were trypsinised and then 
re-suspended in complete media+10% DMSO (Sigma-Aldrich) and divided into 1 ml 
aliquots in 1.5 ml cryovials (Thermo-scientific). Initial freezing was carried out in a 
Mr Frosty container (Fisher Scientific) (containing isopropanol) at -70°C to give a 
cooling rate of 1°C /minute. Once a temperature of -70°C was reached the cells were 
transferred to storage in liquid nitrogen tanks at -180°C.  
To grow cell from frozen vials, they were quickly warmed by submerging in a 37°C 
water bath. Then the thawed cells were added to pre-warmed culture media and let to 
adhere overnight. The next day the cells were passaged (or the media was changed if 
the cells were not confluent). 
 
2.2.3.6. Transfection 
 
Both cell lines were transfected with either wild-type or mutant GFP-E-cadherin 
plasmid using the Amaxa cell line nucleofector Kit V (Cell Line Nucleofactor® Kit 
V Lonza) according to manufacturer’s protocol. Prior to transfection the plasmid was 
linearized with transfected cells were selected by G418 sulphate at 0.7 mg/ml 
(Formedium) and stable pools generated. 
 
2.2.3.7. Cell sorting 
 
After selection of stably transfected cells by G148, cells were harvested with trypsin-
EDTA, and then washed in PBS three times to obtain a single cell suspension. The 
cells were suspended in 1% trypsin in PBS. Then cells were sorted by FACS into two 
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populations of low and high GFP expressing cells using a FACS Vantage Cell Sorter 
(BD Biosciences). The sorted cells were kept cultured in G418 solution. 
 
2.2.3.8. Organotypic assays 
 
Organotypic assays were done as described previously (Tipmson 2011-2). Initially, 
the 3D collage matrixes with fibroblast cells were made. ~7.5×104/ml primary human 
fibroblasts were mixed with rat tail tendon collagen to polymerize the gel at 35 mm 
petri dishes. Rat tail tendon collagen solution was prepared by the extraction of 
tendons with 0.5 M acetic acid to a concentration of ~2 mg/ml. the polymerized gels 
were detached from dish and allow to contract for approximately 6 days in complete 
media until the fibroblasts had contracted the matrix to ~1.5 cm diameter. The media 
on the matrixes was changed every 2 days. 
Next, PDAC cells were seeded on top of these matrixes and allowed to invade. 4 × 
104 cells were plated on the matrix and allowed to grow to confluence for 5 days in 
complete media. The matrix was then mounted on a metal grid and raised to the 
air/liquid interface resulting in the matrix being in contact to media just from below. 
the culture media that was changed every 2 days. After 8–12 days, the cultures were 
fixed using 4% paraformaldehyde and processed by standard methods for staining 
with Hematoxylin & Eosin (H&E), which marks the nucleus, cytoplasm and 
connective tissue in sections, was carried out by Histology Service of Beatson 
Institute. 
 
2.2.3.9. Cross linking 
 
PDAC cells were seeded confluently in 35 mm glass-bottomed dishes (MatTek), then 
cells were washed three times with HEPES/PBS buffer (20 mM HEPES, pH 7.6, 1 
mM CaCl2, 150 mM NaCl). Then the buffer aspirated and 100 µM BS3 cross linker 
(Thermo Scientific) freshly solved in water was added to the cells for 10 or 20 
minutes. For quenching the cross linker the cells were incubated for 10 minutes in 20 
mM Tris-HCl, pH 7.5. Cells were imaged for FRAP in cell culture media for 2 hours, 
and then the cells were lysed for western blotting. 
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2.2.3.10. SDS-PAGE electrophoresis and western blotting 
 
The cells were scraped and lysed in Laemmli sample buffer (62.5 mM Tris-HCl 
pH6.8, 10% Glycerol, 2% SDS, 5% Mercaptoethanol, 0.0025% Bromphenol Blue). 
Next the cell lysate was sonicated 5×15 seconds. Then the cell lysates in sample 
buffer were heated to 95ºC for 5 minutes. After a short spin, samples were loaded on 
appropriate SDS-polyacrylamide gels (3-8% NuPage Tris-acetate gradient gels, Life 
Technologies). Electrophoresis was performed in SDS-PAGE buffer at 180V for 90 
minutes using Power Pac Basic (Biorad) 
By Western blotting protein was transferred to nitrocellulose membrane 
(Nitrocellulose Protran BA 83 0.2μm, Perkin Elmer) at 250 mA for an hour. Staining 
with PonceauS was used to check protein load (0.1 % (w/v) in 5% acetic acid 
solution Sigma-Aldrich). After imaging the protein staining the membrane was 
washed with water to remove the PonceauS solution. Then the membranes were 
blocked in 5% milk powder in TBS-T for one hour and incubated with primary 
antibodies over night at 4ºC. Anti-E-cadherin antibody (BD Transduction 
Laboratories™, Cat. No.610182) was used for western blots.  
Membranes were then washed three times in TBS-T and incubated for 1 hour with 
secondary antibodies (horse anti-mouse IgG HRP-linked at 1:10,000 dilutions). 
Proteins were visualized by Pierce ECL reagent, using Fuji X-Ray Film Super RX on 
an AGFA classic E.O.S film processor. 
 
2.2.3.11. Cell adhesion measurement 
 
2.2.3.11.1. TEER measurement 
 
Before measuring TEER, the 12 well transwell supports (costar) were treated for 30 
min with DMEM. Then 3x105 PDAC cells (or 6x105 in L cells case) were seeded 
overnight on transwells. TEER was measured using an EVOM2 epithelial 
voltohmmeter with an STX2 electrode (World Precision Instruments). The results 
were reported as percentage of control cell resistance. 
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2.2.3.11.2. Dispase 
 
For Dispase assays, a confluent cell monolayer in a 6 well dish was treated with 6 
mg/ml dispaseII (Sigma) in PBS, the detached monolayer was broken up by pipetting 
up and down, and single cells were counted after passing through a cell strainer (BD 
Falcon, 40 um nylon) using a hemocytometer. The single cell number was reported 
as percentage of the total cell number which was counted after treating a control well 
with trypsin. 
 
2.2.4. In vivo models 
 
The PDAC mice models which used for in vivo experiments or for establishing cell 
lines were already described (Morton 2010). Pdx1-Cre, LSL-KRASG12D/+, 
Trp53LoxP/+ mice have KRAS mutation and loss of p53 expression. Pdx1-Cre, LSL-
KRASG12D/+, LSL-Trp53R172H/+ mice have both KRAS and p53R172H mutation. These 
mice get more malignant tumours.  
In order to investigate E-cadherin dynamics in the context of pancreatic tumours, I 
used a mouse engineered to express E-cadherin-GFP from the Rosa26 locus under 
the control of cre-recombinase which was generated by D. Strathdee and colleagues 
in the Beatson Transgenic Production facility. This mouse crossed with mice 
expressing cre recombinase under control of PDX1 promoter which lead to 
expression of E-cadherin-GFP in the pancreas. 
 
2.2.4.1. Breeding strategy and colony maintenance 
 
All mice were bred and maintained in the Beatson Institute for Cancer Research 
animal facility and in accordance with UK Home Office guidelines and regulations. 
The experiments are done Under Project Licence Number (PPL): 60/4264. 
Experimental cohorts and breeding stocks were maintained for defined periods of 
time. The animals were checked at least two times weekly. Animals were culled 
according to Schedule 1 techniques as addressed in our project licence. Mouse ear 
notching and general maintenance (food, water and housing) was carried out by the 
Biological Services Unit at the Beatson Institute. 
 
Chapter 2: Materials and Methods                                                                                              68 
2.2.4.2. Animal genotyping 
 
All animals were ear clipped at weaning and samples sent to Transnetyx for 
genotyping (Transnetyx, Cordova, TN, US). Transnetyx analyses samples using real 
time PCR.  
 
2.2.4.3. Preparation and administration of cell suspension for xenografts 
 
PDAC cells for subcutaneous injection into CD1 nude mice were grown in DMEM 
cell culture media up to ~70% confluency. Then the cells were trypsinized and 
counted using the Casy cell counter. The cells were then washed in PBS 3 times and 
the resuspended in required amount of PBS for injection. For each mouse 106 
cells/100μl of PBS was injected.. The mice subcutaneous injections were done by 
Biological Services Unit at the Beatson Institute. 
 
2.2.4.4. Tissue fixation 
 
The tissue samples were fixed in 4 % paraformaldehyde (Electron microscopy 
sciences) in PBS for 24 hours after sample collection. They were paraffin embedded 
and tissue sections cut and fixed onto slides by the Histology Service at the Beatson 
Institute. Staining with Hematoxylin & Eosin (H&E), which marks the nucleus, 
cytoplasm and connective tissue in sections, was also carried out by Histology 
Service. 
 
2.2.4.12. Dasatinib treatment in vitro and in vivo 
 
Dasatinib (Bristol-Myers Squibb, Princeton, NJ) was administered daily by oral 
gavage in 80 mM citrate buffer (10 mg/kg) (or 100 nM in vitro). After pancreatic 
tumours were observed in mice, the animals were dosed three times, and after third 
treatments the tumours were imaged (Morton 2010-2). 
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2.2.5. FRAP and data analysis 
 
2.2.5.1. FRAP in cell line: 
 
For performing FRAP on cell line, 2.5x106 PDAC cells were plated onto glass-
bottomed dishes. The cells were left to adhere overnight. For L cells 4x106 cells were 
seeded in dishes. The cells monolayer should be completely confluent. The glass 
bottom dishes maintained at 37 ºC on a heated stage during FRAP. 
 
2.2.5.2. FRAP in tissue 
 
For performing the FRAP on xenograft the PDAC cells were injected subcutaneously 
into the flank of nude mice and then allowed to grow the tumour until it was reached 
the length between 1-1.4 mm. then while the mice was kept under anesthesia, small 
incisions in the skin surrounding xenograft tumors are made and a skin flap is 
created, allowing images to be acquired at a distance from the body of the mouse. 
The blood flow was kept through a skin flap attached to the body. The tumour is 
placed on a glass bottom dish on the heated microscope stage. A small amount of 
DMEM was added to prevent the tissue from drying. After FRAP the tumour was 
fixed and stained with H&E. performing the FRAP in xenograft ex vivo, the skin flap 
was cut before starting the imaging.  
Ex vivo FRAP on pancreatic tissue (from the tumour or normal pancreas) performed 
on the freshly dissected tissue which was cut through with a clean edge and placed 
on a glass bottom dish on the heated microscope stage.  
 
2.2.5.3. Performing FRAP and analysis 
 
Photo-bleaching experiments were performed using an Olympus FV1000 confocal 
microscope with SIM scanner. Cells were imaged using the following settings: 4 μs 
pixel dwell time, 512 x 512 pixel resolution, 2% 488 nm laser power. For bleaching, 
a circular ROI with 30 pixel diameter (3 μm) was bleached to approximately 50% of 
its initial intensity using 35% 405 nm laser power, 20 μs/pixel dwell time for one 
frame. Images were captured every 1.6 seconds for 5 minutes. Individual recovery 
curves were exported into SigmaPlot (Systat Inc, London, UK) for exponential curve 
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fitting. Data were fit to the exponential equation I(t) = I(0) + a×(1-exp(-b×t)), where 
I(t) denotes the percentage of recovered fluorescence intensity at time t after 
bleaching, I(0) is percentage of fluorescent intensity after bleach and a and b are 
extracted by fitting the curve. The half-time of recovery was then calculated using 
the formula T1/2 = ln(2)/b, and the immobile fraction (Fi) was calculated (as a 
percentage) using the formula Fi =100*(1-a/(1-I(0))).  
 
2.2.5.1. Statistical analysis 
 
Statistical significance (p <0.05) of differential findings between each pair of 
experimental groups was determined by a two tailed unpaired Student’s t-test. In 
cases that the Kolmogorov-Smirnov normality test or the Equal Variance test failed, 
a Mann-Whitney Rank Sum test was used to test for statistical difference between 
groups of T1/2 and Fi. 
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3. Cis, trans and actin interactions form adhesive E-cadherin 
clusters. 
 
In this chapter I employed FRAP to understand the dynamics of E-cadherin in cell-
cell junctions. I studied the effect of disrupting each interaction of E-cadherin (cis, 
trans and actin binding) on E-cadherin mobility and the strength of cell-cell 
adhesions. Moreover, I want to investigate the effect of expression level of E-
cadherin-GFP molecules on their E-cadherin dynamics and the cell-cell junctions 
adhesiveness. 
 
3.1. Localization of E-cadherin-GFP molecules in PDACfl cells 
 
Initially, I wanted to study FRAP parameters of wild-type E-cadherin molecules in 
PDACfl cells. These cells are pancreatic cancer cells isolated from Pdx1-Cre, LSL-
KRasG12D/+, Trp53LoxP/+ mice which do not express p53 (Morton 2010). PDACfl cells 
express endogenous E-cadherin and they were stably transfected with GFP-chimeras 
of wild-type E-cadherin or mutants. After drug selection, the transfected cells were 
FACS sorted into two groups of high expression and low expression (figure 3.1).   
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A)  B) C) 
Figure 3.1. The expression levels of E-cadherin and E-cadherin-GFP in high and low expressing 
PDACfl cells. A) PDACfl cells were sorted by FACs, after transfection with E-cadherin-GFP plasmid. 
B) A FACS report demonstrating how high and low expressing cells are sorted C) western blot 
showing the difference between expression levels of E-cadherin (Ecad) and E-cadherin-GFP (GFP-
Ecad) in PDACfl cells.  
 
In order to understand the effect of expression level of wild-type or mutant E-
cadherin-GFP on FRAP results, each experiment was carried out separately on low 
and high expressing cells.  
Chapter 3: Cis, trans and actin interactions form adhesive E-cadherin clusters.                               73 
Before performing the FRAP experiment; I examined the localization of E-cadherin-
GFP in cell junctions. In order to visualize the 3-dimensional structure of junctions in 
PDACfl cells expressing high E-cadherin-GFP level and the extent of photo 
bleaching, I fixed the cells and then imaged the cells by serial confocal sections 
acquired before and after photo bleaching. Figure 3.2.A shows the 3-dimensional 
structure of junctions in high expressing cells. These images showed a relatively 
homogeneous distribution of E-cadherin-GFP in the plasma membrane, unlike the 
punctuate localization of E-cadherin reported elsewhere (Hong 2010, Ozaki 2011, 
Harrison 2011) When viewed en face, the photo-bleached region appeared as a 
column of reduced fluorescence intensity (Figure 3.3.B). 
 
A) B) V 
Figure 3.2. Localization of wild-type E-cadherin-GFP in high expressing PDACfl cells. PDACfl 
cells expressing E-cadherin-GFP were fixed and serially sectioned before (A) and after photo-
bleaching (B) using confocal microscopy. Data sets were reconstructed to produce top-down (top), en 
face (bottom), and cross-section views (side) of the junction. Bar = 2 µm.  
 
Next, FRAP was performed on wild-type E-cadherin-GFP in PDACfl high expressing 
cells. To perform FRAP a small region in the membrane was bleached with high 
laser power and the recovery of fluorescent intensity was monitored for 5 minutes. 
The measured fluorescent intensity of the bleached ROI was divided by the 
fluorescent intensity of the ROI before the bleach and plotted against time. Then 
several individual FRAP recovery curves were averaged to get a representative 
recovery curve (Figure 3.3.B) For quantification of the results, Fi% and T1/2 were 
extracted from each single recovery curve, then averaged from all the recovery 
curves. To calculate Fi% and T1/2 recovery curve for each bleached point were fit by 
the exponential equation I(t) = I(0) + a (1-exp (-bt)), where I(t) is the percentage of 
recovered fluorescence intensity at time t after bleaching. The values a and b are 
calculated from the fitted curve. The half-time of recovery was then calculated using 
the formula T1/2 = ln (2)/b, and the immobile fraction (Fi%) was calculated (as a 
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percentage) using the formula Fi =100*(1-a /(1-I(0))). Then t test have been used to 
analyse if the difference between each pair of data is statistically significant or not 
(See methods section 2.2.5).  
Quantification of the FRAP result on  PDACfl cells expressing high level of wild-
type E-cadherin-GFP showed that these cells have 58.6% immobile fraction and 41 
seconds T1/2 value ( FRAP data for all experiments and t test values are summarized 
in Table 3.1 and 3.2) 
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Figure 3.3. FRAP on high expressing wt-E-cadherin-GFP in PDACfl high cells. A) PDACfl cells 
expressing wild-type E-cadherin-GFP before bleaching, immediately after bleach, at T1/2 and after 
complete recovery. These cells are PDACfl with High E-cadherin-GFP expression. Bar = 5 µm.  
B) The averaged fluorescent recovery curve of wt-E-cadherin-GFP. The measured fluorescent 
intensity of the bleached ROI was divided by fluorescent intensity of the ROI before the bleach and 
the plotted against time. Ten individual FRAP recovery curves were averaged. Error bars show SEM. 
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3.2. ΔEC1Δcyt-E-cadherin-GFP is non-specifically immobilized in the plasma 
membrane structure. 
 
FRAP results for wild-type E-cadherin-GFP in PDACfl cells revealed that both high 
and low cells had the same Fi% (58% immobile fraction). The immobile fraction 
determined by FRAP is typically used to estimate the amount of E-cadherin 
immobilized in cell-cell junctions. However, single particle tracking experiments at 
the free cell surface have previously shown that a fraction of E-cadherin is 
immobilized within the plasma membrane by non-specific trapping (Kusumi 1993, 
Sako 1993). In order to estimate the amount of E-cadherin non-specifically trapped 
in PDACfl cell-cell junctions, an E-cadherin-GFP molecule with deletion of both 
EC1 and cytoplasmic domains was made. This mutant (abbreviated ΔEC1Δcyt in 
short form) is unable to form cis, trans, or actin interactions and therefore does not 
form any interactions with other E-cadherins or the cytoskeleton. ∆EC1∆Cyt-E-
cadherin-GFP has approximately similar molecular weight and geometry as E-
cadherin-GFP and should therefore report the rate at which wild-type E-cadherin 
moves by diffusion alone. Consequently, I used this mutant as a control for free 
diffusion of trans-membrane protein in these cells. The FRAP data from PDACfl 
ΔEC1Δcyt-E-cadherin-GFP High cells showed that this mutant has significantly 
lower Fi and T1/2 compared to WT E-cadherin-GFP high expressing cell (p values 
for Fi and T1/2  are 0=<0.001 and 0=<0.001  respectively). However, the ΔEC1Δcyt 
mutant still had 31% immobile fraction (Figure 3.4).  
Consistent with single particle tracking experiments of Kusumi et al, our FRAP 
results showed a high immobile fraction for ΔEC1Δcyt-E-cadherin-GFP which is an 
inert molecule (Kusumi 1999, Sako 1998). Moreover, as a control, I analyzed GFP 
targeted to the inner leaflet of the plasma membrane via the 20 amino-acid 
farnesylation signal from HRas (GFP-F). The immobile fraction for GFP-f in PDACfl 
cells was also close to immobile fraction of ΔEC1Δcyt-E-cadherin-GFP (GFP-f 
Fi=26.3%). These data suggest that approximately half of E-cadherin trapped in cell-
cell junctions (58%) were immobilized through non-specific interactions (31%). 
In order to examine if endogenous wild-type E-cadherin affects the recovery of 
mutant E-cadherin-GFP, the FRAP recovery of ΔEC1Δcyt-E-cadherin-GFP was 
examined in a different cell line. L cells are mouse fibroblasts cells, which do not 
express endogenous E-cadherin. These cells were transfected with the E-cadherin-
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GFP constructs and the sorted to high and low expressing cells. Figure 3.5 shows the 
FRAP results for wild-type, ΔEC1Δcyt and GFP-f in L cells. ΔEC1Δcyt-E-cadherin-
GFP has 34.9% immobile fraction in L cells expressing high levels of E-cadherin-
GFP, which is similar to the Fi% of ΔEC1Δcyt in PDACfl cells. ΔEC1Δcyt mutant 
Fi% and T1/2 are significantly lower than WT molecules (p values for Fi% and T1/2 
compared in high expressing cells are 0=<0.001 and 0=<0.001   respectively).  
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Figure 3.4. FRAP data for ΔEC1Δcyt-E-cadherin-GFP and GFP-f compared to wild-type E-
cadherin-GFP in PDACfl cells. Immobile fraction (Fi%) is shown on y-axis and T1/2 on x-axis. A) 
FRAP results for high expressing cells (Nwt=24 NΔEC1Δcyt=39 NGFP-f=9). B) Data for low expressing 
cell (Nwt=32 NΔEC1Δcyt=23 NGFP-f=9). Error bars show SEM.  
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Figure 3.5. FRAP data for ΔEC1Δcyt-E-cadherin-GFP and GFP-f compared to wild-type E-
cadherin-GFP in L cells. A) FRAP results for high expressing cells (Nwt=19 NΔEC1Δcyt=15 NGFP-
f=26. B) Data for low expressing cell (Nwt=19 NΔEC1Δcyt=11 NGFP-f=26). Error bars show SEM. 
 
As expected, there was a significant difference in the immobile fraction and T1/2 
between wild-type E-cadherin-GFP and the non-interacting ΔEC1Δcyt E-cadherin-
GFP mutant both in PDACfl and L cells. Disruption of E-cadherin cis, trans and actin 
interactions dramatically mobilized these molecules. The difference between the 
immobile fractions of wild-type E-cadherin and mutant demonstrates that around 
30% of E-cadherin-GFP molecules are stably clustered to stationary complexes. 
Disruption of these three interactions dissociated the molecules from these 
complexes and decreased the mobile fraction. Moreover, the significant reduction in 
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T1/2 between wild-type E-cadherin-GFP and ΔEC1Δcyt E-cadherin-GFP mutant 
indicates that the recovery of E-cadherin-GFP molecules is restrained by transient 
binding to E-cadherin clusters which are relatively stationery in junctions in our 
FRAP experiment. 
Therefore, E-cadherin is immobilized at cell-cell junctions through two mechanisms: 
by specific interactions mediated by the EC1 and/or cytoplasmic domain, and by 
non-specific interactions such as the cortical membrane fence. It is also apparent that 
the recovery rate of E-cadherin-GFP is much slower than would be expected for a 
process limited by the rate of diffusion only, suggesting that transient interactions 
with stationary binding partners slowed down its recovery. 
 
3.3. Expression level of wild-type E-cadherin-GFP affects T1/2 but not Fi 
 
The FRAP results from both PDACfl and L cells showed that E-cadherin dynamics 
are different in high and low expression levels of wild-type GFP-E-cadherin (In 
figure 3.6.A and B, FRAP results from figure 3.4 and 3.5 for high and low 
expression of wild-type and ΔEC1Δcyt E-cadherin-GFP are put together in one 
figure).  
T test analysis of the result illustrated that there is no statistical difference between 
Fi% of high and low expression level of wild-type E-cadherin-GFP (p values for 
PDACfl and L cells are P=0.916 and P=0.281 respectively). This indicates that the 
amount of E-cadherin immobilized in cell-cell junctions was the same for different 
expression levels in each cell type. However, high expressing cells have significantly 
slower recovery rate of E-cadherin-GFP molecules than low cells in both PDACfl and 
L cell lines (p values for PDACfl and L cells are P=0.014 and P=<0.001 
respectively). Moreover, there was no difference between Fi% and T1/2 of high and 
low ΔEC1Δcyt E-cadherin-GFP in either PDACfl or L cells (P values for Fi% and 
T1/2 in ΔEC1Δcyt mutant in high expressing PDACfl cell are P=0.284 and P=0.153. 
P values for Fi and T1/2 in ΔEC1Δcyt mutant in high expressing L cells are P=0.449 
and P=0.133 respectively). This indicates that the level of non-specific trapping does 
not change by increasing expression level of the mutant E-cadherin-GFP. 
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Figure 3.6. FRAP data for high and low expression of wild-type E-cadherin-GFP compared to 
high and low expression of ΔEC1Δcyt-E-cadherin-GFP. High expressing cells have significantly 
higher t1/2 values for wild-type E-cadherin-GFP. In both PDACfl and L cells there is no significant 
difference between Fi% of high and low E-cadherin-GFP cells.  A) FRAP results in PDACfl cells. B) 
Data for L cells. Error bars show SEM. The data are duplicated from figure 3.4 and 3.5.  
 
3.3.1. The level of E-cadherin-GFP expression influences cell-cell adhesion 
strength: 
 
The FRAP data showed there is no difference in the proportion of E-cadherin 
molecules immobilized in cell-cell junctions between E-cadherin-GFP high and low 
expressing cells. However, previous work has demonstrated that the level of E-
Chapter 3: Cis, trans and actin interactions form adhesive E-cadherin clusters.                               80 
cadherin influences cell adhesion strength (Steinberg 1994). To asses the effects of 
expression level on cell-cell junctions strength, I used two techniques: Dispase assay 
and TEER.  
In the dispase assay, the cell monolayer was treated with dispase enzyme, which 
digests fibronectin, collagen IV and to a lesser extent collagen I, until it was 
separated from substrate. The detached cell layer was then broken up by mechanical 
force and the number of single cells was counted. For comparison, the number of 
single cells in high and low expressing cell lines was normalized to the number of 
single cells for PDACfl cells. In this assay, cells with stronger cell-cell adhesion show 
a lower number of single cells.  
Comparison of cell-cell adhesions between parental PDACfl cells with PDACfl cell 
with high and low level of E-cadherin-GFP expression with dispase assay showed 
that PDACfl cell have significantly higher number of single cells than PDACfl E-
cadherin-GFP low cells (p=<0.001) and cells with low expression have significantly 
higher number of single cells than high expressing cells (p=<0.001) (figure 3.7.A). 
These data indicate that by increasing the expression level of E-cadherin from 
PDACfl cells to PDACfl cells with low and high cells cell adhesion became stronger. 
Similar results were obtained in L cell with high and low expression levels of E-
cadherin-GFP (figure 3.8.A). L cell have significantly higher number of single cells 
than E-cadherin-GFP low cells (p=0.026) and cells with low expression have 
significantly higher number of single cells than high expressing cells (p=0.014). 
therefore, high expressing cells showed significantly higher cell-cell adhesion in both 
cell types.  
In order to assess the effects of E-cadherin expression level on junctional integrity, I 
measured Trans-Epithelial Electrical Resistance (TEER) using an EVOM2 epithelial 
ohm-meter. TEER was measured for PDACfl cells expressing high and low levels of 
wild-type E-cadherin-GFP and high expression of ΔEC1Δcyt-E-cadherin-GFP 
(figure 3.8.B). The numbers are normalized to TEER in PDACfl cells. Statistical 
analysis of the results showed that, there is a significant difference between high and 
low expressing cells (p=<0.001). In addition, even low expression of E-cadherin-
GFP in addition to endogenous protein increased TEER in comparison to PDACfl 
cells (p=<0.001). Furthermore, expression of the ΔEC1Δcyt-E-cadherin-GFP mutant 
decreased the junctional integrity compared to PDACfl cells alone (p= 0.013). 
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Figure 3.7. Cell-cell adhesion and junctional integrity in high and low expressing PDACfl cells. 
A) Measuring cell-cell adhesion with dispase assay in PDACfl cells and cells expressing high and low 
level of wild-type E-cadherin-GFP. PDACfl cells transfected with E-cadherin-GFP have significantly 
lower number of single cells than PDACfl cells indicating that Cell-cell adhesion in high expressing 
cells is significantly higher than low cells. B) Trans-Epithelial Electrical Rresistance (TEER) 
measured in PDACfl cells expressing high and low level of wild-type E-cadherin-GFP and high 
expression of ΔEC1Δcyt-E-cadherin-GFP. N=3. Error bars show SEM.  
 
Subsequently, TEER was used to measure junctional integrity in L cells expressing 
high and low levels of E-cadherin-GFP in comparison to L cell with no E-cadherin 
expression, and L cells expressing high levels of ΔEC1Δcyt-E-cadherin-GFP. These 
measurements revealed a significant difference in barrier function between high and 
low expressing cells (figure 3.8.B). In addition, expression of ΔEC1Δcyt-E-cadherin-
GFP in L cells did not affect junctional integrity in these cells compared to L cells 
with no E-cadherin expression.  
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Figure 3.8. Cell-cell adhesion and junctional integrity in high and low expressing L cells 
measured. A) Measuring cell-cell adhesion with dispase assay in L cell expressing high and low level 
of wild-type E-cadherin-GFP. Expression of high or low expression levels of E-cadherin-GFP in L 
cells significantly decreased the number of single cells compared to L cells. Cell-cell adhesion in high 
expressing cells was significantly higher than low cells. B) Trans-Epithelial Electrical Resistance 
(TEER) is measured in cells expressing high and low level of wild-type E-cadherin-GFP and high 
expression of ΔEC1Δcyt-E-cadherin-GFP. N=3. Error bars show SEM. 
 
In summary, these results showed that increasing the cadherin expression level 
enhanced cell-cell adhesion, although there was no difference in the fraction of E-
cadherin immobilized in cell-cell junctions in high and low expressing cells. This 
implies that although the high-expressing cells engage more E-cadherin in cell 
adhesion than the low-expressing cells, the proportion of E-cadherin molecules 
engaged in junctions remains constant at both expression levels. Therefore, by itself, 
the immobile fraction does not represent an absolute measure of cell-cell adhesion 
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strength. Similar expression level of E-cadherin is necessary to use immobile fraction 
as an indicator of cell-cell adhesion strength. 
In contrast, the recovery rate was significantly affected by expression level of E-
cadherin-GFP. Although there was no significant difference between T1/2 of high 
and low expression of ΔEC1Δcyt-E-cadherin-GFP mutants (both in PDACfl and in L 
cells), increasing the expression level of wild-type E-cadherin-GFP significantly 
increased the recovery time of E-cadherin FRAP.  
 
3.4. Trans dimers are essential for immobilizing E-cadherin-GFP: 
 
In order to investigate the relative contributions of cis-, trans-, and actin interactions 
to immobilizing E-cadherin within cell-cell junctions I made mutants defective for 
each interaction and analyzed those using FRAP to establish the influence of each 
interaction on mobility and recovery rate. 
 
3.4.1. The Availability of E-cadherin on the neighbouring cell membrane affects 
FRAP data. 
  
In order to determine how different expression levels of E-cadherin on adjacent 
membrane affects Fi% and T1/2, I mixed high expressing E-cadherin-GFP PDACfl 
cells with PDACfl cells with no E-cadherin-GFP cells. Then, I performed FRAP at 
the junctions between a green cell and a non-GFP cell (see figure 3.9).  
As shown in figure 3.1 by western blot analysis, high expressing E-cadherin-GFP 
PDACfl cells express more E-cadherin that parental PDACfl cells. Therefore, mixing 
these cells results in formation of junctions, which do not have same level of E-
cadherin on two neighbouring membranes (here referred to Hi-No junctions between 
PDACfl cells just express endogenous E-cadherin and no E-cadherin-GFP).  
The FRAP data in Hi-No junctions showed that there is a significant reduction in 
both Fi% and T1/2 compared to Hi-Hi junctions (High expression level of E-
cadherin-GFP on both sides of junction) (figure 3.9.B). T test p values for Fi% and 
T1/2 are P=0.005 and P=<0.001. This indicates that reducing trans dimer formation 
because of limitation in availability of E-cadherin on parental PDACfl cell (P), 
reduced Fi% in high E-cadherin-GFP expressing cells (Hi).  
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Next, the FRAP experiment was done at the free cell edge in PDACfl cells expressing 
high level of E-cadherin-GFP (Hi-Bo). For stabilizing the free cell edge in order to 
perform FRAP, high expressing E-cadherin-GFP PDACfl cells are mixed with L 
cells. L cells do not express E-cadherin and do not form any contact with PDACfl 
cells. FRAP at a free cell edge (Hi-Bo) showed that Fi% and T1/2 are significantly 
reduced compared to Hi-Hi junctions (T test p values for Fi% and T1/2 are P=<0.001 
and P=<0.001). E-cadherins at a free cell edge is able to form cis and actin 
interactions, which indicates that cis interaction and binding to the actin cytoskeleton 
are not enough to immobilized E-cadherin in the membrane.  
Moreover, FRAP for E-cadherin-GFP molecules at free-cell edge which are unable 
to form trans dimers have the same immobile fraction as ΔEC1Δcyt mutant. These 
data indicate that trans dimer formation is necessary for immobilizing E-cadherin in 
the membrane. To confirm this idea, I disrupted trans dimer formation with point 
mutation and measured how it affects FRAP recovery. 
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Figure 3.9. E-cadherin mobility is affected by availability of E-cadherin in the neighbouring 
plasma membrane. A) FRAP data for two high expressing cells (Hi-Hi) is shown as a blue dot. The 
FRAP data is from figure 3.4.A. Black dot (Hi-No) represents data for FRAP at a contact between a 
Hi cell and a PDACfl cell (P). Red dot (Hi-Bo) is FRAP at free edge of a cell. The FRAP data for 
ΔEC1Δcyt  mutant is from figure 3.4.A. B) schematic drawing of cell-cell contacts which are used for 
FRAP experiments in A. C) microscopic image showing how FRAP is performed at contact of a green 
cell and a non-GFP cells (Hi-No dot) compared to FRAP of membrane between to high expressing 
cells or two green cells (Hi-Hi dot). NHi-No=16, NHi-Bo=14. Error bars show SEM. 
 
3.4.2. Disruption of trans interaction by W2A mutation: 
 
In order to investigate the effects of specifically disrupting trans dimers on E-
cadherin mobility, I performed FRAP on E-cadherin-GFP with W2A mutation. This 
mutation disrupts the β strands needed for strand swapping (Laur 2002). Therefore, 
the W2A mutant is unable to form trans dimers. I expressed this mutant in PDACfl 
cells which also express wild-type endogenous E-cadherin and sorted the cells to 
high and low expression similar to wild-type E-cadherin-GFP and ΔEC1Δcyt-E-
cadherin-GFP expressing cells. 
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Analysis of E-cadherin mobility by FRAP showed that reduction of trans dimer 
formation reduces immobilized E-cadherin to 36% and the recovery rate to around 
20 seconds in PDACfl cells with high expression of W2A-E-cadherin-GFP, 
compared to 60% Fi and 40 seconds T1/2 for wild-type E-cadherin-GFP in PDACfl 
cells (figure 3.10.A). (T test p values for Fi% and T1/2 are P=<0.001 and P=<0.001).  
The data for wild-type E-cadherin-GFP and ΔEC1Δcyt mutant are duplicated from 
figure 3.4. PDACfl cells expressing low level of the W2A mutant showed similar 
decrease in both Fi% and T1/2 (T test p values for Fi% and T1/2 are P=<0.001 and 
P=0.009).  
The W2A mutation significantly decreased the amount of E-cadherin immobilized at 
cell-cell junctions. This is in agreement with the data from the previous section and 
confirms that formation of strand swapped trans dimers is necessary for inclusion of 
E-cadherin into adhesive clusters of E-cadherin on membrane. 
Moreover, W2A mutant recovered significantly more slowly than ΔEC1Δcyt-E-
cadherin-GFP but there is no significant difference between their immobile fractions. 
(T test p values in high expressing cells for Fi% and T1/2 are P=0.075 and 
P=<0.001). The W2A mutant can form cis dimers and bind to the actin cytoskeleton. 
This slower recovery rate of the W2A mutant compared to the non-binding mutant 
indicates that cis dimerization or binding to actin are responsible for slowing down 
the recovery of W2A-E-cadherin-GFP molecules. 
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Figure 3.10. FRAP data for GFP-W2A-E-cadherin (trans interaction mutant) compared to WT 
E-cadherin-GFP and ΔEC1Δcyt-E-cadherin-GFP in PDACfl cells. The data for wild-type E-
cadherin-GFP and ΔEC1Δcyt mutant are duplicated from figure 3.4. There is a significant decrease in 
both T1/2 and Fi% between wild-type and trans mutant (W2A-E-cadherin-GFP). Although W2A 
mutant and ΔEC1Δcyt-E-cadherin-GFP have the same Fi%, T1/2 is significantly higher in W2A 
mutant. A) FRAP results for high expressing cells. Ntrans Hi=24. B) Data for low expressing cell. Ntrans 
Low=20. Error bars show SEM.  
  
Next I examined whether the presence of endogenous wild-type E-cadherin affects 
the recovery of W2A-E-cadherin-GFP in PDACfl cells. To do this, I transfected L 
cells with trans mutant (W2A-E-cadherin-GFP) construct and sorted for high and low 
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expression. L cells with W2A mutant expression do not express any wild-type E-
cadherin. I analysed FRAP in both high expressing and low expressing cells (figure 
3.11). The results showed that, similar to PDACfl cells, in L-cells the W2A mutant 
had the same immobile fraction as the non-binding ΔEC1Δcyt mutant, but the rate of 
mobility was significantly reduced in W2A mutant.  (T test p values in high 
expressing cells for Fi% and T1/2 are P=0.890 and P=<0.001). 
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Figure 3.11. Mobility of for GFP-W2A-E-cadherin (trans interaction mutant) compared to 
Wild-type E-cadherin-GFP and ΔEC1Δcyt-E-cadherin-GFP in L cells. The data for wild-type E-
cadherin-GFP and ΔEC1Δcyt mutant are duplicated from figure 3.5. There is significant decrease in 
both T1/2 and Fi% between wild-type and trans mutant (W2A-E-cadherin-GFP). Although, W2A 
mutant and ΔEC1Δcyt-E-cadherin-GFP have same Fi%, but T1/2 is significantly higher in W2A 
mutant. A) FRAP results for high expressing cells Ntrans Hi=41. B) Data for low expressing cell Ntrans 
Lo=33. Error bars show SEM. 
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The FRAP data showed a significant decrease in E-cadherin immobilized in W2A 
mutant cells. This suggests that W2A mutant E-cadherin affects cell-cell adhesion. 
Therefore, I analysed how this mutant affects cell-cell adhesion in PDACfl cells 
expressing the W2A mutant using the dispase assay (Figure 3.12). The data showed 
that expression of GFP-W2A-E-cadherin in significantly increased the number of 
free cells following dispase treatment compared to the PDACfl cells (P=0.003) or 
PDACfl cells with high expression of wild-type E-cadherin-GFP (P = <0.001). 
Therefore, W2A-E-cadherin-GFP molecules not only were not able to increase the 
cell-cell adhesion like wild-type E-cadherin-GFP molecules but these molecules 
significantly weakened the cell-cell adhesion compared to parental PDACfl cells as 
well. 
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Figure 3.12. Cell-cell adhesion measurement by Dispase assay. Measuring cell-cell adhesion with 
dispase assay in PDACfl cell and PDACfl cells expressing high level of wild-type E-cadherin-GFP and 
trans mutant (W2A-E-cadherin-GFP). For each case, the number of single cells is normalized to 
PDAC cell number. PDACfl cells transfected with E-cadherin-GFP have significantly fewer cells 
following dispase treatment than PDACfl cells. Expression of W2A-E-cadherin-GFP in PDACfl cells 
significantly increased single cells number indicating reduced cell-cell adhesion strength. N=3. Error 
bars show SEM.  
 
Moreover, measurement of cell-cell adhesion by dispase assay in L cells showed that 
W2A mutant expressing L cells have same number of single cells as L cells (figure 
3.13) (P = 0.188). Which confirms that W2A mutant E-cadherin-GFP is not capable 
of forming adhesive complexes and increasing cell-cell adhesion in L cells. In 
Chapter 3: Cis, trans and actin interactions form adhesive E-cadherin clusters.                               90 
summary, W2A-E-cadherin-GFP was unable to form junctions in L-cells and 
disrupted formation of junctions in PDACfl expressing endogenous E-cadherin. 
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Figure 3.13. Cell-cell adhesion measurement by Dispase assay. Measuring cell-cell adhesion with 
dispase assay in L cell and L cells expressing high level of wild-type E-cadherin-GFP and trans 
mutant (W2A-E-cadherin-GFP). For each case, the number of single cells is normalized to L cell 
number. Expression of E-cadherin-GFP in L Cells significantly decreased the number of single cells. 
However, expression of W2A-E-cadherin-GFP in L cells does not affect single cells number 
significantly compared to L cells. N=3. Error bars show SEM. 
 
3.5. Disruption of cis interaction by V81D/V175D mutation 
 
In order to examine the effects of cis-interaction on E-cadherin mobility I used 
V81D/V175D mutant E-cadherin-GFP. This mutation destroys the hydrophobic core 
of the cis interface and inhibits cis interaction between E-cadherin molecules 
(Harrison 2011). 
Here, FRAP was used to analyse E-cadherin in PDACfl cells expressing high and low 
levels of cis mutant E-cadherin-GFP (figure 3.14). The data for wild-type E-
cadherin-GFP and ΔEC1Δcyt mutant are duplicated from figure 3.4.  The data 
showed that, in both high and low, cells cis mutants had significantly lower immobile 
fraction and T1/2 compared to cells expressing wild-type E-cadherin-GFP. (T test p 
values in high expressing cells for Fi% and T1/2 are P=<0.001 and P=<0.001).The 
immobile fraction of the cis mutant was similar to the ΔEC1Δcyt mutants, which 
indicates that cis interactions are necessary to immobilize E-cadherin-GFP molecules 
in adhesive complexes in cell-cell junctions.  
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However, the ΔEC1Δcyt mutant recovered significantly faster than V81D/V175D-E-
cadherin-GFP molecules (p values in high expressing cells for Fi% and T1/2 are 
P=0.075 and P=<0.001), this indicates that interaction with actin is responsible for 
slowing down the recovery of cis mutant compared to non-binding freely diffusing 
ΔEC1Δcyt mutant cadherins. 
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Figure 3.14. FRAP data for V81D/V175D-E-cadherin-GFP (cis interaction mutant) compared to 
WT E-cadherin-GFP and ΔEC1Δcyt-E-cadherin-GFP in PDACfl cells. The data for wild-type E-
cadherin-GFP and ΔEC1Δcyt mutant are duplicated from figure 3.4. A) FRAP results for high 
expressing cells. Ncis Hi=26. B) Data for low expressing cell. Ncis Low=31. Error bars show SEM. 
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Next to analyse how the presence of endogenous wild-type E-cadherin affect the cis 
mutant E-cadherins, I expressed V81D/V175D mutant in L cells. The FRAP data 
showed that for the V81D/V175D mutant Fi is 37% and T1/2 is around 17 seconds in 
L cells with high GFP expression. L cells with low expression also showed similar 
FRAP data (figure 3.15.A and B).  In high expressing cells, the V81D/V175D mutant 
showed a significant decrease in both Fi% and T1/2 compared to wild-type E-
cadherin-GFP in high expressing L cells (p values for Fi% and T1/2 are P=<0.001 
and P=<0.001). Moreover, the V81D/V175D mutant had significantly higher T1/2 
than the non-binding mutant ΔEC1Δcyt-E-cadherin-GFP but there is no significant 
difference between their immobile fractions (p values in high expressing cells for 
Fi% and T1/2 are P=0.671 and P=<0.001). These data indicates that similar to 
PDACfl cell results V81D/V175D-E-cadherin-GFP molecules are not able to form 
stationary E-cadherin clusters in cell-cell junctions. 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3: Cis, trans and actin interactions form adhesive E-cadherin clusters.                               93 
L-Cells High
0
10
20
30
40
50
60
70
80
90
100
0 5 10 15 20 25 30 35 40 45
T1/2 (s)
Fi
 (%
)
WT
Cis
ΔEC1ΔCyt
L-Cells Low
0
10
20
30
40
50
60
70
80
90
100
0 5 10 15 20 25 30 35 40 45 50
T 1/2 (s)
Fi
 %
WT
Cis
ΔEC1ΔCyt
A)  
B)  
Figure 3.15. FRAP data for V81D/V175D-E-cadherin-GFP (cis interaction mutant) compared to 
WT E-cadherin-GFP and ΔEC1Δcyt-E-cadherin-GFP in L cells. The data for wild-type E-
cadherin-GFP and ΔEC1Δcyt mutant are duplicated from figure 3.5. A) FRAP results for high 
expressing cells. Ncis Hi=28. B) Data for low expressing cell. Ncis Low=25. Error bars show SEM. 
 
Next, I analysed junctional integrity in L cells expressing V81D/V175D mutant E-
cadherin-GFP by measuring TEER. L cells expressing high or low level of 
V81D/V175D-E-cadherin-GFP have same level of TEER (figure 3.21). This 
indicates that cis mutant E-cadherin was unable to engage in adhesive E-cadherin 
complexes and expressing this mutant in L cells did not affect junctional integrity in 
L cells. 
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3.6. Deletion of EC1 domain interrupts both cis and trans interactions. 
 
In order to study the combined effect of cis and trans interaction disruption, I made a 
E-cadherin-GFP mutant with deletion of EC1 domain. In this mutant, residues 2-109 
were deleted. Therefore, the ΔEC1 mutant is unable to form both cis and trans 
interactions. I analyzed the mobility of this mutant using FRAP in PDACfl cells 
expressing high and low level of ΔEC1-E-cadherin-GFP (figure 3.16).  The data for 
wild-type E-cadherin-GFP and ΔEC1Δcyt mutant are duplicated from figure 3.4. 
Interestingly, the FRAP data showed that ΔEC1 mutant had the same Fi% and T1/2 
as trans or cis mutants (in both high and low expressing cells) (p values for t test 
comparing trans mutant (W2A-E-cadherin-GFP) and ΔEC1 mutant in high 
expressing cells for Fi% and T1/2 are P=0.593 and P=625). Moreover, cis, trans and 
ΔEC1 mutants, which all retained cytoplasmic tail, had significantly higher T1/2 than 
ΔEC1Δcyt-E-cadherin-GFP in PDACfl (p values for t test comparing ΔEC1 and 
ΔEC1Δcyt mutants in high expressing PDACfl cells are P=0.178 and P=<0.001for 
Fi% and T1/2). Therefore, cytoplasmic interaction and binding to actin significantly 
decreased the mobility of E-cadherin molecules. 
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Figure 3.16. Mobility of ΔEC1-E-cadherin-GFP (cis and trans interaction mutant) compared to 
WT E-cadherin-GFP and ΔEC1Δcyt-E-cadherin-GFP in PDACfl. ΔEC1 mutant (pink circle) has 
same Fi% and T1/2 as trans mutant (yellow circle) and cis mutant (green circle). ΔEC1 expressing 
cells have significantly higher T1/2 than ΔEC1Δcyt. The data for wild-type E-cadherin-GFP and cis, 
trans and ΔEC1Δcyt mutants are duplicated from figure 3.4, 3.10 and 3.14. A) FRAP results for high 
expressing cells. NΔEC1 Hi=32. B)Data for low expressing cell. NΔEC1 Hi=24. Error bars show SEM. 
 
Next, I expressed ΔEC1-E-cadherin-GFP in L cells. The FRAP data in L cells was 
similar to PDACfl cells (figure 3.17). The ΔEC1 mutant has the same Fi% and T1/2 
as trans mutant and cis mutant in both high and low expressing cells (p values for t 
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test comparing cis and ΔEC1 mutant in high expressing cells for Fi% and T1/2 are 
P=0.297 and P=1.0). ΔEC1 expressing cells have significantly slower rate of 
mobility than the ΔEC1Δcyt mutant (p values for t test comparing ΔEC1 and 
ΔEC1Δcyt mutants in high expressing L cells are P=0.824 and P=<0.001for Fi% and 
T1/2). 
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Figure 3.17. Mobility of for ΔEC1-E-cadherin-GFP (cis and trans interaction mutant) compared 
to Wild-type E-cadherin-GFP and ΔEC1Δcyt-E-cadherin-GFP in L cells. ΔEC1 mutant (pink 
circle) has same Fi% and T1/2 as trans mutant (yellow circle) and cis mutant (green circle). The data 
for wild-type E-cadherin-GFP and cis, trans and ΔEC1Δcyt mutants are duplicated from figure 3.5, 
3.11 and 3.15. ΔEC1 expressing cells have significantly higher T1/2 than ΔEC1Δcyt. A) FRAP results 
for high expressing cells. NΔEC1 Hi=31. B) Data for low expressing cell. NΔEC1 Hi=22. Error bars show 
SEM. 
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Moreover, in order to see whether ΔEC1 mutants form functional adhesive 
complexes or not, I analysed junctional integrity in L cells expressing high and low 
level of ΔEC1 mutant using TEER. The results showed that TEER in L cells 
expressing ΔEC1 mutant was similar to L cells with no E-cadherin expression (figure 
3.21) (p values for t test comparing L cell with high or low expressing EC1 mutant 
with are P = 0.996 and P = 0.996 respectively), indicating that GFP-ΔEC1-E-
cadherin did not form adhesive complexes and can not affect cell-cell junction 
strength. 
In summary, these data showed that disruption of trans or cis interactions, or both 
reduces the immobile fraction to similar level of ΔEC1Δcyt mutant. However, all 
three of these mutants recovered more slowly than the non-binding ΔEC1Δcyt 
mutant, which recovers at the rate of free diffusion. These three mutants all retain the 
cytoplasmic tail. Therefore, the cytoplasmic tail is responsible for the reduced rate of 
mobility in W2A, V81D/V175D and ΔEC1-E-cadherin-GFP mutants (which retained 
the cytoplasmic tail) compared to the ΔEC1Δcyt mutant. The cytoplasmic tail binds 
to actin, which suggests that actin binding could slow recovery. In next section, I 
analysed the effect of disrupting actin binding in E-cadherin dynamics. 
 
3.7. Deletion of cytoplasmic domain disrupts interaction with actin cytoskeleton: 
 
The cytoplasmic tail of E-cadherin has two domains: JMD (Juxta-membrane 
domain), which binds to p120, and the β-catenin binding domain. Interaction with 
catenins connects the cytoplasmic domain of E-cadherin to the actin cytoskeleton. To 
understand how disrupting interaction with actin affects E-cadherin mobility, I 
expressed an E-cadherin-GFP mutant with deletion of residues 580 to 726 in PDACfl 
cells. In this deletion, the cytoplasmic domain of E-cadherin, which consists of both 
the juxta-membrane domain and the β-catenin binding domain, is deleted. Therefore, 
this mutant is unable to form any interaction with the actin cytoskeleton.  
FRAP analysis of Δcyt mutants in PDACfl cells with high and low expression level 
showed that in high expressing cells, the Δcyt mutant has the same immobile fraction 
and recovery rate as the ΔEC1Δcyt mutant (figure 3.18) (p values for Fi% and T1/2 
are P=0.465 and P=0.718). This means that retention of both cis and trans 
interactions did not slow down the diffusion of the Δcyt mutant compared to rate of 
free diffusion of the ΔEC1Δcyt mutant. Moreover, cis and trans interactions in 
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ΔEC1-E-cadherin molecule were not able to immobilize E-cadherin molecules stably 
within E-cadherin adhesive clusters in the membrane.  
Comparing FRAP data for all E-cadherin-GFP mutants in high expressing cells 
reveals that all mutants have similar immobile fraction. Which indicates all three 
interactions of E-cadherin molecules: cis, trans and actin are necessary for 
immobilizing E-cadherin in adhesive clusters and disrupting any one of these 
interaction is enough to bring down the immobilized E-cadherin fraction to the same 
level as the non-binding mutant. However, the recovery rate was significantly faster 
for E-cadherin mutants in which actin interaction is disrupted.  
Next, I analysed FRAP of the Δcyt mutant in low expressing PDACfl cells (figure 
3.18.B). In low expressing cells Δcyt mutant have smaller Fi% and T1/2 than wild-
type E-cadherin (P values for Fi and T1/2 are P = 0.033 and P = 0.003). However, 
low expressing Δcyt mutant have significantly higher Fi% and T1/2 compared to 
ΔEC1Δcyt mutant (P = <0.001 and P = 0.001). The t test showed there is significant 
difference between Fi% and T1/2 in Δcyt mutants between high and low expressing 
cells (P = <0.001 and P = <0.001). 
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Figure 3.18. FRAP data for GFP-Δcyt-E-cadherin compared to other mutant and WT-E-
cadherin-GFP and ΔEC1Δcyt-E-cadherin-GFP in PDACfl cells. . The data for wild-type E-
cadherin-GFP and cis, trans, ΔEC1 and ΔEC1Δcyt mutants are duplicated from figure 3.4, 3.10, 3.14 
and 3.16. A) FRAP results for high expressing cells. Δcyt mutant have same Fi% and T1/2 as 
ΔEC1Δcyt mutant. NΔcyt High=18. B) Data for low expressing cell. NΔcyt Low=26. Error bars show SEM.  
 
To further investigate the different mobility of GFP-Δcyt-E-cadherin in high and low 
expressing cells, I looked at junctional integrity of high and low expressing PDACfl 
cells using TEER (figure 3.19). High expression of the Δcyt mutant in PDACfl cells 
significantly lowered cell layer electrical resistance compared to PDACfl cells (P = 
0.006); in contrasts, low expressing cells have similar barrier function as PDACfl 
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cells (P = 0.100).  Moreover, high expression of the ΔEC1Δcyt mutant in PDAC 
cells reduces TEER in PDACfl cells as well (data duplicated from figure 3.7.). These 
data suggest that a small amount of mutant Δcyt molecules in PDACfl cells, which 
already express wild-type endogenous E-cadherin, was tolerated by adhesion 
complexes. Under these circumstances, the Δcyt mutant can interact via cis and trans 
interactions with other E-cadherin molecules. Therefore, low expressing Δcyt mutant 
cells are more immobile and recover slower than the ΔEC1Δcyt mutant that do not 
foms clusters. However, at higher expression levels, TEER measurements indicated 
that cell-cell adhesion decreased compared to PDACfl cells, and the immobile 
fraction of GFP-Δcyt-E-cadherin was reduced to the same level as other E-cadherin 
mutants.  
 
TEER in PDACfl Cells
85
90
95
100
105
110
115
PDAC Δcyt low Δcyt high ΔEC1Δcyt high WT Ecad-GFP-low WT Ecad-GFP-high
TE
ER
 (%
 o
f P
D
AC
fl 
C
el
ls
) 
 
3.19. Junctional integrity in PDACfl cells expressing high and low level of GFP-Δcyt-E-cadherin. 
The trans-epithelial electrical resistance is normalized to PDACfl cells. Low expressing GFP-Δcyt-E-
cadherin cells have TEER similar to PDACfl cells, but high expression of GFP-Δcyt-E-cadherin 
mutant significantly decreased cell-cell adhesion in these cells. TEER for high expression of 
ΔEC1Δcyt-E-cadherin-GFP and high and low expression of wild-type E-cadherin-GFP are duplicated 
from figure 3.7. N=3. Error bars show SEM. 
 
Subsequently, I expressed the tailless Δcyt mutant in L cells. FRAP analysis revealed  
that, this mutant had a significantly lower immobile fraction and increased rate of 
mobility than wild-type E-cadherin-GFP in both high and low expressing cells 
(figure 3.20) (p values for t test comparing WT and Δcyt mutant in high expressing 
cells for Fi% and T1/2 are P=<0.001 and P=<0.001. P values are P=0.004 and 
P=<0.001 for low expressing cells). L cells (which do not express wild type 
endogenous E-cadherin) had similar Fi% and T1/2 for high and low expressing cells 
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(P values for Fi% and T1/2 are P=0.702 and P=0.947). These data confirm that, the 
difference between high and low expression of Δcyt mutant in PDACfl cells is due to 
interactions between mutant E-cadherin molecules with wild-type endogenous E-
cadherin molecules. 
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Figure 3.20. Mobility of Δcyt-E-cadherin-GFP compared to other mutant and wild-type E-
cadherin-GFP and ΔEC1Δcyt-E-cadherin-GFP in L cells. The Δcyt mutant recovers significantly 
faster than ΔEC1 and cis or trans mutants in both high and low expressing cells. The data for wild-
type E-cadherin-GFP and cis, trans, ΔEC1 and ΔEC1Δcyt mutants are duplicated from figure 3.5, 
3.11, 3.15 and 3.17. A) FRAP results for high expressing cells. NΔcyt Hi=23. B) Data for low expressing 
cell. NΔcyt Low=21. Error bars show SEM. 
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The FRAP results demonstrate that all E-cadherin mutants have Fi% similar to 
ΔEC1Δcyt mutant in L cells. Mutation of any single interaction reduces the 
immobile fraction to the level of the non-functional mutant. This indicates that, all 
mutants are incapable of forming adhesive E-cadherin complexes. To confirm this, I 
measure TEER in L cells expressing high and low expression level of wild-type E-
cadherin-GFP and cis, trans, ΔEC1 and Δcyt mutants (figure 3.21). The results 
revealed that only wild-type E-cadherin-GFP expression increased junctional 
integrity in L cells. Moreover, this increase in TEER is dependent on the amount of 
E-cadherin-GFP expressed in the cells. However, high or low expression level of cis, 
trans, ΔEC1 or Δcyt mutant molecules do not increases TEER in L cells. This 
indicates that none of these mutants are able to form adhesive E-cadherin complexes.  
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3.21. Junctional integrity of L cells expressing high and low levels of wild-type E-cadherin-GFP, 
cis, trans, ΔEC1 and Δcyt mutants. Wild-type E-cadherin-GFP expression increased cell-cell 
adhesion in L cells. However, high or low expression level of cis, trans, ΔEC1 or Δcyt mutant 
molecules do not increases TEER in L cells. This indicates that none of these mutants are able to form 
adhesive E-cadherin complexes. The data for L cell expressing high and low wt-E-cadherin_GFP are 
duplicated from figure 3.8. N=3. Error bars show SEM. 
 
In summary, these data showed that disruption of any single interaction of the E-
cadherin molecule was sufficient to reduce Fi to 30%. This 30% immobile fraction is 
the same level as the non-functional mutant ∆EC1∆Cyt-E-cadherin-GFP and is most 
likely due to non-specific trapping in the plasma membrane (Kusumi 2005). This 
indicates that, all three interactions (cis-, trans-, and actin) are required for inclusion 
of E-cadherin-GFP into adhesive immobile E-cadherin clusters in junctions.  
Chapter 3: Cis, trans and actin interactions form adhesive E-cadherin clusters.                               103 
Moreover, all the mutants recovered faster than E-cadherin-GFP. In PDACfl cells, the 
cytoplasmic deletion mutant ∆Cyt-E-cadherin-GFP recovered at the rate of 
∆EC1∆Cyt mutant, demonstrating that cis- and trans- interactions mediated by the 
EC1 domain did not restrain the diffusion of this mutant. In contrast, mutants 
retaining the cytoplasmic tail recovered significantly more slowly, irrespective of the 
cis and trans interactions which retained by the EC1 domain. However, none of the 
mutants recovered as slowly as wild-type E-cadherin retaining all three interactions. 
This suggests that the slow mobility of wild-type E-cadherin-GFP depends on the 
ability to form all three interactions: cis, trans, and actin. 
 
3.8. Wild-type E-cadherin-GFP but not mutants have diffusion uncoupled 
FRAP recovery. 
 
The results in section 3.2 showed that the recovery rate of ∆EC1∆Cyt-E-cadherin-
GFP was much faster than wild-type E-cadherin-GFP, suggesting that wild-type E-
cadherin binds to stationery complexes in the membrane by the cis, trans and actin 
interactions. These associations immobilize 30% of E-cadherin molecules, and that is 
the source for reduction of Fi from 60% in wild-type E-cadherin-GFP to 30% in 
GFP-∆EC1∆Cyt-E-cadherin. In addition, ∆EC1∆Cyt-E-cadherin-GFPmutants (or 
other mutants) recovered much faster than wild-type E-cadherin-GFP, which 
indicates that cis, trans and actin interactions also bind E-cadherin to stationary 
adhesive clusters transiently. The recovery of the non-binding ∆EC1∆Cyt-E-
cadherin-GFP mutant does not depend on any binding so it recovers as fast as the 
diffusion rate. However, binding\unbinding from these adhesive clusters delayed the 
diffusion rate of wild-type E-cadherin-GFP molecules. One way to confirm that 
FRAP recovery is determined by association\dissociation rates and not by the rate of 
diffusion is to vary the size of the bleached region (Sprague 2005, Nanes 2012).  If 
recovery occurs by diffusion only, T1/2 will depend on the diffusion of monomers 
from the centre to the edge of the ROI. Therefore, T1/2 should increase with growing 
ROI diameter. On the other hand, if recovery is driven by binding\unbinding of 
stationary complexes rather than diffusion, the ROI size does not affect T1/2 and the 
recovery rate reflects the molecular association and dissociation rates. 
Analyzing FRAP recovery time for GFP-f, GFP-∆EC1∆Cyt-E-cadherin, ∆EC1-E-
cadherin-GFP and wild-type E-cadherin-GFP molecules in PDACfl cells using ROIs 
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of 2, 3, and 4 μm in diameter in PDACfl cells showed that the recovery time of GFP-f 
and ∆EC1∆Cyt-E-cadherin-GFP significantly increased with increasing ROI 
diameter (Figure 3.22.A). GFP-f and ∆EC1∆Cyt-E-cadherin-GFP cannot bind to 
anything in the plasma membrane. Therefore, their FRAP recovery are only driven 
by diffusion rates. 
In addition, FRAP analysis of the ∆EC1-E-cadherin-GFP mutant in PDACfl cells 
using different ROI sizes showed there is a significant difference between T1/2 of 2 
μm and 4 μm ROI diameter (P = 0.013). This mutant is able to bind to the actin 
cytoskeleton and this interaction slows down the recovery compared to ∆EC1∆Cyt-
E-cadherin-GFP mutants. However, the recovery still depends on ROI size. This 
indicates that the recovery of ∆EC1-E-cadherin-GFP mutants diffusion coupled (see 
section 1.4.5.2). This indicates that the time for diffusion of molecules across the 
ROI is longer than the time needed to form new binding and E-cadherin molecules 
may bind and unbind several times as they move across the bleached region. 
In contrast, there is no significant difference between recovery time of wild-type E-
cadherin-GFP molecules in 2, 3, and 4 μm ROIs and the recovery time remained 
constant with increasing ROI diameter (p value for t test between 2 and 4 μm ROIs is 
P = 0.801). This indicates that recovery of wild-type E-cadherin-GFP molecules is 
diffusion-uncoupled recovery. In other words, diffusion of wild-type E-cadherin-
GFP molecules is much faster than the rate of association\dissociation of cadherin 
molecules with stationary complexes.  This means that the recovery due to diffusion 
happens first, and is followed by dissociation of bleached molecules and binding of 
unbleached molecules. 
FRAP analysis of GFP-f and wild-type E-cadherin-GFP in L cells showed similar 
results to PDACfl cells. The recovery of GFP-f molecules, which diffuse freely, 
significantly increased as the ROI size increased from 2 to 3 and from 3 to 4 μm in 
diameter (figure 3.22.B) (p value for t test between 2 and 4 μm ROIs is P = 0.005). In 
addition, similar to PDACfl cells, there is no significant difference between T1/2 of 
wild-type E-cadherin-GFP in different ROI sizes, which indicates that the recovery 
of wild-type E-cadherin-GFP molecules is diffusion uncoupled in L cells (p value for 
t test between 2 and 4 μm ROIs is P = 0.804). 
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Figure 3.22. FRAP data for different bleach sizes. A) T1/2 for GFP-f and ΔEC1Δcyt-E-cadherin-
GFP, GFP-ΔEC1-E-cadherin compared to WT E-cadherin-GFP in high expressing PDACfl cells. B) 
T1/2 for GFP-f and WT-E-cadherin-GFP in high expressing L cells. Data for 3 and 4 μm ROI are 
normalized to 2 μm ROI. Error bars show SEM. 
 
 
3.9. Cross-linking showed that the mobile fraction of E-cadherin-GFP molecules 
consists of two components. 
 
The FRAP results using different ROI sizes showed that wild-type E-cadherin-GFP 
molecules had diffusion uncoupled recovery but recovery of E-cadherin mutants are 
limited by the rate of diffusion only. This indicates that the recovery of wild-type E-
cadherin molecules depends on the rate of association\dissociation from E-cadherin 
clusters in membrane. To confirm that the recovery of E-cadherin was driven by 
binding\unbinding from stationary complexes, a cross-linker was used to covalently 
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bind E-cadherin molecules in clusters and then the recovery rate was analysed by 
FRAP. 
For cross-linking experiment the cell-impermeable homo-bifunctional cross-linker 
Bis[sulfosuccinimidyl] substrate (BS3) was used. Based on the short linking radius 
of this compound (11.4 Å), it is expected only to cross-link molecules in direct 
proximity. For comparison with wild-type E-cadherin-GFP, I used ∆EC1∆Cyt-E-
cadherin-GFP mutants as these molecules are unable to form extracellular 
interactions (cis or trans dimerization) and should not be cross-linked. 
Initially, I established conditions in which BS3 cross-linked E-cadherin effectively 
by western blot analysis (Figure 3.23). 20 minutes of treatment with 35 mM BS3 
resulted in a weak band of cross-linked E-cadherin. However, 10 minutes of 100 mM 
BS3 treatment increases the cross linked E-cadherin-GFP band and 20 minutes of 
100 mM BS3 treatment resulted in the majority of both E-cadherin and E-cadherin-
GFP monomers being cross-linked.  
Endogenous E-cadherin has 120 KD molecular weight and GFP fusion with E-
cadherin increases the molecular weight of E-cadherin-GFP molecule to around 147 
KD. Therefore, the molecular weight of the dimer between two endogenous E-
cadherin molecules is around 240 KD and the molecular weight of dimers between 
two E-cadherin-GFP molecules is 294 KD. The molecular weight of a dimer between 
an endogenous E-cadherin molecule and an E-cadherin-GFP fusion is 267 KD. 
Therefore, in the PDACfl cells expressing wt-E-cadherin-GFP, the E-cadherin cross-
linked dimers could have three different molecular weight ranges between 240 to 294 
KD. Analysing cell lysate from these cells in western blot probed with E-cadherin 
antibody showed three bands between 240 and 300 molecular weight. However, by 
probing the blot with anti-GFP antibody only two bands was recognized between 240 
and 300 Molecular weigh markers. This indicates that cross-linker is able to cross-
link dimers from endogenous E-cadherins and E-cadherin-GFP. Moreover, cross-
linking was able to cross-link endogenous and E-cadherin-GFP molecules, which 
confirms that E-cadherin-GFP is able to form dimers with endogenous E-cadherin in 
PDACfl cells. 
Cell lysates from PDACfl cells expressing ∆EC1∆Cyt-E-cadherin-GFP probed with 
an anti-E-cadherin antibody demonstrated that BS3 cross-linking only shows one 
band between 250 and 300 molecular weights. Moreover probing with GFP antibody 
does not show any cross-linked band on western-blot. Therefore, the dimers in E-
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cadherin antibody probed blot are Endogenous E-cadherin molecules and cross-
linker is not able to cross-link ∆EC1∆Cyt-E-cadherin-GFP molecules. This indicates 
that ∆EC1∆Cyt mutant are binding together and they are only presents as monomers 
in the plasma membrane. This suggests that BS3 treatment is only able to cross-link 
cis or trans dimerized molecules in the plasma membrane. 
 
Figure 3.23. The western blots for demonstrating cross-linking of E-cadherin. The blot on the 
right is probed with GFP antibody and the plot o the right is probed with anti-E-cadherin antibody. 
First lane from left on both blots is PDACfl cells with no E-cadherin-GFP expression. cell lysates from 
PDACfl cells with high expression of E-cadherin-GFP are treated with 0, 35, 100 mM concentrations 
of BS3 cross-linker for 10 or 20 min. Two lanes on the right on both blots show cell lysate form 
PDACfl cells expressing high level of ∆EC1∆Cyt-E-cadherin-GFP analysed before and after treatment 
with 100 mM cross-linker for 20 min. BS3 is not able to cross-linking ∆EC1∆Cyt-E-cadherin-GFP 
molecules. 
 
FRAP analysis on BS3-treated PDACfl cells expressing a high level of wild-type E-
cadherin-GFP showed that the treatment with cross-linker in all the conditions 
(20min 35mM, 20min 100mM or 10min 100mM) significantly increased the amount 
of E-cadherin immobilized and decreases T1/2 compared to non-treated cells (Figure 
3.24). 
In agreement with western blot analysis, BS3 cross-linker was unable to affect the 
mobility of ∆EC1∆Cyt-E-cadherin-GFP mutants (p values for t test comparing 
before and after cross-linker treatments are P = 0.138 and P = 0.060 for Fi% and 
T1/2). 
FRAP data showed that 20 minutes of 100mM BS3 treatment significantly increased 
the Fi% of E-cadherin-GFP from 60% to 85% (p values are P = <0.001 and P = 
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<0.001 for Fi% and T1/2). Furthermore, T1/2 was dramatically reduced from 50 
seconds to 7 seconds, which is not statistically different from the recovery rate of 
freely diffusing ∆EC1∆Cyt-E-cadherin-GFP molecules (P = 0.353).  
Moreover, following 20 min of treatment with BS3, increasing the ROI size from 3 
μm to 6μm in diameter caused an increase in the recovery rate of E-cadherin-GFP 
(P=<0.001). This indicates that the recovery of E-cadherin-GFP became diffusion 
coupled following treatment with BS3. 
When the time of cross-linking was reduced from 20 minutes to 10 minutes, the 
resulting partial decrease in T1/2 between 3 μm to 6 μm diameter ROI was not 
statistically significant (P = 0.270).  
These data suggest that the 40% mobile fraction of E-cadherin-GFP is comprised of 
two components. The first component is not cross-linkable. It represents the mobile 
fraction, which remains after cross-linking E-cadherin-GFP. This component is 
approximately 15% of total E-cadherin-GFP and consisting of free monomers which 
are not affected by BS3 treatment. The second component is the difference between 
the immobile fractions of cross-linked and non-cross-linked E-cadherin-GFP and 
consists of monomers, which transiently bind\unbind from stationary E-cadherin 
clusters. Cross-linking with BS3 covalently bound the transiently associated 
cadherins molecules and prevented dissociation of these molecules from stationary 
complexes. Therefore, cross-linking significantly increased immobile fraction of E-
cadherin molecules from 60% to 85%. This 25% represents the component of mobile 
E-cadherin molecules that are able to bind\unbind from stationary complexes. 
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Figure 3.24. FRAP results in PDACfl cells expressing either WT E-cadherin-GFP or ∆EC1∆Cyt-
E-cadherin-GFP, after treatment with BS3 cross-linker. Treatment with BS3 cross-linker 
significantly increased Fi% and decreases T1/2 compared to no cross-linking (orange circle). Green 
squares show FRAP results after 20 min treatment with 35 mM of BS3 for 3 μm  ROI size (3μm Ø) 
and 6μm Ø. Orange diamond and red square show FRAP result after 10 min treatment 100 mM BS3 
for 3μm Ø and 6μm Ø respectively. The FRAP data show there is no significant difference between 
3μm Ø and 6μm Ø in both cases. However, after 20 min treatment with 100 mM BS3 there is a 
significant difference between T1/2 of 3μm Ø and 6μm Ø (blue circle and blue square). BS3 treatment 
on ∆EC1∆Cyt-E-cadherin-GFP expressing cells doesn’t has any significant difference in FRAP data 
(purple circles). Data for WT-E-cadherin-GFP and ∆EC1∆Cyt-E-cadherin-GFP is duplicated from 
figure 3.4. Error bars show SEM. 
NWT,3μmø,100mM,20minXlink=15, NWT,6μmø,100mM,20minXlink=16, N∆EC1∆Cyt,3μmø100mM,20minXlink=16, 
NWT,3μmø,100mM,10minXlink=27, NWT,6μmø,100mM,10minXlink=10, NWT,3μmø,35mM,20minXlink=14, 
NWT,3μmø,35mM,20min Xlink=14. 
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PDACfl cells:          T test values: 
  N  Fi% ±SEM T1/2 ±SEM   N  Fi% ±SEM T1/2 ±SEM FI% t1/2 
wtEcad Hi 24 40.9 2.57 40.9 3.64 w2a Hi 24 36.7 1.89 19.76 1.99 P=<0.001 P=<0.001 
wtEcad Hi 24 40.9 2.57 40.9 3.64 Δcyt Hi 18 33.8 2.47 10.85 1.48 P=<0.001 P=<0.001 
wtEcad Hi 24 40.9 2.57 40.9 3.64 cis Hi 26 37.1 2.58 17.01 1.80 P=<0.001 P=<0.001 
wtEcad lo 24 40.9 2.57 40.9 3.64 Δcyt lo 26 50.2 3.13 21.29 1.86 P = 0.033 P = 0.003 
wtEcad Hi 24 40.9 2.57 40.9 3.64 ΔEC1 Hi 32 35.2 1.94 18.58 1.92 P=<0.001 P=<0.001 
wtEcad Hi 24 40.9 2.57 40.9 3.64 ΔΔ Hi 39 31.4 1.96 9.57 0.78 P=<0.001 P=<0.001 
wtEcad lo 32 58.3 2.17 30.6 2.25 wtEcad Hi 24 40.9 2.57 40.94 3.64 P = 0.916 P = 0.014 
w2a Hi 24 36.7 1.89 19.8 1.99 w2a lo 20 35.4 2.36 21.01 1.78 P = 0.679 P = 0.650 
Δcyt lo 26 50.2 3.13 21.3 1.86 Δcyt Hi 18 33.8 2.47 10.85 1.48 P=<0.001 P=<0.001 
cis lo 31 37.5 2.18 18.8 1.71 cis Hi 26 37.1 2.58 17.01 1.80 P = 0.755 P = 0.543 
ΔEC1 lo 24 34.7 2.70 18.4 1.60 ΔEC1 Hi 32 35.2 1.94 18.58 1.92 P = 0.875 P = 0.637 
ΔΔ lo 23 34.8 2.45 7.91 0.78 ΔΔ Hi 39 31.4 1.96 9.57 0.78 P = 0.284 P = 0.153 
Δcyt Hi 18 33.8 2.47 10.9 1.48 cis Hi 26 37.1 2.58 17.01 1.80 P = 0.382 P = 0.009 
Δcyt Hi 18 33.8 2.47 10.9 1.48 ΔEC1 Hi 32 35.2 1.94 18.58 1.92 P = 0.676 P = 0.002 
Δcyt Hi 18 33.8 2.47 10.9 1.48 ΔΔ Hi 39 31.4 1.96 9.57 0.78 P = 0.465 P = 0.718 
Δcyt Hi 18 33.8 2.47 10.9 1.48 GFP-f 9 26.3 1.82 5.54 0.48 P = 0.047 P = 0.010 
cis Hi 26 37.1 2.58 17.0 1.80 ΔEC1 Hi 32 35.2 1.94 18.58 1.92 P = 0.540 P = 0.521 
cis Hi 26 37.1 2.58 17.0 1.80 ΔΔ Hi 39 31.4 1.96 9.57 0.78 P = 0.076 P=<0.001 
ΔEC1 Hi 32 35.2 1.94 18.58 1.92 ΔΔ Hi 39 31.4 1.96 9.57 0.78 P = 0.178 P=<0.001 
ΔΔ Hi 39 31.4 1.96 9.57 0.78 GFP-f 9 26.3 1.82 5.54 0.48 P = 0.210 P = 0.005 
w2a Hi 24 36.7 1.89 19.8 1.99 Δcyt Hi 18 33.8 2.47 10.85 1.48 P = 0.360 P=<0.001 
w2a Hi 24 36.7 1.89 19.8 1.99 cis Hi 26 37.1 2.58 17.01 1.80 P = 0.869 P = 0.303 
w2a Hi 24 36.7 1.89 19.8 1.99 Δec1 Hi 32 35.2 1.94 18.58 1.92 P = 0.593 P = 0.625 
w2a Hi 24 36.7 1.89 19.8 1.99 ΔΔ Hi 39 31.4 1.96 9.57 0.78 P = 0.074 P=<0.001 
Δcyt lo  26 50.2 3.13 21.3 1.86 cis lo 31 37.5 2.18 18.75 1.71 P=0.001 P = 0.697 
Δcyt lo 26 50.2 3.13 21.3 1.86 ΔEC1 lo 24 34.7 2.70 18.43 1.60 P=<0.001 P = 0.854 
Δcyt lo 26 50.2 3.13 21.3 1.86 ΔΔ lo 23 34.8 2.45 7.91 0.78 P=<0.001 P=0.001 
Δcyt lo 26 50.2 3.13 21.3 1.86 GFP-f 9 26.3 1.82 5.54 0.48 P <0.001 P=0.001 
w2a lo 20 35.4 2.36 21.0 1.78 Δcyt lo 26 50.2 3.13 21.29 1.86 P = 0.007 P = 0.724 
w2a lo 20 35.4 2.36 21.0 1.78 cis lo 31 37.5 2.18 18.75 1.71 P = 0.786 P = 0.875 
w2a lo 20 35.4 2.36 21.0 1.78 ΔEC1 lo 24 34.7 2.70 18.43 1.60 P = 0.720 P = 0.943 
w2a lo 20 35.4 2.36 21.0 1.78 ΔΔ lo 23 34.8 2.45 7.91 0.78 P = 0.740 P=<0.001 
w2a lo 20 35.4 2.36 21.0 1.78 GFP-f 9 26.3 1.82 5.54 0.48 P = 0.113 P=<0.001 
cis lo 31 37.5 2.18 18.8 1.71 ΔEC1 lo 24 34.7 2.70 18.43 1.60 P = 0.411 P = 0.893 
cis lo 31 37.5 2.18 18.8 1.71 ΔΔ lo 23 34.8 2.45 7.91 0.78 P = 0.372 P=<0.001 
cis lo 31 37.5 2.18 18.8 1.71 GFP-f 9 26.3 1.82 5.54 0.48 P = 0.007 P=<0.001 
ΔEC1 lo 24 34.7 2.70 18.4 1.60 ΔΔ lo 23 34.8 2.45 7.91 0.78 P = 0.969 P=<0.001 
ΔEC1 lo 24 34.7 2.70 18.4 1.60 GFP-f 9 26.3 1.82 5.54 0.48 P = 0.056 P=<0.001 
ΔΔ lo 23 34.8 2.45 7.91 0.78 GFP-f 9 26.3 1.82 5.54 0.48 P = 0.036 P = 0.063 
wtEcad lo  32 58.3 2.17 30.6 2.25 w2a lo 20 35.4 2.36 21.01 1.78 P <0.001 P = 0.009 
wtEcad lo  32 58.3 2.17 30.6 2.25 cis lo 31 37.5 2.18 18.75 1.71 P=<0.001 P=<0.001 
wtEcad lo  32 58.3 2.17 30.6 2.25 ΔEC1 lo 24 34.7 2.70 18.43 1.60 P=<0.001 P=<0.001 
wtEcad lo  32 58.3 2.17 30.6 2.25 ΔΔ lo 23 34.8 2.45 7.91 0.78 P=<0.001 P=<0.001 
Table 3.1. Summary of FRAP data and T test values for PDACfl cells. 
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L cell                       T test values 
  N  Fi% ±SEM T1/2 ±SEM   N  Fi% ±SEM T1/2 ±SEM imob t1/2 
wtEcad lo  19 50.5 3.33 31.7 2.39 wtEcad Hi 30 54.9 2.25 40.0 2.66 P = 0.281 P=<0.001 
wtEcad lo  19 50.5 3.33 31.7 2.39 w2a lo 33 39.1 1.89 18.0 1.37 P = 0.003 P=<0.001 
wtEcad lo  19 50.5 3.33 31.7 2.39 Δcyt lo 21 37.0 2.76 12.3 1.46 P = 0.004 P=<0.001 
wtEcad lo  19 50.5 3.33 31.7 2.39 cis lo 25 37.7 2.54 18.1 1.97 P=0.001 P=<0.001 
wtEcad lo  19 50.5 3.33 31.7 2.39 ΔEC1 lo 22 37.1 1.95 20.2 0.92 P = 0.003 P=<0.001 
wtEcad lo  19 50.5 3.33 31.7 2.39 ΔΔ lo 11 32.3 3.48 6.4 0.86 P=0.001 P=<0.001 
wtEcad lo  19 50.5 3.33 31.7 2.39 GFP-f 26 28.8 2.16 4.5 0.36 P=<0.001 P=<0.001 
wtEcad Hi 30 54.9 2.25 40.0 2.66 w2a Hi 41 35.5 2.28 18.2 1.48 P=<0.001 P=<0.001 
wtEcad Hi 30 54.9 2.25 40.0 2.66 Δcyt Hi 23 35.6 2.48 12.4 1.16 P=<0.001 P=<0.001 
wtEcad Hi 30 54.9 2.25 40.0 2.66 cis Hi 28 36.9 1.99 17.1 1.18 P=<0.001 P=<0.001 
wtEcad Hi 30 54.9 2.25 40.0 2.66 ΔEC1 Hi 31 34.1 1.78 20.1 1.15 P=<0.001 P=<0.001 
wtEcad Hi 30 54.9 2.25 40.0 2.66 ΔΔ Hi 15 34.9 1.32 8.6 0.78 P=<0.001 P=<0.001 
wtEcad Hi 30 54.9 2.25 40.0 2.66 GFP-f 26 28.8 2.16 4.5 0.36 P=<0.001 P=<0.001 
w2a lo 33 39.1 1.89 18.0 1.37 w2a Hi 41 35.5 2.28 18.2 1.48 P = 0.258 P = 0.798 
Δcyt lo 21 37.0 2.76 12.3 1.46 Δcyt Hi 23 35.6 2.48 12.47 1.16 P = 0.702 P = 0.947 
cis lo 25 37.7 2.54 18.1 1.97 cis Hi 28 36.9 1.99 17.1 1.18 P = 0.699 P = 0.670 
ΔEC1 lo 22 37.1 1.95 20.2 0.92 ΔEC1 Hi 31 34.1 1.78 20.1 1.15 P = 0.103 P = 0.814 
ΔΔ lo 11 32.3 3.48 6.4 0.86 ΔΔ Hi 15 34.9 1.32 8.6 0.78 P = 0.449 P = 0.133 
w2a lo 33 39.1 1.89 18.0 1.37 Δcyt lo 21 37.0 2.76 12.3 1.46 P = 0.529 P = 0.010 
w2a lo 33 39.1 1.89 18.0 1.37 cis lo 25 37.7 2.54 18.1 1.97 P = 0.657 P = 0.808 
w2a lo 33 39.1 1.89 18.0 1.37 ΔEC1 lo 22 37.1 1.95 20.2 0.92 P = 0.500 P = 0.091 
w2a lo 33 39.1 1.89 18.0 1.37 ΔΔ lo 11 32.3 3.48 6.4 0.86 P = 0.091 P=<0.001 
w2a lo 33 39.1 1.89 18.0 1.37 GFP-f 26 28.8 2.16 4.5 0.36 P = 0.018 P=<0.001 
Δcyt lo 21 37.0 2.76 12.3 1.46 cis lo 25 37.7 2.54 18.1 1.97 P = 0.887 P = 0.042 
Δcyt lo 21 37.0 2.76 12.3 1.46 ΔEC1 lo 22 37.1 1.95 20.2 0.92 P = 0.757 P=<0.001 
Δcyt lo 21 37.0 2.76 12.3 1.46 ΔΔ lo 11 32.3 3.48 6.4 0.86 P = 0.316 P = 0.008 
Δcyt lo 21 37.0 2.76 12.3 1.46 GFP-f 26 28.8 2.16 4.5 0.36 P = 0.124 P = 0.002 
cis lo 25 37.7 2.54 18.1 1.97 ΔEC1 lo 22 37.1 1.95 20.2 0.92 P = 0.871 P = 0.127 
cis lo 25 37.7 2.54 18.1 1.97 ΔΔ lo 11 32.3 3.48 6.4 0.86 P = 0.204 P=<0.001 
cis lo 25 37.7 2.54 18.1 1.97 GFP-f 26 28.8 2.16 4.5 0.36 P = 0.019 P=<0.001 
ΔEC1 lo 22 37.1 1.95 20.2 0.92 ΔΔ lo 11 32.3 3.48 6.4 0.86 P = 0.204 P=<0.001 
ΔEC1 lo 22 37.1 1.95 20.2 0.92 GFP-f 26 28.8 2.16 4.5 0.36 P = 0.045 P=<0.001 
ΔΔ lo 11 32.3 3.48 6.4 0.86 GFP-f 26 28.8 2.16 4.5 0.36 P = 0.685 P = 0.591 
w2a Hi 41 35.5 2.28 18.2 1.48 Δcyt Hi 23 35.6 2.48 12.4 1.16 P = 0.972 P = 0.004 
w2a Hi 41 35.5 2.28 18.2 1.48 cis Hi 28 36.9 1.99 17.1 1.18 P = 0.656 P = 0.691 
w2a Hi 41 35.5 2.28 18.2 1.48 ΔEC1 Hi 31 34.1 1.78 20.1 1.15 P = 0.541 P = 0.064 
w2a Hi 41 35.5 2.28 18.2 1.48 ΔΔ Hi 15 34.9 1.32 8.6 0.78 P = 0.890 P=<0.001 
w2a Hi 41 35.5 2.28 18.2 1.48 GFP-f 26 28.8 2.16 4.5 0.36 P = 0.342 P=<0.001 
Δcyt Hi 23 35.6 2.48 12.47 1.16 cis Hi 28 36.9 1.99 17.1 1.18 P = 0.666 P = 0.008 
Δcyt Hi 23 35.6 2.48 12.47 1.16 ΔEC1 Hi 31 34.1 1.78 20.1 1.15 P = 0.631 P=<0.001 
Δcyt Hi 23 35.6 2.48 12.47 1.16 ΔΔ Hi 15 34.9 1.32 8.6 0.78 P = 0.585 P = 0.018 
Δcyt Hi 23 35.6 2.48 12.47 1.16 GFP-f 26 28.8 2.16 4.5 0.36 P = 0.208 P=<0.001 
cis Hi 28 36.9 1.99 17.1 1.18 ΔEC1 Hi 31 34.1 1.78 20.1 1.15 P = 0.297 P = 1.000 
cis Hi 28 36.9 1.99 17.1 1.18 ΔΔ Hi 15 34.9 1.32 8.6 0.78 P = 0.671 P=<0.001 
cis Hi 28 36.9 1.99 17.1 1.18 GFP-f 26 28.8 2.16 4.5 0.36 P = 0.070 P=<0.001 
ΔEC1 Hi 31 34.1 1.78 20.1 1.15 ΔΔ Hi 15 34.9 1.32 8.6 0.78 P = 0.824 P=<0.001 
ΔEC1 Hi 31 34.1 1.78 20.1 1.15 GFP-f 26 28.8 2.16 4.5 0.36 P = 0.296 P=<0.001 
ΔΔ Hi  15 34.9 1.32 8.6 0.78 GFP-f 26 28.8 2.16 4.5 0.36 P = 0.374 P = 0.037 
Table 3.1. Summary of FRAP data and T test values for L cells. 
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4. FRAP Analysis of E-Cadherin Dynamics as a Read-Out for Cell 
Motility 
 
In the previous chapter, I showed how FRAP was used on to analyse the molecular 
dynamics of E-cadherin molecules in cell-cell junctions in pancreatic cancer cells. In 
this chapter, I will analyze how E-cadherin dynamics are related to cell motility and 
invasion. In many cancer cells, mis-regulation of adherens junctions causes increased 
progression and invasion of cancer (Birchmeier 1994). Alteration in E-cadherin 
dynamics could therefore serve as an early molecular biomarker of metastasis. In this 
chapter, I employed FRAP to compare E-cadherin dynamics in two PDAC cell lines 
derived from primary pancreatic tumours of the KPC mouse model. In this model 
tumour formation is driven by mutant KRAS; however, tumour metastasis is driven 
by mutant p53 (Morton 2010). In particular, I will focus on the effect of the local 
micro environments on the mobility of E-cadherin in cell lines derived from mouse 
primary tumours. 
 
4.1. P53 mutation drives cell invasion in PDAC cells. 
 
In the KPC mouse model KRASG12D mutation drives formation of PanINs, then loss 
of p53 promotes formation of pancreatic tumours. Mice with Pdx1-Cre, LSL-
KRASG12D/+, Trp53LoxP/+ genetic background form tumours which are not invasive. In 
this study, I used a cell line derived from pancreatic tumours of these mice. These 
PDAC cells with loss of p53 expression will be referred to as PDACfl cells. On the 
other hand, mice with Pdx1-Cre, LSL-KRASG12D/+, LSL-Trp53R172H/+ genetic 
background form invasive tumours. In this chapter, cell line derived from these 
tumours is called PDACR172H. PDACfl cell which derived from pancreatic tumours 
with Pdx1-Cre, LSL-KRASG12D/+, Trp53LoxP/+ genetic background were stably 
transfected with plasmid with p53R175H or empty vector. Here, these cell lines are 
called PDACflR175H and PDACflvector respectively. In FRAP experiments reported 
in this thesis all this cell lines are stably transfected with E-cadherin-GFP plasmid.  
PDAC cell with loss of p53 expression (PDACfl) are not invasive in organotypic 
assay and xenograft tumours. On the other hand, PDAC cells from tumours with 
p53R172H mutation (PDACR172H) are more progressive and invasive than PDACfl 
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cells. Moreover, expression of human mutant p53 protein (p53R175H) in PDACfl cells 
is sufficient to activate cell invasion in PDACfl cells (Morton 2010). Here, I studied 
PDAC cell line stably transfected with E-cadherin-GFP plasmid. 
Initially, an organotypic assay was used to study the invasion of PDACfl and 
PDACR172H cells lines. To perform organotypic assay, 4 × 104 PDAC cells were 
seeded on top of the matrix in complete media and allowed to grow to confluence for 
5 days. The matrix was then mounted on a metal grid and raised to the air/liquid 
interface resulting in the matrix being fed from below with complete media. The 
cells media was changed every 2 days and the cells were grown for 8–12 days.  Then 
the cultures were fixed and stained by H&E method. Representative images in figure 
4.1 (A, B and C) showed that PDACfl cells continue to grow on the surface but did 
not invade in to the organotypic gel. In contrast, PDACR172H cells were highly 
invasive. Additionally, as previously reported by Morton et al, transfecting PDACfl 
cells with human p53 mutant protein (p53flR175H) was adequate to make these cells 
invasive. The PDACR172H cells invade to the gel as single cells and have a more 
mesenchymal phenotype; in contrast PDACflR175H cells have stronger cell-cell 
adhesions and invade collectively into the gel (figure 4.1 B and C). 
In order to study the effects of mutant p53 on E-cadherin dynamics using FRAP, I 
transfected these cells with a plasmid for E-cadherin-GFP. As shown previously in 
section 3.3.1, increasing the expression level of E-cadherin could affect cell-cell 
adhesion. Therefore, I analysed how expression of E-cadherin-GFP on top of 
endogenous E-cadherin would affects PDAC cell invasion. I repeated the 
organotypic assay using the same cell lines which now expressed E-cadherin-GFP 
(Figure 4.1. D, E and F).  Representive figures show that PDACR172H and 
PDACflR175H cells with expression of E-cadherin-GFP are still highly invasive. To 
quantify the invasion, I measured the depth of each cell in the gel (Figure 4.2). On 
the Y axis the average of depth of invasion of single cells are shown. The data 
showed that PDACR172H and PDACflR175H cells with E-cadherin-GFP expression 
are still highly invasive, and there was no significant difference in depth of invasion 
between original cells and E-cadherin-GFP expressing cells (t test p values were P = 
0.305 and P = 0.330 respectively).  
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A) PDACfl 
 
D) PDACfl +E-cadherin-GFP 
B)PDACR172H 
 
E)PDACR172H +E-cadherin-GFP  
C) PDACflR175H 
 
F) PDACflR175H+E-cadherin-GFP 
 
Figure 4.1. PDAC cells expressing mutant p53 are invasive in Organotypic assays. A-F show 
representative images of organotypic gels. PDACfl cells (A) do not invade in the organotypic gel. 
However, PDACR172H (B) and PDACflR175H (C) cells are highly invasive. D-F show PDAC cells 
with E-cadherin-GFP expression. Expression of E-cadherin-GFP in these cells does not inhibit cell 
invasion. (Bar is 100 μm.) 
 
Comparing organotypic invasion of PDACR172H cells which are directly driven from 
p53 mutant mouse tumours with PDACflR175H cells which are driven from p53 null 
mice tumours and then the human mutant p53 protein is expressed in them shows 
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that although both cells are invasive; the invasion mode is different in two cell lines. 
PDACR172H cells migrated as individual cells and invaded far more in the gel. But 
PDACflR175H cells invaded more in groups of cells and the depth of invasion is 
slightly less than PDACR172H cells. The PDACR172H cells are from mice tumours and 
these cells might acquire additional genetic alteration during progression 
tumorigenesis. Moreover, these cells are exposed to the immune response in vivo 
which could affect these cells invasive phenotype. 
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Figure 4.2. Quantification of depth of invasion of PDAC cells. Depth of each cell in the gel is 
averaged. PDACfl cells do not invade in the gel and cell invasion for these cells is zero. PDACR172H 
and PDACflR175H cells with E-cadherin-GFP expression are still highly invasive, and there is no 
significant difference in depth of invasion between original cells and E-cadherin-GFP expressing 
cells. Error bars are SEM. (each organotypic assay repeated three times). 
 
Moreover, I studied the effect of E-cadherin-GFP expression in PDAC cells on 
xenograft tumours in nude mice. PDACflvector and PDACflR175H cells were 
trypsinized and 106 cells were injected subcutaneously into the flank of CD1 nude 
mice. The Home Office guidelines dictate that the mice were culled before the 
tumours reached 15 mm size or alternatively if the tumours became ulcerated. The 
data showed that the tumours from PDACflR175H cells with E-cadherin-GFP 
expression grow faster than PDACflvector cell tumours (Figure 4.3.A).  
This showed that xenograft tumours from PDAC cells with mutant p53 are more 
progressive than tumours with loss of p53 and stable expression of E-cadherin-GFP 
does not have any affect on it.  
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Figure 4.3. Xenograft tumours expressing mutant p53 are more progressive. (A) Analysis of the 
rate of tumour growth, as assessed by the increase in tumour area over time in PDACflR175H cells 
with E-cadherin-GFP expression compared to PDACflvector cells expressing E-cadherin-GFP. The 
tumour shape is assumed an oval shape and length and width of tumour is measured to estimate the 
tumour area. Statistically significant difference (*) as assessed by Mann-Whitney Rank Sum Test at 
days 8, 15, 21; P = 0.002, P = <0.001 and P = 0.003 respectively. (B) Analysis of the survival time in 
PDACflR175H xenografts compared to PDACflvector tumours. Error bars shows STDV (n=10) 
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4.2. Mutant p53 weakens cell-cell adhesion in PDAC cells. 
 
The organotypic data showed that p53 mutation dramatically promotes PDAC cell 
invasion. Subsequently, I used a dispase assay to study how this mutation affects 
cell-cell adhesion in these cells (Figure 4.4.A). For performing the Dispase assays, a 
confluent cell monolayer in a 6 well dish was treated with dispase II, the detached 
monolayer then was broken up by pipetting up and down, and after passing through a 
cell strainer, the single cells were counted using a hemocytometer. The single cell 
number was reported as percentage of the PDACflvector cells. The data showed that, 
PDACflR175H cells have significantly higher number of single cells than 
PDACflvector cells (P = <0.001). Moreover, TEER was used to measure cell-cell 
junctional integrity. For measuring TEER cells were seeded on 12 well transwells, 
and then electrical resistance was measured using an EVOM2 epithelial 
voltohmmeter. The results were reported as percentage of PDACflvector cell 
resistance. Measurement of TEER across a confluent monolayer showed that cells 
expressing mutant p53 have significantly lower junctional integrity than cells 
expressing no p53 (figure 4.4.B) (P = 0.047).  
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Figure 4.4. Mutant p53 reduces cell-cell adhesi junctional integrity in PDAC cells. A) 
Dispase assay results comparing PDACflR175H with PDACflvector cells. The data shows that 
p53R175H mutation significantly increased the number of single cells, whic
ced 
 
on and 
h indicates that cell-cell 
adhesion is disrupted in PDACflR175H cells. B) TEER measurements in PDACflR175H and 
PDACflvector cells. Electrical resistance is significantly lower in p53 mutant cells indicating 
redu barrier function. Error bars shows SEM. (n=3) 
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4
b
AC cells. Serrels et al have previously shown that E-cadherin in cell-
ell junctions is mobilized in migrating A431 cells (Serrel 2009). Therefore, I 
.3. Mutant p53 increases the mobility of E-cadherin on cells grown on CDM 
ut not glass. 
 
The data showed that mutant p53 has a significant effect on invasion and cell-cell 
adhesion in PD
c
hypothesized that mutant p53 might promote invasion by mobilizing E-cadherin in 
PDAC cells. To test this idea, PDACflvector and PDACflR175H cells were grown on 
glass bottom dishes and FRAP was used to look at E-cadherin dynamics. As shown 
in blue and green colours in figure 4.5, PDACflR175H and PDACflvector cells grown 
on glass have similar recovery curves. 
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Figure 4.5. Mutant p53 affects dynamics of E-cadherin-GFP in PDAC cells grown on CDM 
not glass. FRAP curves for PDACflvector and PDACflR175H cells growing on glass or CDM. 
PDACflR175H cell line when grown on CDM show more dynamic E-cadherin-GFP compared to 
 
H
e re size, which are not 
presented by glass substrates. So, I studied the effect of mutant p53 on E-cadherin 
PDACflvector cells. Error bars show SEM. (n=at least 10 for each curve) 
owever, many aspects of cell migration depend on features of the local 
nvironment including elasticity, protein composition, or po
re
dynamics on CDM, which is a widely used 3D model to study cell motility 
(Hakkinen 2011). Cell Derived Matrix (CDM) is a collagen and fibronectin-rich 
matrix formed by the deposition of ECM and growth factors by fibroblasts in vitro. 
The formed matrix is ~30 μm thick and highly fibrous and with high stiffness. Cells 
have been shown to migrate faster along ECM fibers. The FRAP data showed that 
when these cells were grown on cell derived matrix (CDM), PDACflR175H cells 
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showed different recovery curve (orange colour in figure 4.5) compared to 
PDACflvector cells (red).  
Quantification of the Fi% and T1/2 of FRAP results in figure 4.6 shows there was no 
significant difference in immobile fraction and T1/2 values between PDACflvector 
and PDACflR175H cells grown on glass (p values for Fi% and T1/2 are P = 0.890 
and P = 0.921). However, when PDACflR175H cells were grown on CDM, the 
immobile fraction and T1/2 were significantly reduced compared to PDACflvector 
cells (p values are respectively P = <0.001 and P = <0.001) 
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Figure 4.6. Mutant p53 decreased the Fi and T1/2 of E-cadherin when cells are cultured on 
CDM. FRAP results for PDACflR175H cells growing on glass showed no significant difference in 
Immobile fraction and T1/2 compared to PDACflvector cells (purple and green triangles). 
However, f he cells grown on CDM there is a significant decrease in Fi% and T1/2 i p53 
 
A . 
There is no statistically significant difference in E-cadherin dynamics between 
DACfl and PDACR172H cells grown on glass (p values for Fi% and T1/2 are P=0.663 
or t
mutants (pink and blue triangles). Error bars show SEM. (n=at least 10 junctions for each data 
point) 
nalysis of FRAP in PDACfl and PDACR172H shows similar results (figure 4.7)
n 
P
and P=0.683). However, when cells were grown on CDM, there is significant 
increase in mobility of E-cadherin in PDACR172H cells (p values for Fi% and T1/2 are 
P = <0.001 and P = <0.001). 
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Figure 4.7. The effect of mutant p53 on E-cadherin dynamics depends on the cell environment. 
Mutant p53 does not affect the dynamics of E-cadherin in PDACfl and PDACR172H cells grown on 
glass (green and brown triangles). However, for the cells grown on CDM there is a significant 
decrease in immobile fraction and recovery rate in cells with mutant p53.  There is a sign t 
 
T
o rin mobility was 
ignificantly increased in PDACflR175H cells in comparison to PDACflvector cells 
ifican
difference between T1/2 and Immobile fraction of PDACfl and PDACR172H cells (blue and pink 
triangles). Error bars show SEM. (n=at least 10 junctions for each data point) 
hese data suggests that the effect of mutant p53 on E-cadherin dynamics depends 
n the local cell environment. Figure 4.6 showed E-cadhe
s
when grown on CDM. Similar results were obtained with PDACfl and PDACR172H 
cells (Figure 4.7). As discussed in chapter 3, when cells express comparable levels of 
E-cadherin Fi is related to the amount of E-cadherin stabilized at junctions. 
Consequently, higher Fi indicates more stabilized junctions and stronger cell-cell 
adhesion. Next, the dispase assay was used to study cell-cell adhesion in 
PDACflvector and PDACflR175H cells in CDM (Figure 4.8). There was a significant 
reduction in single cell number of PDACflR175H cells when grown in CDM 
compared to PDACflvector cells (P = 0.041). The FRAP data are consistent with the 
dispase assay results, which also indicates that mutant p53 loosens cell-cell junctions 
by mobilizing E-cadherin.  
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Figure 4.8. Mutant p53 reduces cell-cell adhesion in PDAC cells grown on CDM. Dispase 
assay results comparing cell-cell adhesion of PDACflR175H with PDACflvector cells growing 
on CDM. The data shows that p53R175H mutation significantly increased the number of single 
cells, which indicates that cell-cell adhesion is disrupted in PDA R175H cells. Error bars 
 
 
4.4. Mutant p53 increases mobility of E-cadherin in PDAC cells in xenograft 
mours. 
of mutant p53 on E-cadherin dynamics and cell migration. Extracellular 
atrix strongly affects cell migration. However, CDM is a very artificial 
Cfl
shows SEM. (n=3) 
tu
 
The data suggested that micro environment plays an important role in determining 
the effects 
m
environment compared to tumours. The composition of ECM and its rigidity is 
different compared to in vivo. Moreover, presence of immune cells and inflammation 
could affect cell invasion. FRAP experiments on cells in xenograft tumours show 
different E-cadherin dynamics compared to cells in culture (Serrels 2009). Therefore, 
for better understanding of the effects of mutant p53 on E-cadherin dynamics in the 
functional and physiological context of real tumors, I have measured FRAP in 
xenograft tumors. To do this, the PDAC cells were injected subcutaneously into the 
flank of nude mice and then allowed to grow until the tumour reached a length of 
between 1-1.4 cm. Then while the mouse was under anesthesia the tumour was 
dissected and the exposed tumor placed on a glass bottom dish while the blood flow 
was kept through a skin flap attached to the body. After FRAP the mouse was culled 
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and the tumour was fixed and stained with H&E to investigate how PDAC cell 
invade. Many cell lines derived from metastatic tumours are non-invasive when 
cultured subcutaneously in nude mice. However, xenograft tumours derived from 
PDACflR175H cell line were highly invasive compared to PDACflvector tumours 
and the cells invaded through muscle and peritoneal cavity (Figure 4.9. A and B).  
The E-cadherin FRAP results showed that immobile fraction was significantly 
smaller in mutant p53 xenograft tumours compared to PDACflvector cells in 
xenografts (Figure 4.9.C). This reduction in immobile fraction was similar to the 
Cflvector cells.  
 non-specific 
in E-cadherin 
effect of p53 mutation on mobilizing E-cadherin, and consequently weakening cell-
cell adhesions, in mutant p53 cells cultured on CDM.  
In contrast, p53 mutation had a different effect on T1/2 in xenograft tumours 
compared to CDM. On CDM mutant p53 reduced T1/2 but in xenograft tumours 
PDACflR175H cells have larger T1/2 compared to PDA
Moreover, FRAP results showed higher immobile fraction and much smaller T1/2 
for xenogfrats compared for cells growing on glass or CDM.  The higher Fi could be 
due to increased non-adhesive immobile fraction (which is because of
trapping of molecules in membrane structures (see section 5.1.5)) or increased 
adhesive clustering. This question will be addressed later in section 4.5. Moreover, 
the reduction in mobile fraction in conjunction with decrease in the recovery rate of 
E-cadherin in tumours indicates that the adhesive mobile fraction of E-cadherin is 
smaller in cells in xenograft than CDM. In other word although fewer E-cadherin 
molecules are mobile in xenograft compared to cells in CDM, the interaction of the 
mobile molecules to adhesive complexes are weaker or less frequent. 
The dramatic change in FRAP data in xenograft tumours compared to cells in culture 
suggested that the local cell environment could significantly alter the regulation of E-
cadherin within cell-cell junctions. Alternatively, this difference 
dynamics could be due to altered cell membrane structure in vivo which affect E-
cadherin dynamics non-specifically. My data on chapter 3 showed that non-specific 
trapping of free transmembrane proteins in membrane structure or cell cytoskeleton 
underneath could dramatically affects their mobility. To address this question, a 
mutant form of E-cadherin-GFP was expressed in PDACflvector xenograft tumours 
and FRAP used to study diffusion rate of E-cadherin in the plasma membrane. 
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FRAP on PDAC cell lines in xenograft tumour
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Figure.4.9. PDACflR175H cells are more invasive in xenografts and have more mobile E-
cadherin. (A and B) H&E staining of tumours shows p53 mutant cells are more invasive than 
PDACflvector cells. (A) The PDACflvector cells are not invasive and have a smooth boundary 
tumour. (B) PDACflR175H xenografts are highly invasive and the black arrows show where cells 
 
4.5. The mobile fraction of w
d
ces between E-cadherin dynamics of cells grown on CDM or in 
ivo, the ΔEC1ΔCyt mutant (see section 3.2) of E-cadherin-GFP was stably 
invaded through muscle. (C) FRAP on xenografts showed that E-cadherin in PDACflR175H 
xenograft tumours is significantly more mobile than in PDACflvector tumours (p=0.002). T1/2 is 
significantly higher in p53 mutant xenografts compared to PDACflvector xenografts (p=0.001). 
Error bars show SEM. (n=at least 14 junctions for each data point) 
ild-type E-cadherin recovers at the rate of free 
iffusion in vivo.  
 
In order to explore the possibility that differences in membrane properties could 
explain the differen
v
expressed in PDACflvector cells. These cells were injected into mice as described in 
section 4.4 and allowed to form tumours which were analysed by FRAP.  
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As I showed in chapter 3, the mutant ΔEC1ΔCyt E-cadherin can not form cis or trans 
dimers or interact with actin cytoskeleton. So it can be used to estimate the level of 
 
 E-cadherin-GFP in 
s so it can be used as a control for rate of recovery of a free diffusing 
immobile fraction due to non-specific trapping. ΔCytΔEC-E-cadherin-GFP in 
PDACfl xenograft had approximately 60% immobile fraction which is significantly 
higher than 30% Fi in these cells grown in culture (figure 4.10). This establishes the 
baseline for non-adhesive immobile fraction in PDACfl cells in xenograft tumours.   
Next, the ΔCyt-E-cadherin-GFP mutant was expressed in PDACflvector cells. This 
mutant can form cis and trans dimers but can not bind to actin, and does not form any
adhesive immobile fraction (see section 3.7). As expected the dynamics of ΔCyt 
mutant are not significantly different than the dynamics of the ΔEC1ΔCyt-E-
cadherin-GFP mutant. Next, the ΔCyt mutant was expressed in PDACflR175H cells. 
In PDACflR175H xenografts, the ΔCyt mutant had the same immobile fraction as 
ΔEC1ΔCyt-E-cadherin-GFP mutant in PDACflvector xenografts. This data confirms 
that the non-adhesive immobile fraction due to non-specific trapping in membrane 
structure is similar in PDACflR175H and PDACflvector xenografts. So the significant 
difference observed in Fi in wild-type E-cadherin in xenografts is due to a difference 
in the adhesive immobile fraction and indicates that cell-cell adhesion is stronger in 
PDACflvector tumours compared to PDACflR175H xenografts. 
Moreover, the FRAP data for the ΔCyt-E-cadherin-GFP mutant showed that there 
was no significant difference in Fi% compared to wild-type
PDACflR175H xenografts (figure 4.10 red triangle and square).  In contrast, the ΔCyt 
mutant in PDACflvector xenograft tumour had a significantly higher immobile 
fraction than wild-type E-cadherin. This indicates that mutant p53 significantly 
reduced the adhesive immobile fraction in E-cadherin-GFP molecules in xenograft 
tumours. 
Moreover, the ΔEC1ΔCyt mutant does not form any interaction to adhesive cadherin 
complexe
molecule with the approximate size of E-cadherin. The results showed that although 
there is a significant difference in Fi% between wild-type E-cadherin-GFP and the 
ΔEC1ΔCyt mutant in PDACflvector xenograft, there is no significant difference 
between T1/2 (blue square and green circle in figure 4.10). Thus, in xenograft 
tumours wild-type E-cadherin recovers very fast, similar to the recovery rate of the 
non-binding mutant. This similarity in T1/2 shows that the mobile fraction of wild-
type E-cadherin-GFP molecules does not interact with any cadherin complexes in 
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membrane. In other word, there are no transient interactions in wild-type E-cadherin-
GFP in cells in tissue. The cadherin molecules are either immobile (in junctions or 
trapped non-specifically) or completely freely diffusing in the membrane. In contrast, 
in cell culture wild-type E-cadherin-GFP had a significantly higher T1/2 than 
ΔEC1ΔCyt mutant. These data indicate that in cell culture the mobile E-cadherin 
molecules in the membrane could bind to adhesive complexes and this interaction 
slows down their recovery rate. In cell culture, E-cadherin interactions can be stable 
during FRAP time (as in immobile fraction) or transient during FRAP time (mobile 
fraction with slow recovery time). But in tumours, the E-cadherin molecules are 
either stably bound to adhesive complexes or do not have any interactions. So the 
recovery time of wild-type E-cadherin-GFP is as fast as the non binding mutant.  
However, when p53 was expressed in PDAC tumour the adhesive immobile fraction 
significantly reduced while the recovery rate increases. This indicates that p53 
mutation inhibits immobilization of wild-type E-cadherin molecules in adhesive 
cadherin complexes. But, the mobilized wild-type E-cadherin-GFP molecules now 
form transient interactions which slow its diffusion and increase the recovery time of 
E-cadherin. 
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Figure.4.10. Wild-type E-cadherin-GFP and the ΔCyt mutant have similar Fi in PDACflR175H 
cells in xenograft tumours.  PDACflvector and PDACflR175H cell lines were transfected with wild-
type E-cadherin-GFP, or mutant E-cadherin with the cytoplasmic domain deleted (ΔCyt-Ecadherin-
GFP). FRAP on PDACflvector cells with wild-type E-cadherin-GFP compared to ΔCyt-Ecadherin-
GFP or ΔEC1ΔCyt mutant showed a significant decrease in Fi%. However, in PDACflR175H cells 
expressing wild-type E-cadherin-GFP showed no increase in Fi% compared to ΔCyt-Ecadherin-GFP. 
Error bars shows SEM. (n=at least 12 junctions for each data point) 
 
4.6. E-cadherin dynamics in a mouse model of pancreatic cancer. 
 
Although xenografts are good models for studying cells in vivo, cell migration in 
vivo is a complex process strongly affected by the tissue environment on or through 
which the cell migrates. Interaction with other cell types, including stromal 
fibroblasts and immune cells, has been shown to play a critical role in promoting the 
invasion of cancer cells and subcutaneous growth of pancreatic tumour cells does not 
recapitulate the native environment. Moreover, pancreatic cells growing under skin 
have different local micro environment compared to pancreas. Ideally, it would be 
best to study cell migration in its naturally occurring context in living organisms. 
In order to investigate E-cadherin dynamics in the context of pancreatic tumours, I 
used a mouse engineered to express E-cadherin-GFP from the Rosa26 locus under 
the control of cre-recombinase which was generated by D. Strathdee and colleagues 
in the Beatson Transgenic Production facility. Crossing this mouse with mice 
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expressing cre recombinase under control of the PDX1 promoter, lead to expression 
of E-cadherin-GFP in the pancreas (figure 4.11. A and B). This mouse was crossed 
with KPC mice to express E-cadherin-GFP in pancreatic tumours. This enabled us to 
use FRAP to asses E-cadherin dynamics for the first time in pancreatic normal tissue 
and tumours (Fig. 4.11. C and D).  
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Figure.4.11. FRAP on healthy and diseased pancreas. (A) E-cadherin-GFP was expressed in the 
mouse pancreas under the control of PDX1 cre-recombinase. (B) Expression of E-cadherin-GFP in the 
pancreas in addition to endogenous E-cadherin is shown by western blot. (C and D) E-cadherin-GFP 
mice crossed with KPC mice to express E-cadherin-GFP in pancreatic tumours and FRAP used to 
study E-cadherin dynamics in normal pancreatic tissue or tumours. (E) FRAP on ex vivo pancreas 
tissue compared to KRAS driven tumours and p53 mutant tumours reveals, that p53 mutation decreases 
the Immobile fraction significantly in these tumours. T1/2 is measured in normal tissue, KRAS 
tumours and p53 mutant tumours. Error bars show SEM. (For each data point 3 mice is studied and 
n=at least 12 recovery curves) 
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Due to the location of the pancreas deep within the peritoneal cavity, it was not 
possible to image this organ in situ. Instead pancreata were excited and examined ex 
vivo. To confirm that performing the FRAP ex vivo is comparable with in vivo I 
designed an experiment to FRAP on xenograft tumours ex vivo and compare it with 
in vivo results. The formation of tumour and preparation for imaging was similar to 
in vivo situation but just before starting the imaging the skin flap that attached the 
tumour to body and kept the blood flow was cut. For imaging the tumours in vivo the 
mouse was kept under anesthesia for 3 hours. The same time period of 3 hours was 
used for ex vivo imaging. The FRAP results showed no significant difference in Fi 
and T1/2 between ex vivo and in vivo tumours either in for PDACflR175H or 
Chapter 4: FRAP Analysis of E-Cadherin Dynamics as a Read-Out for Cell Motility                      129 
PDACflvector cells (figure 4.12). The results showed that E-cadherin FRAP can be 
performed ex vivo up to 3 hours. (P values for PDACflR175H cells for Fi% and T1/2 
are P = 0.512 and P = 0.992. For PDACflvector cells p values are P = 0.238 and P = 
0.360). 
FRAP on xenograft tumour in vivo and ex vivo
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Figure 4.12. FRAP in xenograft tumours showed the same results ex vivo and in vivo. FRAP is 
performed in xenograft tumours from PDACflR175H and PDACflvector cells either at tumours with 
blood flow through a skin flap attached to the mouse (in vivo) or at tumours excited from skin flap 
just before imaging (ex vivo).  The results showed no significant difference of Fi and T1/2 between 
ex vivo and in vivo tumours. Error bars show SEM. (n=at least 12 junctions for each data point)  
 
Ex vivo analysis of p53 mutant tumours revealed significant differences in E-
cadherin mobility compared to normal pancreatic tissue tumours or tumours with loss 
of p53 expression (figure 4.11.E). However, normal pancreatic tissue and tumours 
with loss of p53 expression showed no significant difference in E-cadherin 
dynamics. Also, pancreatic tumours in mouse with just the KRAS mutation had 
similar FRAP results to normal pancreatic tissue. This indicates loss of p53 does not 
alter E-cadherin dynamics. However, the FRAP data on ex vivo normal pancreas 
tissue compared to tumours from Pdx1-Cre, LSL-KRASG12D/+, Trp53LoxP/+ mice 
revealed that p53 mutation decreases the immobile fraction significantly in these 
tumours and increased the T1/2 (t test p values are P = <0.001 and P = 0.011 
respectively) (figure 4.11.E).  
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The effect of mutant p53 on E-cadherin mobility in pancreas tissue is similar to 
xenograft tumours. My data suggest that mutation in p53 is a gain of function 
mutation which weakened E-cadherin molecules interaction, therefore reduced the 
adhesive immobile fraction and increased the T1/2. This increased mobility of E-
cadherin in junctions disrupts cell-cell adhesion between p53 mutant tumour cells 
which enables these cells to metastasize from the primary tumour. 
Previous experiments in the KPC mouse model showed that treatment of mice with 
the Src inhibitor dasatinib hinders the tumour cells metastasis by approximately 50%. 
In addition, dasatinib was able to inhibit PDACR172H cell migration and invasion in 
vitro (Morton 2010-2). Performing FRAP on PDACflR175H and PDACflvector cells 
grown on CDM showed that dasatinib significantly increased the Fi and T1/2 of 
mutant p53 cells (figure 4.13.A).  Mutant p53 cells treated with dasatinib Fi and T1/2 
significantly increased (T1/2: P=0.023 Fi%: P=0.017). Fi and T1/2 of PDACflR175H 
and PDACflvector cells treated with dasatinib is not significantly different (T1/2: 
P=0.191 Fi%: P = 0.484). 
Moreover, FRAP showed that treating PDACflR175H xenograft tumours with 
dasatinib increased the immobile fraction and decreased T1/2 (T1/2: P=<0.001 Fi%: 
P=0.001). The Fi and T1/2 of E-cadherin on PDACflR175H xenograft tumours 
treated with dasatinib is not significantly different than PDACflvector tumours (T1/2: 
P =0.441 Fi%: P = 0.223) (figure 4.13.B).  
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Figure 4.13. Dasatinib overturns the effect of mutant p53 on the reduction in mobility of E-
cadherin. A) FRAP results for PDACflR175H and PDACflvector cells grown on CDM treated with 
anti invasive drug. Dasatinib is a Src inhibitor. PDACflR175H cells grown on CDM had significantly 
lower Fi and T1/2 than PDACflvector cells. But when the Mutant p53 cells treated with dasatinib Fi 
and T1/2 significantly increased. Fi and T1/2 of PDACflR175H and PDACflvector cells treated with 
dasatinib is not significantly different. B) FRAP results for PDACflR175H and PDACflvector cells in 
xenograft tumours in nude mice treated with anti invasive drug dasatinib. PDACflR175H tumours 
have significantly lower Fi and higher T 1/2 compared to PDACflvector tumours. However, after 
treatment with dasatinib FRAP data showed no significant difference in FI and T1/2 in 
PDACflR175H and PDACflvector tumours. Error bars show SEM. (n=at least 10 junctions for each 
data point)  
 
This suggests that the mutant p53 weakens cell-cell adhesion by mobilizing E-
cadherin in junctions and dasatinib inhibits metastasis through stabilizing E-cadherin 
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is. Consequently, FRAP can be used as biosensor 
arker to asses metastasis in vivo. 
 
at adhesions. Then, I used FRAP to assess how dasatinib treatment affects E-
cadherin dynamics in mutant p53 pancreatic tumours. Mutant p53 significantly 
lowered Fi in pancreatic tumours compared to tumours with loss of p53 or normal 
pancreas tissue. The FRAP results showed that dasatinib treatment significantly 
decreased mobility of E-cadherin in mutant p53 tumours (blue triangle in figure 4.14) 
(T1/2: P = 0.008 Fi%: P = <0.001). This indicates that FRAP can be used to asses 
real time dynamics of cadherin junctions in tumours. Regulation of cell-cell adhesion 
strongly affects cancer cell metastas
m
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Figure 4.14.  Dasatinib overturns the effect of mutant p53 on the reduction in mobility of E-
cadherin in pancreatic tumours. FRAP on ex vivo p53 mutant pancreatic tumours after treatment 
with dasatinib. dasatinib treatment increased the Fi% and decreased the T1/2. E-cadherin-GFP 
dynamics in p53 mutant tumours treated with dasatinib is similar to normal pancreatic tissue or 
tumours with loss of 53. The data for normal pancreas, p53172 and p53-/- tumours are duplicated 
from figure 4.11.E. Error bars show SEM. (For each data point 3 mice is studied and n=at least 12 
covery curves).  
 
re
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5.  Discussion 
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5.1. E-cadherin molecules need cis, trans and actin interactions to 
form adhesions: 
 
E-cadherin is a cell adhesion protein required for epithelial tissue integrity. Down-
regulation of E-cadherin expression is often associated with a phenotypic switch 
from a benign epithelial state to a metastatic mesenchymal state (Birchmeier 1994). 
However disruption of cell-cell adhesion occurs not just through down-regulation of 
E-cadherin levels, but also through mis-regulation of its dynamics and interaction 
with other proteins (Gumbiner 2000). Many forms of metastatic cancer retain E-
cadherin expression (Gaida 2012), and recent evidence supports the hypothesis that 
mis-regulation of E-cadherin dynamics can also drive metastasis (Serrels 2009). 
E-cadherin can form extra-cellular interactions with monomers from the same cell 
(cis) and interactions with monomers from adjacent cells (trans) via association of 
the EC1 domain (Thiery 2002, Harrison 2011, Hong 2011), and interact with the 
cortical actin cytoskeleton via association of its cytoplasmic domain with beta-
catenin and alpha-catenin (Desai 2013). However the interactions governing E-
cadherin dynamics remain poorly understood. To address this issue I have 
systematically investigated the mobility of mutant E-cadherins which can not form 
cis, trans dimers or bind to actin.  
FRAP (Fluorescence Recovery After Photobleaching) has been widely used to study 
E-cadherin dynamics (Harrison 2011, Serrels 2009, Yamada 2005, de Beco 2009, 
Hong 2010). The technique involves rapid bleaching of a small region of interest 
(ROI) at the mid point of a cell-cell junction, and observation of fluorescence 
recovery into the bleached region using time-lapse microscopy. Simple 
quantification of FRAP is achieved by fitting an exponential curve to a time series of 
fluorescence intensity measurements from the ROI, which results in 2 primary read-
outs: the half-time of recovery (T1/2) and the immobile fractions (Fi) (Lippincott 
2001, Sprague 2005). T1/2 is a measure of the rate at which mobile molecules moves 
in and out of the bleached ROI, whereas Fi represents fluorescent molecules trapped 
in the ROI. 
It is unclear how E-cadherins different interactions regulate its partitioning into 
mobile and immobile fractions, and determine the recovery rate of the mobile 
fraction. In the present study, I have used a pancreatic cancer model (Morton 2010-1, 
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Morton 2010-2) to systematically investigate the molecular determinants of E-
cadherin FRAP, using mutant analysis, chemical cross-linking and co-culturing of 
expression level variants. FRAP experiments are commonly designed to compare a 
single mutant, or a group of related mutants, with wild-type E-cadherin. By 
interfering with all three E-cadherin interactions, individually and in selected pairs, I 
have revealed general behavior about E-cadherin binding which could not be 
deduced from any single comparison with wild-type protein. 
 
5.1.1. Immobilization of E-cadherin-GFP in cell-cell junctions is due to both 
non-specific trapping and binding to adhesive clusters. 
 
I analysed FRAP in PDACfl cells derived from tumors from KRASG12D/+ p53+/- 
which were stably transfected with wild-type E-cadherin-GFP (and mutants). The 
results showed that around 60% of wild-type E-cadherin-GFP molecules are 
immobilized in cell-cell junction in cells in a complete confluent monolayer grown 
on glass. 
It has been previously shown that photo-activatable GFP (PA-GFP) linked to the 
plasma membrane via the H-Ras membrane targeting sequence (farn-farn-palm) had 
an Fi of approximately 25% in vivo (Serrels 2009). PA-GFP is not expected to bind 
to any component of the actin cytoskeleton; however it has been proposed that 
membrane components could be non-specifically trapped through a membrane fence 
mechanism (Kusumi 2005). I hypothesized that non-specific trapping might also 
contribute to the immobile fraction of E-cadherin.  
To test this idea I generated a GFP-labelled mutant of E-cadherin lacking both the 
EC1 and cytoplasmic domains (∆EC1∆Cyt-GFP) and compared its FRAP with wild-
type E-cadherin-GFP. This mutant is unable to form cis-, trans-, or actin interactions 
and its fluorescence intensity should therefore recover completely by a diffusion only 
mechanism. Although this mutant recovered quickly, it had an unexpectedly high 
immobile fraction (30%), which was half the level of wild-type E-cadherin-GFP 
(60%).  
To provide a reference for unrestrained diffusion, FRAP analysis was performed on 
PDACfl cells stably transfected with GFP alone targeted to the inner leaflet of the 
plasma membrane via the farn-farn-palm sequence (GFP-F). Again I found a 
surprisingly high Fi supporting the idea that ∆EC1∆Cyt-GFP was trapped in the 
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plasma membrane through non-specific interactions. Taken together, these data 
suggested that the 60% Fi of wild-type E-cadherin-GFP was comprised of two 
components: 30% non-specifically trapped in the manner of ∆EC1∆Cyt-GFP, and 
30% trapped via specific interactions involving the EC1 and/or cytoplasmic domains.  
Analysis of the same mutant in L cells which do not express endogenous E-cadherin 
showed that the high non-adhesive immobile fraction of E-cadherin is presents in L 
cells as well.  
 
5.1.2. The recovery rate of wild-type E-cadherin-GFP is limited by monomer 
turnover within adhesive clusters. 
 
Next I analysed whether the recovery of mobile E-cadherin molecules is determined 
by diffusion or by dissociation from adhesive complexes in membrane. One 
approach for distinguishing between diffusion-coupled and uncoupled recoveries is 
to vary the size of the ROI used for bleaching and analysis. For a diffusion-coupled 
process, the recovery half-time should increase with increasing ROI diameter, 
because T1/2 depends on the diffusion of monomers from the centre to the edge of 
the ROI. Conversely, the ROI size should not affect T1/2 for diffusion uncoupled 
recovery because the rate of monomer turnover is related to dissociation\association 
rate from clusters and it is independent of ROI size (see section 1.4.5.3). I analyzed 
GFP-F, ∆EC1∆Cyt-GFP, ∆EC1-E-cadherin-GFP and wild-type E-cadherin-GFP 
using ROIs of 20, 30, and 40 pixels in diameter. GFP-F and ∆EC1∆Cyt-GFP are not 
able to bind to any immobile complex in the plasma membrane. Consequently the 
recovery is just due to diffusion. As expected, the recovery time of both GFP-F and 
∆EC1∆Cyt-GFP increased with increasing ROI diameter, confirming that these 
processes are driven by diffusion alone. In contrast, wild-type E-cadherin-GFP can 
bind through cis and trans dimmerization and by interaction with actin with 
stationary complexes in the membrane. The recovery time of E-cadherin-GFP 
remained constant with increasing ROI diameter, indicating that this recovery is 
diffusion uncoupled and it is limited by the interaction of E-cadherin with stationary 
binding partners. This diffusion uncoupled behaviour of FRAP recovery was also 
reported for VE-cadherin molecules (Nanes 2012).  
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Moreover, the mutant ∆EC1-E-cadherin-recovery time increased by increasing ROI 
size. So by disrupting the cis and trans interactions the dissociation rate of cadherin 
molecules increased and the recovery of E-cadherin became diffusion coupled. 
To confirm that recovery rate of E-cadherin FRAP depends on the rate 
association\dissociation rather than diffusion rate, I performed cross-linking 
experiments using the cell-impermeable zero-order cross-linker BS3. Based on the 
small size of the linker (11.4 Å), it is expected to only cross-link molecules in direct 
proximity. For comparison with wild-type E-cadherin-GFP I used ∆EC1∆Cyt-GFP. 
Cell lysates probed with an anti-E-cadherin antibody demonstrated that BS3 was able 
to cross-link E-cadherin-GFP but not ∆EC1∆Cyt-GFP. This indicates that a 
component of E-cadherin-GFP is self-associated in the plasma membrane, whereas 
∆EC1∆Cyt-GFP is entirely present as monomers. I next performed FRAP analysis on 
PDACfl cells treated with BS3. Interestingly, I found that cross-linking significantly 
increased the Fi of E-cadherin-GFP from 60% to 85% and dramatically reduced T1/2 
from 50 seconds to 7 seconds, similar to the recovery rate of freely diffusing E-
cadherin-∆EC1∆Cyt-GFP. Moreover, in PDACfl cells treated with the cross-linker, 
increasing ROI size increased the recovery time which indicates that the recovery of 
E-cadherin-GFP became diffusion coupled. Interestingly, when the incubation time 
of cross-linking was reduced by half, the resulting partial increase in Fi and decrease 
in T1/2 suggested a partial shift from diffusion coupled to diffusion uncoupled 
recovery. In contrast to E-cadherin-GFP, and in agreement with western blot 
analysis, ∆EC1∆Cyt-GFP was unaffected by BS3 cross-linking. These data confirm 
the diffusion uncoupled nature of wild-type E-cadherin recovery. The recovery of the 
non binding mutant E-cadherin (∆EC1∆Cyt-E-cadherin-GFP) is due to diffusion of 
moleculese in and out of the bleached ROI. But the recovery of wild-type E-
cadherin-GFP is not limited by diffusion rate and it is determined by the rate of 
association and dissociation of E-cadherin molecules from stationary complexes in 
the membrane. When these transient interactions (association and dissociation from 
stationary complexes) are stabilized by cross-linking then the recovery is just 
determind by diffusion of non cross-linkable E-cadherin molecules which recovered 
at the rate of freely diffusing mutant E-cadherin. 
Consequently, the cross-linking experiment results suggest that the 40% mobile 
fraction (Fm) of E-cadherin-GFP is comprised of two components. The first 
component is the Fm of cross-linked E-cadherin-GFP, consisting of free monomers 
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which could not be cross-linked by BS3 treatment and representing approximately 
15% of total E-cadherin-GFP. The other component is the difference between cross-
linked and non-cross-linked E-cadherin-GFP, consisting of monomers prevented 
from leaving stationary complexes after cross-linked with BS3 and representing 
approximately 25% of the total E-cadherin-GFP. These data suggest that some 
mobile E-cadherin molecules in the membrane are unable to form any interaction 
with other cadherin molecules or bind to actin. Moreover, the remaining cross-
linkable cadherin molecules form transient interactions with adhesive clusters which 
associate\disassociate from adhesive complexes during FRAP recovery time. Further 
investigation is required to uncover the basis for this differential behaviour.  
 
5.1.3. Trans-dimer equilibrium regulates the size of Fi 
 
Subsequently I wanted to explore the relationship between Fi and cell adhesion 
strength. In order to analyse how the expression level of E-cadherin influences cell 
adhesion strength, first I sorted PDACfl cells into high and low groups according to 
the level of E-cadherin-GFP expression. The integrity and strength of cell-cell 
adhesions of confluent cell monolayers was assessed using trans-epithelial electrical 
resistance (TEER) and resistance to dispase treatment, which confirmed that the 
integrity and strength of cell-cell junctions depends on the E-cadherin-GFP 
expression level, and was greater for high expressing cells. I next performed FRAP 
on E-cadherin-GFP-high and E-cadherin-GFP-low cells and found that the immobile 
fraction was equal for both cell types, indicating that Fi was not directly linked to 
cell adhesion strength when E-cadherin expression levels are not similar.  
In contrast, the recovery half-time of E-cadherin-GFP-low cells was substantially 
reduced compared to E-cadherin-GFP-high cells. In other words, the E-cadherin-GFP 
molecules recovered more quickly in cell-cell junction in cells with lower E-cadherin 
expression level. Then I studied whether the immobile fraction of E-cadherin in one 
cell depends on the availability of E-cadherin on the neighbouring cell. PDACfl cells 
expressing E-cadherin-GFP-high were co-cultured with the parental PDACfl line. 
The total level of E-cadherin expression is lower in the parental line because it does 
not express E-cadherin-GFP on top of endogenous levels, and FRAP experiments 
therefore report on behaviour only within the E-cadherin-GFP-high cells. I found that 
both Fi and T1/2 were significantly reduced compared to FRAP performed between 
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two E-cadherin-GFP-high cells. This demonstrates that the availability of E-cadherin 
in the partner cell of a junction significantly influences the amount of cadherin 
stabilized in the junctions. Moreover, analysis of E-cadherin mobility at a free cell 
edge, in the absence of any trans-dimer associations, revealed that Fi and T1/2 were 
reduced nearly to the level of ∆EC1∆Cyt-GFP, demonstrating that trans-interactions 
are necessary for formation of stationary clusters. 
The data showed that the major difference between E-cadherin-GFP-high and low 
cells was in T1/2 not immobile fraction. E-cadherin FRAP recovery is diffusion 
uncoupled, so the diffusion of bleached molecules happens very fast and the recovery 
rate is limited by rate of association\dissociation of E-cadherin molecules 
Imaging E-cadherin-GFP-high junctions and E-cadherin-GFP-low junctions using 
NSTORM super-resolution microscopy revealed that E-cadherin-GFP formed 
clusters of similar sizes in both junction types, but that the average distance between 
cluster centres was 65% greater for the E-cadherin-GFP-low cells (Figure 5.1).  
These data indicate that PDACfl cells respond to different expression levels of E-
cadherin by varying the density of similarly sized clusters, rather than maintaining 
the same density of differentially sized clusters. This indicates that a higher density 
of stationary clusters in E-cadherin-GFP-high cells slows down the movement of E-
cadherin molecules probably by decreasing the distance that released monomers 
diffuse before binding to a new stationary cadherin cluster. This result suggests that 
individual E-cadherin monomers undergo multiple rounds of unbinding, diffusion, 
and rebinding before moving out of bleached ROI. In other word, recovery of E-
cadherin is related to association rate of monomers to stationary binding sites (Kon) 
rather that just dissociation rates (Koff). This implies that the recovery of E-cadherin 
molecules should be diffusion coupled. This is in contrast to FRAP results in 
different ROI size which suggested a diffusion uncoupled FRAP behaviour. One 
simple explanation would be that when binding interactions are present the effect of 
ROI size on recovery is small and the FRAP analysis is not sensitive enough to 
detect the difference. 
However, E-cadherin recovery is not due to just one binding\unbinding reaction. E-
cadherin molecules attach to other molecules through cis, trans and actin binding. 
There are two mobile components that determine the recovery rate of E-cadherin: 
Adhesive mobile fraction and non-adhesive mobile fraction (see section 5.1.5). The 
difference in recovery rate of E-cadherin could be due to change in proportion of 
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these two populations rather than change in association\dissection rate of E-cadherin 
monomers. 
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Figure 5.1. Cells expressing high level of E-cadherin have similar size clusters which spaced 
more densely. E-cadherin-GFP-high (A) and -low (B) cells were imaged using N-STORM super 
resolution microscopy. C) The quantification of the data showed that the average cluster size was the 
same for both high and low cells (131.0 ± 45.6 nm vs. 123.8 ± 46.5 nm, respectively), but the 
spacing between clusters was smaller for E-cadherin-GFP-high cells (205.9 ± 113.5 nm vs. 341.6 ± 
151.6 nm). (The bars is 0.2 microns) (unpublished data in collaboration with Wu Yao and Ronen 
Zaidel-Bar) 
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5.1.4. Inclusion of E-cadherin into the adhesive Fi requires cis-, trans-, and 
cytoplasmic interactions 
 
FRAP analysis of E-cadherin at a free cell edge suggested that trans- interactions 
contribute to Fi and T1/2. To further determine the relative contribution of these 
interactions to E-cadherin FRAP, I made mutants defective for each interaction. 
Disruption of any single interaction was sufficient to reduce Fi to the non-specific 
level of the free diffusing mutant ∆EC1∆Cyt-E-cadherin-GFP. This suggests that all 
three interactions (cis-, trans-, and actin) are required for inclusion of E-cadherin-
GFP into the adhesive immobile fraction.  
It has been previously suggested that formation of cis and trans interactions in tailless 
E-cadherin is enough for clustering E-cadherins at junctions (Hong 2010). However, 
my TEER and dispase assay results showed that although ∆Cyt-E-cadherin mutant 
may form clusters at the cell-cell junctions in absence of actin interaction, they are 
unable to increase cell-cell adhesion strength.   
My data showed that all three E-cadherin interactions cis, trans and actin binding are 
necessary to form adhesive clusters. By disrupting any interaction the E-cadherin 
mutants are unable to increase cell-cell adhesion. Hong et al also reported similar 
effect, that cis and trans dimerization cooperate with actin binding to decrease 
mobility of E-cadherin molecules (Hong 2013). 
With respect to T1/2, the mutants clustered into two groups: mutants retaining the 
cytoplasmic tail recovered more slowly, whereas the cytoplasmic deletion mutants 
recovered more quickly. It is interesting to note that the recovery of E-cadherin-GFP 
at the free cell edge was similar to the recovery of E-cadherin mutants that retained 
the cytoplasmic interaction with the actin cytoskeleton. These data show that 
cytoplasmic interactions significantly slow the free diffusion of E-cadherin-GFP, 
whereas cis- or trans-interactions (alone or in conjunction) do not. 
 
5.1.5. There are four distinct components of E-cadherin in cell-cell junctions. 
 
I have systematically investigated the determinants of E-cadherin FRAP in 
pancreatic cancer cells. By interfering with all three E-cadherin interactions, 
individually and in selected pairs, the data revealed a general behaviour about E-
cadherin binding which could not be deduced from any single comparison with wild-
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type protein. The data clearly showed that E-cadherin FRAP is diffusion uncoupled, 
and that the mobile and immobile fractions have adhesive and non-adhesive 
components, which can be defined according to specific molecular interactions.  On 
this basis I can define four distinct components that contribute to E-cadherin FRAP: 
 
  
Non-Adhesive Adhesive 
Immobile 
Non-adhesive immobile fraction 
 
30% 
 Fi% (∆EC1∆Cyt) 
 Non- specifically trapped in 
membrane structures 
Adhesive immobile fraction 
 
30% = 60% - 30% 
 Fi (wt Ecad) – Fi(∆EC1∆Cyt) 
 Stabilized in adhesive clusters 
 Requires cis, trans, and actin 
Mobile 
Non-adhesive mobile fraction 
 
15% = 100% - 85% 
 Fm (X-linked wt Ecad) 
 Diffusion Coupled 
 presents in monomeric form 
Adhesive mobile fraction 
 
25% = 85% - 60% 
 Fi (X-linked) – Fi (wt Ecad) 
 Diffusion Uncoupled 
 Transiently bind\unbinds from adhesive 
clusters  
Table .5.1. Four fractions of E-cadherin in plasma membrane in cells grown on glass. 
 
5.1.5.1. The non-adhesive immobile fraction  
 
This sub-population (~30% in PDAC cells) consists of E-cadherin non-specifically 
trapped in the plasma membrane in the same way as GFP-F and ∆EC1∆Cyt-E-
cadherin-GFP, neither of which can form cis-, trans-, or actin interactions. My results 
are consistent with single molecule imaging of E-cadherin in the plasma membrane, 
which previously suggested that a significant fraction of E-cadherin is restrained in 
its diffusion (Iino 2001). Such non-adhesive trapping has been previously 
demonstrated in the plasma membrane for trans-membrane proteins and 
phospholipids and appears to be a consequence of membrane compartmentalization 
induced by the cortical actin meshwork (Kusumi 2005, Kusumi 1993). However, 
Kusumi et al. used FRAP and SPT (single particle tracking) to study the E-cadherin 
mobility in dorsal surface of cell, which is not similar to mobility of E-cadherin at 
cell-cell junctions. Dynamics of actin cytoskeleton is different in cell-cell contacts 
which could affect trapping of trans-membrane molecules in membrane. However, in 
this study, the non-specific immobile fraction of ∆EC1∆Cyt mutant E-cadherin was 
measured at cell-cell contacts, and the mobility of wild-type E-cadherin-GFP was 
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measured in similar way. This provides a control for non-specific trapping of E-
cadherin molecules to distinguish between specific immobilization in adhesive E-
cadherin clusters and non-specific trapping at cell-cell junctions. 
 
5.1.5.2. The adhesive immobile fraction  
 
Deletion of cis-, trans-, or actin interactions reduced the Fi of E-cadherin-GFP from 
60% to the level of ∆EC1∆Cyt-GFP (~30% in PDAC cells), suggesting that all three 
interactions are required for adhesive immobilization of E-cadherin in cell-cell 
junctions. These data are consistent with a model in which individual interactions are 
weak, and multiple interactions are required in order to stabilize E-cadherin within 
the adhesive immobile fraction.  Moreover, the regulation of any single interaction 
(cis-, trans-, or actin) is sufficient to drive E-cadherin out of the adhesive Fi. This 
suggests a mechanism in which regulation of actin association alone could be 
sufficient to regulate adhesive complex formation.  
Furthermore, the mechanism by which association\dissociation of E-cadherins from 
adhesive clusters are regulated remains unclear. One possible mechanism could be 
regulation of catenins by phosphorylation. Tension also could play a role in further 
stabilizing E-cadherin within the adhesive immobile fraction (de Rooij 2005, 
Huveneers 2013). 
 
5.1.5.3. The adhesive mobile fraction  
 
This fraction (~25% in PDAC cells) has a slow recovery time, and the recovery 
depends on dissociation\association of molecules from adhesive complexes rather 
than just free diffusion. Changing the size of the analysis ROI had no effect on T1/2, 
further suggesting that recovery was limited by dynamic equilibrium of monomers 
with stationary binding partners rather than diffusion. Cross-linking experiments, 
which reduced the mobile fraction of E-cadherin-GFP from 40% to 15%, established 
the size of this fraction.  
Recent work has shown that cytoplasmic domain deletion mutants of E-cadherin 
(∆Cyt-E-cadherin-GFP) can form patches at sites of cell-cell contact, which 
approximate the localization of wild-type E-cadherin seen in the light microscope 
(Harrison 2011, Hong 2010, Ozaki 2010). The ability of these mutants to cluster has 
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suggested a mechanism for junction assembly in which extracellular interactions 
precede intracellular interactions (Brasch 2012). However, the ability of cytoplasmic 
deletion mutants to cluster does not necessarily imply that extracellular interactions 
are the preferred first step of assembly if cytoplasmic interactions are possible. My 
data showed that cytoplasmic interactions significantly slowed the diffusion of E-
cadherin mutants, whereas cis- and trans- interactions did not. This suggests that 
cytoplasmic interactions may precede extracellular interactions during junction 
assembly. The reduction in diffusion due to cytoplasmic interactions could be due to 
the strength of cytoplasmic interactions, the abundance of binding sites within the 
cortical actin meshwork, or both. 
 
5.1.5.4. The non-adhesive mobile fraction  
 
This sub-population (~15% in PDAC cells)  is represented by the 15% of E-cadherin-
GFP which could be not cross-linked by BS3 treatment. The recovery of this fraction 
at the rate of free diffusion suggests it is unable to form transient interactions with 
stationary adhesive complexes, which would otherwise limit its recovery rate. A 
possible explanation for this is that this 15% is unable to bind β-catenin due to 
phosphorylation of β-catenin at Y489 by Abl kinase and at Y654 by Src or EGF 
receptor (Lilien 2002, Rhee 2002, Roura 1999, Hoschuetzky 1994). In wild-type 
cells, the rapid recovery of this non-adhesive mobile fraction (15% of total) is 
masked by the slower recovery of the adhesive mobile fraction (25% of total).  
A further conclusion of my work is the importance of certain control experiments for 
the interpretation of E-cadherin FRAP data. The most important is the use of 
∆EC1∆Cyt-GFP to establish the baseline rate of diffusion coupled recovery and the 
non-adhesive Fi. The analysis of different ROI sizes is also useful in order to 
determine whether recovery of a mutant is diffusion coupled or uncoupled. As my 
results demonstrate, full comparison of a mutant series can reveal general behaviour 
patterns not obvious on the basis of a single mutant data point. 
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Non-adhesive Immobile 
Non-adhesive Mobile 
Adhesive Immobile 
Adhesive Mobile 
Figure 5.2. There are four E-cadherin populations within the ROI of a FRAP experiment. Non-
adhesive immobile monomers (purple) are trapped through non-specific interaction with the cortical 
cytoskeleton. Non-adhesive mobile monomers freely move and do not bind to complexes. Adhesive 
immobile monomers are bound to clusters and remain stationary. Adhesive mobile monomers 
alternate between transient binding and diffusion. 
 
 
5.2. FRAP Analysis of E-Cadherin Dynamics as a Read-Out for Cell 
Motility. 
 
In many cancer cells mis-regulation of adherens junctions causes increased 
progression and invasion of cancer (Birchmeier 1994). Alteration in E-cadherin 
dynamics could therefore serve as an early molecular biomarker of metastasis. Here, 
I had analyzed how E-cadherin dynamics are related to cell motility and invasion in 
two PDAC cell lines derived from primary pancreatic tumours of the KPC mouse 
model. In this model tumour formation is driven by mutant KRAS; however, tumour 
metastasis is driven by mutant p53 (Morton 2010). Here, I studied the effect of local 
environments on the mobility of E-cadherin in cell lines derived from mouse primary 
tumours. Moreover, I have used FRAP both in vitro and in vivo to analyse the 
dynamics of E-cadherin in invasive and non-invasive cells, and in response to 
therapeutic intervention with the Src inhibitor Dasatinib.  
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5.2.1. P53 mutation drives cell invasion in PDAC cells and weakens cell-cell 
adhesions. 
 
In the KPC mouse model KRASG12D mutation drives formation of PanINs, then loss 
of p53 promotes formation of pancreatic tumours. Mice with Pdx1-Cre, LSL-
KRASG12D/+, Trp53LoxP/+ genetic background form tumours which are not invasive. 
On the other hand, mice with Pdx1-Cre, LSL-KRASG12D/+, LSL-Trp53R172H/+ genetic 
background form invasive tumours. PDAC cell derived from the tumours with loss of 
p53 expression (PDACfl) are not invasive in organotypic assay and xenograft 
tumours. On the other hand, PDAC cells from tumours with p53R172H mutation 
(PDACR172H) are more progressive and invasive than PDACfl cells. Moreover, 
expression of human mutant p53 protein (p53R175H) in PDACfl cells is sufficient to 
activate cell invasion in PDACfl cells (Morton 2010). Here, I studied PDAC cell line 
stably transfected with E-cadherin-GFP plasmid. The PDACR172H and PDACflR175H 
cells with E-cadherin-GFP expression are still highly invasive, and there was no 
significant difference in depth of invasion between original cells and E-cadherin-
GFP expressing cells. 
Moreover, analysing cell-cell adhesion and integrity of junctions through dispase 
assay and TEER measurements showed that mutant p53 dramatically weakens cell-
cell adhesion compared to cells with loss of p53 expression. 
 
5.2.2. Mutant p53 mobilizes E-cadherin on cells grown on CDM but not glass. 
 
My data showed that the effect of mutant p53 on E-cadherin dynamics depends on 
the local cell environment. E-cadherin mobility increased in PDACflR175H cells in 
comparison to PDACflvector cells when grown on CDM but not glass. P53 mutant 
cells have significantly lower Fi and T1/2 in cells grown on CDM. When cells 
express comparable levels of E-cadherin, Fi is related to the amount of E-cadherin 
stabilized at junctions. Consequently, higher Fi indicates more stabilized junctions 
and stronger cell-cell adhesion. Moreover, the dispase assay was used to study cell-
cell adhesion in PDACflvector and PDACflR175H cells grown on CDM, which 
confirmed that mutant p53 loosens cell-cell junctions by mobilizing E-cadherin.  
It has been previously shown that ECM components such as integrins could affect 
the regulation of E-cadherin cell-cell adhesions (deRooji 2005). My data also showed 
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that interaction of cell derived matrix (CDM) components with cells is necessary for 
mutant p53 de-regulation of E-cadherin cell-cell adhesion. 
Moreover, in colon cancer cells integrin signalling is necessary for disruption of E-
cadherin cell-cell adhesion by Src. Src phosphorylation of focal adhesion kinase 
(FAK) which is regulated by integrin signalling disrupts E-cadherin cell-cell 
adhesions (Avizienyte 2002). My results also showed that treatment of 
PDACflR175H cells growing on CDM with Src inhibitor dasatinib decreased 
mobility of E-cadherin in mutant p53 cells. This suggests that mutant p53 could 
regulate E-cadherin dynamics through Src activation. Moreover, interaction of ECM 
and integrin signalling is required for weakening of cell-cell adhesions by p53 
mutants.  
 
5.2.3. Mutant p53 drives invasion by increasing the mobility of E-cadherin in 
PDAC cells in xenograft tumours: 
 
The data suggested that micro environment plays an important role in determining 
the effects of mutant p53 on E-cadherin dynamics and cell migration. Extracellular 
matrix strongly affects cell migration. However, CDM is a very artificial 
environment compared to tumours. The composition of ECM and its rigidity is 
different in CDM compared to tissue. Moreover, the presence of immune cells and 
inflammation affects cells invasion (Smith 2013). Therefore, for a better 
understanding of dynamics of E-cadherin in functional and physiological context of 
real tumors, I measured FRAP in xenograft tumors. 
Xenograft tumours derived from the PDACflR175H cell line were highly invasive 
compared to PDACflvector tumours. The histological analysis of xenograft tumours 
showed that mutant p53 cells invade through muscle and the peritoneal cavity. The 
FRAP results showed that the immobile fraction of E-cadherin was significantly 
reduced in PDACflR175H xenografts compared to PDACflvector tumours. This 
reduction in E-cadherins stabilized at cell-cell junctions is similar to the effect of 
mutant p53 on mobilizing E-cadherin and consequently weakening cell-cell 
adhesions in cells cultured on CDM. In contrast, p53 mutation had a different effect 
on the rate of E-cadherin recovery in xenograft tumours compared to CDM. On 
CDM mutant p53 reduced T1/2 but in xenograft tumours PDACflR175H cells have 
larger T1/2 compared to PDACflvector cells. This indicates that the recovery time of  
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E-cadherin which determined by rate of dissociation\association of E-cadherin 
molecules from stationary complexes is dramatically different in vivo compared to in 
vitro. 
5.2.4. PDAC cells showed different E-cadherin dynamics in tissue compared to 
CDM. 
 
My FRAP results showed that xenografts, have higher immobile fraction and much 
smaller T1/2 compared to cells growing on glass or CDM.  The higher Fi could be 
due to increased non-adhesive or adhesive immobile fraction. To answer this 
question, the mutant ΔEC1ΔCyt E-cadherin-GFP was stably expressed in 
PDACflvector cells in xenografts to estimate the level of non-adhesive immobile 
fraction. The Fi% of the ΔCytΔEC mutant in PDACfl xenograft was approximately 
60% which is significantly higher than 30% the Fi for these cells grown in culture. 
This 60% immobile fraction establishes the baseline for non-adhesive immobile 
fraction in PDACfl cells in xenograft tumours. 
Moreover, the FRAP on ΔEC1ΔCyt mutant that recovers as fast as free molecule of 
approximate size of E-cadherin showed that although there is a significant difference 
between Fi% in wild-type E-cadherin-GFP and ΔEC1ΔCyt mutant in PDACflvector 
xenograft, there is no significant difference between T1/2. Thus, in xenograft 
tumours wild-type E-cadherin recovered very fast, approximately similar to recovery 
rate of non-binding mutant. This similarity in T1/2 suggests that the mobile fraction 
of wild-type E-cadherin-GFP molecules does not form any transient interaction with 
adhesive cadherin complexes in membrane to slow down its recovery. This suggests 
that the rate of dissociation of E-cadherins from stationary complexes are so slow 
that they are appeared stable and immobilized during the FRAP time period. 
Thus, the adhesive mobile fraction in PDACflvector tumours is vey small. In other 
words, cadherin molecules are either immobile (in junctions or trapped non-
specifically) or completely freely diffusing in the membrane. In contrast, in cell 
culture, 25% adhesive mobile fraction of wild-type E-cadherin-GFP forms transient 
interactions which significantly slowed its recovery.  
Next I analysed the non-interacting E-cadherin mutant in p53 mutant tumours. The 
FRAP data for the ΔCyt mutant showed that there is no significant difference in Fi% 
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compared to wild-type E-cadherin-GFP in PDACflR175H xenografts, which 
indicates that mutant p53 significantly reduced the adhesive immobile fraction in E-
cadherin-GFP molecules. However, T1/2 is significantly increased in wild-type E-
cadherin-GFP compared to ΔCyt mutant. In other word, p53 mutation reduces the 
adhesive mobile fraction of E-cadherin while increased the adhesive immobile 
fraction. This indicates cadherin molecules which are stable in adhesive clusters 
became unstable and this dissociation\association from the clusters slows down their 
recovery. 
Moreover, comparison of the ΔCyt mutant dynamics in PDACflvector and 
PDACflR175H cells showed similar Fi and T1/2 values. This data indicates that the 
difference in Fi between PDACflvector and PDACflR175H xenografts is not due to 
different non-adhesive immobile fraction. Therefore, the mutant p53 specifically 
changed cell-cell adhesion by decreasing the E-cadherin immobilized at junctions. 
 
5.2.5. p53 mutation, not loss, removes the E-cadherins from junctions in 
pancreatic tissue. 
 
Although xenografts are a convenient model for studying cells in vivo, the 
subcutaneous growth of pancreatic tumour cells does not recapitulate the native 
environment of the pancreas.  Ideally, it would be best to study cell migration in its 
naturally occurring context in living organisms. So, I used a genetically engineered 
mouse expressing GFP-E-cadherin crossed with the KPC mouse model to be able to 
study FRAP in the pancreas and pancreatic tumours. Due to the location of the 
pancreas deep within the peritoneal cavity, it was not possible to image this organ in 
situ. So imaging was performed on excised pancreatic tissue ex vivo. 
Comparison of FRAP results in xenograft tumours in vivo and ex vivo showed no 
significant difference, which implies that dynamics of E-cadherin measured in ex 
vivo tissue is comparable to in the vivo situation. 
I studied E-cadherin dynamics in healthy pancreas, tumours with loss of p53 
expression (from mice with Pdx1-Cre, LSL-KRASG12D/+, Trp53LoxP/+ genetics) and 
tumours with mutant 53 expression (Pdx1-Cre, LSL-KRASG12D/+, Trp53R172H/+). The 
FRAP data showed that mutant p53 decreased the immobile fraction of E-cadherin 
and increased the recovery time similar to PDAC cells in xenograft tumours. 
Chapter 5: Discussion                                                                                                                        150  
Moreover, normal pancreatic tissue and tumours with loss of p53 expression showed 
no significant difference in FRAP data. This indicates loss of p53 does not alter E-
cadherin dynamics. Mutation in p53 is a gain of function mutation which weakened 
the interaction between E-cadherin molecules, reduced the adhesive immobile 
fraction and increased the T1/2. This increased mobility of E-cadherin in junction 
disrupts cell-cell adhesion in p53 mutant tumour cells which promotes the metastasis 
of these cells from the primary tumour. 
Previously it has been shown that treatment of mice with the Src inhibitor dasatinib 
hinders the tumour cells metastasis. Treating PDACflR175H xenograft tumours with 
dasatinib increased the immobile fraction and decreased T1/2. Thus mutant p53 
weakens the cell-cell adhesion by mobilizing E-cadherin in junctions and dasatinib 
inhibits metastasis through stabilizing E-cadherin at adhesions. Then, I used FRAP to 
assess how dasatinib treatment affects E-cadherin dynamics in mutant p53 pancreatic 
tumours. Dasatinib treatment significantly decreased the mobility of E-cadherin in 
mutant p53 tumours. Moreover, this indicates that I can use FRAP as a 
pharmacodynamic marker to assess the effect of dasatinib in pancreatic tumours. 
 
In conclusion, I showed that E-cadherin FRAP can be used to asses real time 
dynamics of cadherin junctions in vivo. The cadherin junctions dynamics can be used 
as marker for prediction of tumour cells potential to metastasize. Moreover, this 
project provided a comprehensive framework for understanding E-cadherin 
dynamics at cell-cell junctions based on specific and non-specific molecular 
interactions. This framework will support the design and interpretation of future 
pharmacological and genetic experiments to probe the function of E-cadherin in 
development, disease progression, and response to therapy.  
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